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1. Introduction 
1.1 G protein-coupled receptors 
The G protein coupled-receptors (GPCRs) form one of the largest superfamily of proteins in 
the mammalian genome, including more than 800 human genes [1]. Two main features 
characterize a receptor as a GPCR. The first requirement is the presence of seven amino acid 
sequences with high degree of hydrophobicity which represent seven α-helices spanning the 
cell plasma membrane. Because of this element, GPCRs are also termed “seven 
transmembrane (7TM) receptors” [2]. The second requirement is the ability of the receptor to 
bind to heterotrimeric G proteins. The interaction between GPCRs and different subunits of G 
proteins is responsible for a large variety of alternative signaling pathways. The ligands of 
GPCRs cover a wide spectrum of extracellular signals including photons, ions, lipids, 
nucleotides, amines, peptides and entire proteins [2]. Therefore, GPCRs are one of the 
essential junction for the communication between external and internal environment of the 
cell. After ligand binding, the receptor is subjected to conformational changes which activate 
the complex cytosolic signaling network resulting in a cellular response [3].  
Due to the large variety of biological functions and human diseases associated with GPCRs, 
these receptors are among the most pursued targets for drug development. It has been 
estimated that about 30% of all drugs currently on the market target GPCRs and since the 
knowledge about those receptors and their signalling pathways is constantly increasing the 
potential for drug discovery in this field is also immense [2]. 
 Several classification systems have been used for the GPCR superfamily, including grouping 
of the receptors by their ligand binding mode or by structural features. The International 
Union of Basic and Clinical Pharmacology (IUPHAR) recommends one of the most 
frequently used systems which covers all GPCRs, in both vertebrates and invertebrates, and 
divides them in classes from A to F [4]. Some of those families do not exist in human, such as 
classes D and E, which correspond to fungal pheromone receptors, and class F, which 
contains archaebacterial opsin. Furthermore, vertebrates GPCRs can be classified into five 
main families (Fig 1) according to their pharmacological properties and to which the acronym 
GRAFS has been applied [3]: 
• G: Glutamate or class C receptors 
• R: Rhodopsin or class A receptors 
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• A: Adhesion or class B receptors 
• F: Frizzled/TAS2 or class F receptors  
• S: Secretin receptors, included in class B. 
 
 
 
Figure 1.  Phylogenetic tree of the human GPCR superfamily. The GPCRs can be classified into 
five families: Rhodopsin (class A), Secretin and Adhesion (class B), Glutamate (class C) and 
Frizzled/taste receptor 2. These families can be further divided into subfamilies according to their 
sequence similarity. The receptors are named according to their gene name, as used in UniProt 
database. Receptors whose crystal structure is solved are circled in red and blue. Adapted from [5].  
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The rhodopsin family is the largest and the most diverse class of GPCRs and the members are 
charcterized by similar structural features and activation mechanisms. On the other hand, 
individual GPCRs are associated with unique signal transduction pathways involving multiple 
G protein subtypes and G protein-independent signalling processes [6].  
Heterotrimeric G proteins are composed of an α-, β- and γ-subunit and they are subjected to 
conformational changes leading to the exchange of GDP for GTP bound to the α-subunit after 
receptor activation. Consequently, the heterotrimeric complex is dissociated into the Gα- and 
Gβγ-subunits, which promote the stimulation of effector molecules (Fig 2), such as adenylate 
cyclases (AC), phosphodiesterases, phospholipase A2 (PLA2), phospholipase C (PLC) and 
phosphoinositide 3-kinases (PI3Ks). Finally, they activate or inhibit the production of 
different second messengers (cAMP, cGMP, diacylglycerol, inositol (1,4,5)-triphosphate, 
arachidonic acid and intracellular calcium ions) [7].  
The signaling of the activated GPCR is terminated by phosphorylation of the cytoplasmatic 
loops and tail of the receptor catalyzed by GPCR kinases (GRKs). As consequence, the 
arrestins (β-arrestin 1 and 2, mainly) are recruited and bind to the receptor which is 
internalized in clathrin-coated vesicles. Thus, in the classical GPCR model, heterotrimeric G 
proteins mediate the signal transduction while β-arrestins mediate receptor desensitization [8].  
This classical model for GPCR mechanism of action is considered over-simplified and 
incomplete. Over the last decade, there has been evidence regarding the ability of  β-arrestins 
to act not only as regulators of GPCR desensitization but also as adaptor proteins which have 
the ability to signal through multiple mediators, such as mitogen-activated protein kinases 
(MAPKs), nuclear factor-κB (NF-κB) and phosphoinositide 3-kinase (PI3K). In this new 
perspective, both heterotrimeric G proteins and β-arrestins are able of interacting with 
intracellular signaling molecules mediating distinct functional and physiological 
consequences [9].  
The original model was based on the idea that most ligands binding to GPCRs have balanced 
or unbiased activity activity for signaling through β-arrestins or G proteins meaning that they 
can signal equally through both. However, for some GPCRs it has been found that depending 
on the ligand the receptor display bias toward one pathway over the other thus, it 
preferentially signal through the G protein- or β-arrestin-mediated pathway [8]. This 
behaviour is named biased agonism and it has important implications for the design of drugs 
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that target GPCRs because the signalling derived by these parallel pathways might have 
distinct functional consequences [8].  
 
Figure 2. Diversity of signaling pathways involved in the activation of GPCRs. A large variety of 
ligands stimulate the receptors, activating heterotrimeric G protein-dependent and –independent 
pathways. The principal effector molecules are listed under the corresponding G protein subunit. 
GPCR activation regulates key biological functions, such as cell proliferation, cell survival and 
angiogenesis [7].  
 
Since GPCRs have a fundamental role in health and disease, a detailed understanding of their 
structure and function is critical for new drug discovery. However, the characteristic 
flexibility of these receptors, important for their activity in physiological conditions, interferes 
with the traditional methods of crystallization and structure determination [5]. In 2000, the 
first crystal structure of a mammalian GPCR, the bovine rhodopsin, was solved and since 
then, rapid progresses in protein engineering and crystallography allowed an exponential 
growth in GPCR structure determination [10,11].  
So far, three-dimensional structures of more than 20 different GPCRs have been solved, 
giving progressively new insights into protein function and their interaction with ligands or 
drugs [12,13]. Most of the solved structures belong to class A GPCRs, in particular to the 
cluster of aminergic receptors, of which many are relevant in pharmacology. Beyond the class 
A receptors, at least one crystal structure for each of the other classes of GPCRs have been 
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solved as well. Two structures of the secretin receptor family (class B) have been published, 
corticotropin releasing factor receptor 1 (CRF1R, [14]) and glucagone (GCGR, [15]), while 
for the metabotropic family (class C), the structures of the glutamate receptor 1 (mGluR1, 
[16]) and 5 (mGluR5, [17]) have been solved. For the adhesion family, several crystal 
structures of the neurotensin receptor (NTSR1, [18,19]) are available and for the smoothened 
receptor (SMOH, [20,21]) belonging to the Frizzled/TAS2 family, as well. 
Several GPCRs have been co-crystallized in complexes with different ligands (agonists, 
antagonists, inverse agonists or allosteric compounds), different crystallization methods (i.e. 
lipidic cubic phase or with new detergents) or using different approaches for the receptor 
stabilization (i.e. generation of receptor-T4 lysozyme and receptor-apocytochrome chimeras, 
co-crystallization with monoclonal antibody fragments from mouse or camelids, receptor 
thermostabilization by scanning mutagenesis or engineering disulphide bonds) [3,11].  
The structure of a GPCR can be divided in three main parts: the extracellular region, which 
consists in the N terminal tail and in three extracellular loops (ECL1-3), the transmembrane 
(TM) region, including the seven α-helices, and the intracellular region, which consists in the 
C terminal tail and three intracellular loops (ICL1-3). The extracellular domain modulates the 
ligand access and sequence analysis shows that this region is characterized by a large 
diversity in lenghts and sequence composition. The TM region forms the structural core, 
binds the ligand and transduce this information to the intracellular domain by conformational 
changes. Despite the sequence diversity between TM domains of different GPCRs, they share 
a similar three-dimensional architecture of seven helices held together by tertiary contacts [3]. 
Comparing the ligand positions from class B, class F and across subgroups of class A, all 
ligands have been observed to bind in a extracellular pocket of the TM domain, however they 
have access to different depths within this pocket [22]. Most of the residues in contact with 
the ligand are present in the TM regions (Fig 3), except for ligands of some receptors (e.g. 
chemochine receptor 4, CXCR4; neurotensin receptor 1, NTSR1; adenosine A2A receptor; 
smoothened receptor, SMO) in which the extracellular domains are involved as well. An 
unexpected exception is represented by a class B receptor, corticotropin-releasing hormone 
receptor 1 (CRF1), in which the small antagonist CP-376395 was found in an allosteric 
pocket close to the intracellular boundary, the deepest binding site discovered in GPCRs to 
date [22]. The ligand binding position provides a potential handle for drug design targeting 
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GPCRs. Finally, the intracellular region binds the cytosolic signalling proteins, such as G 
proteins, GPCR kinases and arrestins [3].  
These multiple crystal structures provide unprecedented insights into the structural diversity 
of the GPCR family. This knowledge combined with the biochemical, biophysical and 
computational studies gives us the molecular basis to understand the relationship between 
GPCR structure and function [3].  
 
 
Figure 3. Position of ligand binding sites in GPCRs of solved structure. The structures include a 
selected set of class A, B and F receptor-ligand complexes which were superimposed and the ligand is 
shown to represent the location of the ligand binding site. The TMD4 from bovine rhodopsin (PDB ID 
1HZX) is shown as a reference on the left side, with the Cα-carbon of the highly conserved W4.50 
(Ballesteros-Weinstein numbering [23]) displayed as a black sphere. Peptide-ligands are marked with 
an asterisk. [22] 
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This research project focuses on the characterization of different GPCRs covering structural 
and functional aspects.  
• The first part contains a structural study of adenosine A2A and A2B receptor subtypes, 
in particular regarding the role of their extracellular loops for receptor function and 
with regard to subtype diversity. Furthermore, the extracellular disulfide bond network 
of the A2A adenosine receptor has been studied to obtain insight into the structural 
differences involved in receptor subtype selectivity. 
• In the second part an uncommon intracellular GPCR, GPR143, associated with a 
particular type of albinism is investigated. The signalling pathway and the function of 
this receptor in patho-physiological conditions are still unknown. Thus, this study 
focuses on the investigation of a much needed pharmacological tool to analyze 
GPR143 function and on the identification of potential interaction partners.  
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2. Characterization of adenosine A2A and A2B receptor subtypes 
2.1 Purinergic receptors 
After the release in the extracellular environment, adenosine 5’-triphosphate (ATP) and other 
nucleotides are subjected to enzymatic degradation by ectonucleotidases, which is important 
because ATP metabolites are physiological ligands for the different purinergic receptors (Fig 
4). The ectonucleotidase family includes the E-NTPDase (ectonucleoside triphosphate 
diphosphohydrolases) and the E-NPPs (ectonucleotide pyrophosphatase and/or 
phosphodiesterases) which hydrolyze ATP and ADP to AMP, while ecto-5’-nucleotidase 
hydrolyzes AMP to adenosine [24].  
 
Figure 4. Schematic representation of the elements involved in purinergic signaling. The 
ATP/ADP/AMP present in the extracellular environment can bind to P2X and P2Y receptors. E-
NTDPases (1 and 2 in the right panel) promote the hydrolysis of ATP to ADP or from ADP to AMP. 
AMP is further hydrolyzed by ecto-5’-nucleotidase (3 in the right panel) to adenosine, which activates 
adenosine receptors [25] . 
 
Purinergic receptors are divided into two groups: P1 or adenosine receptors (ARs) activated 
by adenosine and P2 receptors for ATP/ADP [26]. P2 receptors are subdivided into ionotropic 
P2X and metabotropic P2Y receptors. P2X receptors are ligand gated ion channels which 
form trimeric structures using individual subunits (P2X1-7). On the other hand, P2Y receptors 
are GPCRs with eight subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11-14). Purinoceptors might be 
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the most abundant receptors in mammalian tissues thus, they can be found in all types of cells 
including those of neural origin [24,26].  
Recently, a third family of purinergic receptors has been characterized as GPCRs activated by 
adenine, adenine receptors, for which the classification as “P0 receptors” has been suggested 
[27].  
 
2.2 Adenosine receptors 
Adenosine receptors (ARs) belong to the rhodopsin-like (class A) family of GPCRs and are 
divided into four subtypes: A1, A2A, A2B and A3. They are ubiquitously expressed in the 
human body and respond to the same endogenous ligand, adenosine, however they activate 
different intracellular signalling pathways (Table 1) [26]. A1 and A3 receptors are coupled to 
Gi proteins thereby inhibiting adenylate cyclase and decreasing the intracellular cAMP level. 
A2A and A2B receptors are coupled to Gs proteins mediating an increase in intracellular cAMP 
through adenylate cyclase activation [28]. For the A2BAR Gq coupling has also been shown 
[29]. The latter two subtypes share an higher sequence identity of 59%, while the human A1 
and A3ARs only show an identity of 49%.  
ARs are promising therapeutical drug targets due to their involvement in a wide range of 
conditions and diseases [30]. The A2AAR subtype plays a role in anti-inflammatory and 
immunosuppressive effects [31]. A2AAR antagonists are candidates for the treatment of 
Parkinson’s and Alzheimer’s diseases as well as for the treatment of addiction and depression 
[32,33]. Recently, pharmaceutical companies have been investing in the development of 
A2AAR antagonists in combination with antibodies blocking inhibitory receptors, such as PD-
1 and CTLA-4, for an improved immunochemotherapy [32]. On the other hand, the 
involvement of the A2BAR subtype is being evaluated for asthma, bronchial inflammation, 
cancer, diabetes, neuroinflammation and Alzheimer’s diseases [33–37]. Partial agonists A1-
selective have been evaluated for the treatment of tachycardia, atrial fibrillation, type II 
diabetes and neuropathic pain while various A1AR antagonists have been explored for 
improving renal function and for the treatment of heart failure [30]. A3AR agonists have been 
tested for treatment of autoimmune inflammatory disorders, liver cancer, rheumatoid arthritis, 
psoriasis and they seemed to have also cardioprotective effects while A3AR antagonists are 
being studied to cure glaucoma [30].  
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Table 1. Important signaling pathways, selective agonists and body distribution of the human 
adenosine receptor subtypes [38].  
 A1AR A2AAR A2BAR A3AR 
G protein Gi / Go Gs / Golf Gs / Gq/11 Gi / Gq/11 
Affinity for 
adenosine – Ki 
[30] 
ca. 100 nM 310 nM 15 000 nM 290 nM 
Selective 
agonists CPA, CCPA CGS21680 BAY60-6583 Cl-IB-MECA 
High expressing 
tissues 
Brain (cortex, 
cerebellum, 
hippocampus), 
dorsal horn of 
spinal cord, eye, 
adrenal gland, 
atria 
Spleen, thymus, 
leukocytes, blood 
platelets, 
striatopallidal 
GABAergic 
neurons, olfactory 
bulb 
Cecum, colon, 
bladder 
Testis (rat), 
mast cells (rat) 
 
2.3 Cristallographic structures and structural insight 
Despite the high sequence identity between A2BAR and its close homolog the A2AAR, the 
endogenous ligand, adenosine (Fig 5, 1), and its derivatives, NECA (2) and CGS21680 (3), 
show higher affinity for A2AAR. The structural reason for this distinction is unknown. The 
functional knowledge about the A2BAR is increasing in the last years, mostly due to 
mutagenesis studies [39–48], but a clear view about the structure of this receptor is still 
missing.  
 
Figure 5. Selected adenosine A2A and A2B receptor agonists. 
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The so far available A2AAR X-ray structures reveal different snapshots of the receptor 
conformations in complex with different ligands: the inactive conformation bound to 
ZM241385 (3EML, [49] and 4EIY, [50]), XAC (3REY) and caffeine (3RFM, [51]), then the 
intermediate state (NECA, 2YDV, and adenosine, 2YDO, [52]) and the fully activated 
conformation (UK-432097, 3QAK, [53] and CGS21680, 4UG2 and 4UHR, [54]). The 
published crystal structures are summarized in Table 2. 
 
Table 2. Crystal structures of the adenosine A2A receptor. The ligands co-crystallized with the receptor 
are listed together with the resolution of the solved structure and the authors. The identification code 
corresponding to the structure deposited in Protein Data Bank (PDB ID) is listed as well. 
PDB ID Ligand resolution author 
3EML ZM241385, inverse agonist 2.6 Å Jaakola et al, 2008 
3QAK UK432097, full agonist 2.7 Å Xu et al, 2011 
2YDO Adenosine, full agonist 3.0 Å Lebon et al, 2011 
2YDV NECA, full agonist 2.6 Å Lebon et al, 2011 
3PWH ZM241385, inverse agonist 3.3 Å Doré et al, 2011 
3REY XAC, xanthine amine congener, antagonist 3.31 Å Doré et al, 2011 
3RFM Caffeine, antagonist 3.6 Å Doré et al, 2011 
3VG9 Allosteric inverse-agonist antibody 2.7 Å Hino et al, 2012 
3VGA Allosteric inverse-agonist antibody 3.1 Å Hino et al, 2012 
3UZA 6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine 3.27 Å Congreve et al, 2012 
3UZC 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol 3.34 Å Congreve et al, 2012 
4EIY ZM241385, inverse agonist (Na+ allosteric modulation) 1.8 Å Liu et al, 2012 
4UG2 CGS21680, selective A2A agonist (monoclinic crystal) 2.6 Å Lebon et al, 2015 
4UHR CGS21680, selective A2A agonist (orthorhombic crystal) 2.6 Å Lebon et al, 2015 
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Since there is no A2BAR crystal structure available yet, some of the solved A2A structures 
have been used to construct a homology models of the closely related A2BAR [55,56]. The 
most difficult structural elements to model are the extracellular loops (ECLs) of the receptors 
because of their high flexibility and their great variability in terms of sequence and length. 
Over the last decade, it has been proven that the ECLs, in particular the ECL2, have a critical 
role in receptor activation and ligand binding. In class A GPCRs, the ECL2 is associated with 
ligand selectivity, that would explain their large variety [57]. The EL2 is one of the least 
conserved regions between the A2A and A2B receptor subtypes, showing 34% identity and 
46% similarity [39]. The ECL2 of A2BAR is the longest of all four receptor suptypes (Fig 6) 
and possesses four cysteine residues, only one of which is involved in disulfide bond 
formation [55]. Only in four A2AAR crystal structures (the two intermediate state 2YDV and 
2YDO, the inactive conformation 4EIY and the active structure 4UHR) the ECL2 is 
completely solved, while in the other structures the loop resolution is very low and the models 
lack parts of the ECL regions. This underlines the fact that the loops are highly flexible. The 
solved ECL2 in A2A shows a random coil structure including a short α-helix close to the 
transmembrane domain 5 (TMD5) and an anti-parallel β-sheet with the ECL1, that is mainly 
constrained by the three disulfide bonds between the two ECLs [49,51,57]. 
The ECL2 might contribute to the specificity of ligand binding by directly forming part of the 
binding cavity. Several A2AAR crystal structures show direct interactions of residues in ECL2 
(i.e. Phe1685.29 and Glu1695.30) with the bound ligand in the binding pocket [49,51–54,58], 
which were also proven by mutagenesis studies [59,60]. The binding pocket at the 
extracellular surface is influenced by the ligand structure [54], indeed when small molecules 
(NECA) are bound the entrance of the binding pocket is narrow [52], while it widens 
appreciably with ligands with bulky extensions at the adenosine moiety (UK432097) [53]. 
The ECL2 seems also to be an important element for the subtype selectivity of ligands. Both 
ZM241385- and CGS21680-bound crystal structures of A2A receptor clearly show that the 
long side chain of the two ligands is protruding out of the transmembrane regions creating 
interactions with the ECL2. Some of these interactions can be determinant for the receptor 
subtype specificity [54]. Structure-activity relationship studies have already shown that small 
subtituents in position 2 of the adenosine moiety reduce the A2A selectivity [61].  
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Figure 6. Topology model of the human A2A receptor where its extracellular loop 2 is compared 
to the one of the human A2A receptor. The residues included in the human A2AAR extracellular loop 
2 (ECL2) are highlighted in green, while the residues of the human A2BAR ECL2 are shown in blue. 
The extracellular cysteine residues are represented in red. The extracellular and intracellular loops of 
the human A2AAR are indicated as ECL and ICL, respectively. The structure represents the chimera 
receptor generated in this project: the ECL2 of the human A2AAR was exchanged with the ECL2 of 
the human A2BAR creating the hA2A(ECL2 hA2B) receptor. Image realized with TOPO2 software [62]. 
 
Recently, we investigated the hypothesis of the ECL2 as being critical for ligand recognition 
and receptor activation in ARs [39]. The complete ECL2 of the human A2B receptor was 
exchanged for the corresponding loop in A2AAR subtype generating the A2B(ECL2-A2A) 
mutant. This loop exchange had significant effects on ligand binding and receptor function 
[39]. The A2A-selective agonist CGS21680 was able to activate the A2B(ECL2-A2A) mutant, 
but did not show any activation of the wildtype (wt) A2BAR. Moreover, the maximal effect of 
 16 
all agonists tested in cAMP accumulation assays of the Gs-coupled receptor was significantly 
increased in the loop exchange mutant as compared to the wt receptor. These results showed 
that the ECL2 does not only contribute to ligand selectivity but, in addition, appears to 
stabilize agonist-bound active conformations of the receptor [39].  
Most class A GPCRs contain disulfide bonds in their extracellular domains rigidifying the 
structure. In addition, several mutagenesis studies and X-ray structures [63–66], showed that 
the ECL2 adopts different conformations during the activation mechanism, switching between 
an open and closed state. In a previous study by de Graaf et al. the ECL2 sequences of 365 
human non-olfactory GPCRs were aligned and the number of cysteine residues were analyzed 
[67]. The A2A and A2B AR subtypes were found to have the highest number of cysteine 
residues in the ECL2, three and four, respectively (Fig 7). In most rhodopsine-like GPCRs 
two highly conserved cysteine residues are present in the extracellular surface, forming a 
disulfide bond which has been shown to be essential for receptor structure and activation 
[11,68]. Both A2A and A2B AR subtypes possess two cysteine residues which were found to be 
highly conserved in most class A GPCRs: Cys45.50 in the ECL2 and Cys3.25 located at the 
extracellular end of the transmembrane domain 3 (TMD3) (Ballesteros Weinstein 
nomenclature [23] and ECL nomenclature defined by de Graaf et al [67]).  
Mutagenesis studies have previously shown that in A2BAR the two conserved cysteine 
residues (Cys783.25 in TM3 and Cys17145.50 in ECL2) form a disulfide bond which plays an 
essential role in ligand binding and receptor activation [55]. On the contrary, mutations in the 
other three cysteine residues present in the ECL2 of the A2BAR (Cys154, Cys166 and 
Cys167) slightly affect the receptor activation indicating that the potential disulfide bonds 
formed by those cysteine residues are not critical for the A2BAR function [55].  
On the other hand, crystal structures of the closely related A2AAR as well as a molecular 
modeling study, indicated that four disulfide bonds are formed in that receptor (Fig 7): three 
of them linking the ECL2 with the ECL1 (Cys712.69-Cys15945.43, Cys743.22-Cys14645.30 and 
Cys773.25-Cys16645.50), and the fourth one forming an intra-loop bond in the ECL3 
(Cys2596.61-Cys2626.64) [49,50,52,54,69,70]. A recent mutagenesis study suggested that the 
conserved disulfide bond in A2AAR (Cys773.25-Cys16645.50) is not essential for [3H]CGS21680 
binding and for its plasma membrane expression [70].  
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Figure 7. Cysteine residues and disulfide bonds in the extracellular loop 1 and 2 of the human 
A2A and A2B ARs. The amino acid sequence alignment (a) of ECL1 and 2 of A2A and A2B ARs was 
done using ClustalW. The following cysteine residues in ECL2 of A2AAR are highlighted accordingly 
to the colors of cysteine residue mutants: blue C146A2A, yellow C159A2A, green the conserved 
C166A2A. The other extracellular cysteine residues in A2AAR are highlighted in light grey. In A2BAR 
the essential cysteine residues found by mutagenesis study [55] are indicated in red. The residues 
included in transmembrane domains are shown in italics. The identical amino acid residues (*), the 
conserved amino acid substitutions (:) and the semi-conserved amino acid substitutions (.) are 
indicated. The positions of the cysteine residues are given for the A2A and A2B ARs. (b) The disulfide 
bonds found in the crystal structure of A2AAR  and the predicted disulfide bonds in the A2BAR [55] 
have been assigned to arbitrary numbers (I-III) based on the progressive cysteine residues in ECL1 of 
the human A2AAR. The disulfide bonds are represented in (a).   
 
2.4 Aim of the project 
The project focused on the extracellular loops (ECLs) of GPCRs, as they might be involved in 
ligand binding and receptor activation [57]. In class A GPCRs, including adenosine receptors 
(ARs), the ECL2 is the largest and most diverse of the three ECLs. Its high variety even 
within subfamilies has been associated with ligand selectivity [39,71–74]. Among the four 
AR subtypes, the human A2A and A2B AR are the closest homologs and sequence analysis of 
 18 
the two subtypes revealed the largest differences in the loop regions, especially in the 
extracellular loop 2 (ECL2) [55]. The endogenous ligand adenosine and its derivatives NECA 
and CGS21680 show higher affinity for A2AAR than for A2B subtype, despite very similar 
ligand binding sites. The structural reason for this striking difference is still unknown.  
Recently, the complete ECL2 of the human A2BAR was exchanged for the corresponding loop 
of the A2AAR subtype (resulting in the mutant receptor A2B(ECL2-A2A)) and this led to 
significant effects on ligand binding and receptor function. The results showed that the ECL2 
does not only contribute to ligand selectivity but, in addition, can stabilize agonist-bound 
active conformations of the receptor [39].  
The aim of the first part of this study was to investigate the complementary chimera of the 
human A2AAR, in which the ECL2 was exchanged for that of the human A2BAR (resulting in 
A2A(ECL2-A2B)), in order to clarify the role of the ECL2 in the two AR subtypes. Several AR 
agonists were tested in functional assay and their binding to the wildtype and the chimera 
receptors was evaluated with radioligand binding experiments.  
The second part of the study concerns the investigation of the role of extracellular cysteine 
residues of the human A2AAR in the ligand binding and receptor activation using various 
agonists including the endogenous ligand adenosine.  
Recently, a mutagenesis study was published in which extracellular cysteine residues of the 
A2AAR were mutated to alanine [70]. The authors suggested that the formation of the 
conserved disulfide bond Cys77-Cys166 was not essential for receptor localization at the cell 
surface and for ligand binding [70]. Their investigation was based on ligand binding utilizing 
a single adenosine derivative, CGS21680, but functional data of the cysteine mutant receptors 
were not included. Here, we present a comprehensive study on the role of extracellular 
disulfide bonds in A2AAR. We generated three A2AAR mutants replacing each cysteine 
residue present in the ECL2 (Cys14645.30, Cys15945.43 and Cys16645.50) by serine, sterically 
and electronically similar amino acids, thereby disrupting one of the potential single disulfide 
bonds in each mutant receptor. In addition, considering the high homology to the closely 
related A2BAR subtype, we created an A2AAR double mutant exchanging the two cysteine 
residues in ECL2 (Cys14645.30 and Cys15945.43) which were supposed to be involved in 
disulfide bonds with the ECL1, thereby disrupting two potential disulfide bonds in a single 
mutant receptor. Finally, the results obtained experimentally by testing the ligands on 
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functional assays and binding studies were supported by molecular modeling based on 
recently published crystal structures.  
The work shown in the following result sections is included in two manuscripts: 
- De Filippo E., El-Tayeb A., Schiedel A.C. and Müller C.E. (in preparation). 
Characterization of the extracellular loop 2 of adenosine A2A and A2B receptors. 
- De Filippo E., Namasivayam V., Zappe L., El-Tayeb A., Schiedel A.C. and 
Müller C.E. (in preparation). Role of extracellular cysteine residues in the 
adenosine A2A receptor. 
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2.5 Part I: the human adenosine A2A(ECL2 A2B) chimera 
2.5.1 Generation and characterization of the loop exchange mutant  
The complete extracellular loop 2 (ECL2) of the human A2A receptor was exchanged to the 
corresponding one of the human A2B receptor using the Gibson Assembly method [75], 
obtaining the hA2A(ECL2 hA2B) mutant receptor. Chinese Hamster Ovary (CHO) cells were 
stably transfected either with the loop mutant, the wildtype (wt) hA2A or the wt hA2BAR. To 
compare the loop mutant with the wt receptors, the cell surface expression was quantified by 
ELISA. Therefore, the human influenza hemagglutinin (HA) tag was linked to the N terminus 
of the coding sequence of each gene, which had already been shown not to interfere with the 
ligand binding and function of other GPCRs [55,76]. The surface expression level of the wt 
hA2A receptor was set as 100% while untransfected CHO cells were used as 0% (Fig 8 and 
values are listed in Table 3). The cell surface expression level of the three receptors was 
similar and not significantly different from each other.  
 
Figure 8. Cell surface expression levels of the human A2AAR, the human A2BAR and the 
hA2A(ECL2 hA2B) receptor determined by ELISA. Values were normalized to the untransfected 
CHO cells, set as 0%, and to the hA2AAR, set as 100%. Data represent the mean values ± SEM of 
three (hA2BAR), four (hA2AAR) or five (hA2A(ECL2 hA2B) independent experiments performed in 
triplicates. Two-tailed t-test was performed comparing the hA2AAR with the hA2BAR and the 
hA2A(ECL2 hA2B): both comparisons were not significantly different (ns) from the hA2AAR (p = 0.507 
and p = 0.250, respectively). 
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The wt hA2A receptor and the hA2A (ECL2 hA2B) receptor were then analyzed with 
homologous competition binding using the A2A agonist radioligand [3H]CGS21680, obtaining 
KD values, indicating the affinity of the compound for the receptors, and Bmax values, the 
maximal number of receptor binding sites (Table 3). The affinity of the mutant receptor for 
the A2A selective agonist CGS21680 (3, Fig 5) was 3-fold decreased in comparison to the wt 
hA2AAR. The Bmax ratio between the mutant and the wt hA2A receptor was in agreement with 
the percentage of the cell surface expression determined by ELISA.  
 
Table 3. Expression levels (Bmax) and KD values of the hA2AAR and the hA2A(ECL2 hA2B) receptor 
determined by homologous competition binding versus [3H]CGS21680. The cell surface expression 
levels determined by ELISA are shown for comparison. Data represent mean ± SEM of three 
independent experiments, unless otherwise noted.  
receptor Bmax ± SEM 
(fmol/mg of protein) 
KD ± SEM (nM) ELISA 
% expression level 
hA2AAR 480 ± 110 72.1 ± 18.0 100 ± 16 
hA2A(ECL2 hA2B) 799 ± 126 ns, p = 0.179 194 ± 29 ns, p = 0.056 117 ± 31 a, ns 
Results of two-tailed t-test: ns not significantly different from the wildtype human A2AAR. 
a n = 5. 
 
 
2.5.2 Radioligand binding studies 
Competition radioligand binding studies were performed to characterize the loop exchange 
testing different A2A and A2B agonists: the endogenous ligand adenosine (1, Fig 5), the analog 
NECA (2), the A2A selective agonist CGS21680 (3), the A2B selective partial agonist BAY60-
6583 (4) and a bulky 2-substituted adenosine derivative PSB-15826 (5). For binding assays 
membrane preparations of cells stably expressing either the wt or the mutant receptor were 
used. Adenosine deaminase was added for all tested compounds, except for adenosine, 
therefore the values obtained for this particular compound are an underestimation of its real 
affinity for the binding site of the receptor.   
As first, the A2A agonist [3H]CGS21680 was used as radioligand for binding assays. 
Adenosine lost affinity (22-fold) at the loop mutant in comparison to the wt hA2AAR (Fig 9 A, 
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Table 4), while the analog NECA displayed similar affinity for both receptors (Fig 9 B). The 
compounds with a long substituent in position 2 of adenosine show a large loss in affinity at 
the chimeric mutant in comparison to the wt A2A receptor (Fig 9 C-D). The partial A2B agonist 
BAY60-6583 has no affinity to both wt hA2AAR and loop mutant (data not shown).  
 
 
Figure 9. Competition binding studies at the human A2AAR and at the human A2A(ECL2 hA2B) 
receptor versus [3H]CGS21680 (5 nM) using (A) adenosine, (B) NECA, (C) CGS21680 and (D) 
PSB-15826. Membrane preparations from CHO cells stably expressing the receptors were used. Data 
points represent means ± SEM of three independent experiments performed in duplicates. Ki values 
are listed in Table 4. 
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The results obtained with the opposite loop exchange mutant, hA2B(ECL2 hA2A), suggested 
that the ECL2 has a role in the conformation changes in A2A and A2B sutypes [39]. For this 
reason an A2A antagonist radioligand, [3H]MSX-2, was also tested in binding assays versus 
cold agonists. Antagonists have virtually equal affinity for active and inactive state of the 
receptors, while agonists have higher affinity for the active state. The inhibition binding 
curves (Fig 10) show a biphasic behavior, which is more evident in the hA2A(ECL2 hA2B) 
mutant than the wt hA2AAR. Two conformational states are labeled by the antagonist 
radioligand [3H]MSX-2, the active state at lower agonist concentrations and the inactive one 
at a higher concentration range. The difference between the two conformational states is 
larger in the loop mutant than in the wt hA2AAR. NECA and CGS21680 showed an increase 
in affinity at the active state of the loop mutant in comparison with the wt hA2AAR (Fig 10 A-
B, IC50 values in Table 4), while the bulky 2-substituted PSB-15826 (Fig 10 C, Table 4) 
displayed a decreased affinity at the active state than the wt hA2AAR. The percentage of the 
two conformational species for NECA and CGS21680 are similar in the loop mutant and in 
the wt hA2AAR, where the active state represents the most prevalent receptor state. In PSB-
15826 the opposite situation is noticeable, the higher percentage is represented by the inactive 
state of the receptors. The A2B partial agonist BAY60-6583 seems to modulate [3H]MSX-2 
binding at the loop mutant (Fig 10 D), this compound showed a significant increase in affinity 
in comparison to the wt hA2AAR.  
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Figure 10. Competition binding studies at the human A2AAR and at the hA2A(ECL2 hA2B) 
receptor versus [3H]MSX-2 (1 nM) using (A) NECA, (B) CGS21680, (C) PSB-15826 and (D) 
BAY60-6583. Membrane preparations from CHO cells stably expressing the receptor were used. Data 
points represent means ± SEM of three indipendent experiments performed in duplicates. The arrows 
located at the graph side correspond to the two different conformational states of the receptor (black: 
hA2AAR and red: hA2A(ECL2 hA2B) receptor). Two-tailed t-test was performed for each data point in 
graph D: ns not significantly different from the hA2AAR, * p < 0.05, **p < 0.01, ***p < 0.001. 
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Table 4. Affinities of A2A agonists and A2B partial agonist at the human A2AAR and the hA2A(ECL2 
hA2B) receptors defined by radioligand binding studies versus [3H]CGS21680 (5 nM) or [3H]MSX-2 (1 
nM). “Low” refers to the IC50 value of the biphasic curve at the lower agonist concentration, while 
“high” refers to the one at higher agonist concentration. Data represent mean ± SEM of three 
independent experiments, unless otherwise noted.  
Ki values ± SEM (nM) – [3H]CGS21680 
receptor adenosine NECA CGS21680 PSB-15826 
A2AAR 437 ± 15 a 37.3 ± 5.9 72.6 ± 16.3  33.2 ± 3.7 
A2A(ECL2 A2B) 9540 ± 550 a, *** 24.7 ± 6.0 ns, p=0.379 204 ± 45 ns, p=0.119 384 ± 26 ** 
IC50 values ± SEM (nM) – [3H]MSX-2 
receptor NECA CGS21680 PSB-15826 BAY60-
6583 
 low high low high low high  
A2AAR 118 ± 6 7870 ± 276 458±239 >10 000 8.28 ± 0.12 357 ± 164 n.d. 
A2A(ECL2 hA2B) 33 ± 1.5*** >10 000 42.1±3.3ns >10 000 175 ± 97ns >10 000 39.0 ± 13.9 
Results of two-tailed t-test: ns not significantly different from wildtype human A2AAR, ** p<0.01, *** 
p<0.001.  
n.d., not determined. The IC50 value could not be determined since BAY60-6583 has no affinity for 
the hA2AAR. 
a the affinity of adenosine for the receptors is underestimated because adenosine deaminase could not 
be used in the assay. 
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2.5.3 Functional studies 
cAMP accumulation assays induced by A2A agonists (1-3 and 5) and an A2B partial agonist (4) 
were performed to investigate the activation of the wt hA2AAR and hA2BAR in comparison to 
the hA2A(ECL2 hA2B) mutant receptor.  
As expected, adenosine was more potent at the hA2AAR as compared to the hA2BAR (Fig 11 
A, EC50: 170 ± 29 nM and 12 000 ± 670 nM, respectively; see Table 5) showing similar 
efficacy at both wt receptors. Adenosine lost 70-fold potency at the loop mutant in 
comparison to the wt hA2AAR, achieving similar A2B potency (mutant EC50: 15 300 ± 6130 
nM, Table 5).  
The non-selective adenosine derivative NECA was 10-fold more potent at the A2AAR than the 
A2BAR and no significant differences were noted neither in potency nor efficacy between the 
wt hA2AAR and the loop mutant (Fig 11 B and values in Table 4).  
The A2A selective nucleosidic agonist CGS21680 (Fig 11 C) is active at A2BAR only at high 
concentrations (>10 000 nM), while it showed similar potency and efficacy at the wt hA2AAR 
(EC50 16.6 ± 0.9 nM, efficacy 49 ± 2%) and the loop mutant (EC50 27.1 ± 11.3 nM, efficacy 
64 ± 6%).  
The bulky substituted adenosine derivative PSB-15826 (Fig 11 D) is inactive at the wt 
hA2BAR and showed similar potency at the wt hA2AAR and at the loop mutant (EC50 53.5 ± 
17.9 nM and 65.7 ± 6.2 nM, respectively). PSB-15826 displayed a significant decrease in 
efficacy at the loop mutant in comparison to the wt hA2AAR (84 ± 4% and 58 ± 2%, 
respectively).  
The A2B partial agonist BAY60-6583 (Fig 12 A, Table 5) showed no activity at the wt 
hA2AAR and a potency of 195 ± 40 nM at the wt hA2BAR. On the other hand, BAY60-6583 at 
the loop mutant displayed a small reduction in cAMP accumulation, considering that the loop 
mutant showed a slight basal activity. To analyze the hypothetical function of BAY60-6583 
as antagonist at the loop mutant receptor, a cAMP assay with BAY60-6583 preincubation (10 
µM) and then agonist stimulation (adenosine or NECA, Fig 12 inset) was performed. BAY60-
6583 has no inhibitory function at the loop mutant receptor, since no reduction in cAMP 
production was observed.  
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Figure 11. Agonist-induced cAMP accumulation studies at CHO cells stably expressing the 
human A2AAR, the human A2BAR and the mutant hA2A(ECL2 hA2B) AR using (A) adenosine, (B) 
NECA, (C) CGS21680 or (D) PSB-15826 as agonist. Data represent mean ± SEM from three to five 
independent experiments performed in duplicates. Data are normalized to the effect of 100 µM 
forskolin, set as 100%. Corresponding EC50 and maximal effects are listed in Table 5. 
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Figure 12. cAMP accumulation studies at CHO cells stably expressing the human A2AAR, the 
human A2BAR and the mutant hA2A(ECL2 hA2B) receptor using a partial A2B selective agonist, 
BAY60-6583. The agonist-induced cAMP production was normalized to the effect of 100 µM 
forskolin (set as 100%) and a two-tailed t-test was performed comparing point by point the effect of 
the hA2AAR and the mutant hA2A(ECL2 hA2B) receptor (ns not significantly different from the 
hA2AAR). In the inset, comparison of the cAMP inhibition induced by BAY60-6583 (10 µM) at the 
loop mutant before treatment with adenosine and NECA. Data are normalized to the effect of the EC80 
of the agonist (adenosine or NECA), set as 0%. 
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Table 5. EC50 values and maximal effects of selected agonists determined in cAMP accumulation 
assays at the human A2AAR, the human A2BAR and the mutant hA2A(ECL2 hA2B) receptors. Data are 
normalized to the effect of forskolin (100 µM), set as 100%. Data are mean ± SEM of three to five 
independent experiments.  
agonist human A2A  human A2B human A2A(ECL2 A2B) 
 EC50 ± SEM 
(nM) 
Efficacy ± 
SEM (%) 
EC50 ± SEM (nM) Efficacy ± 
SEM (%) 
EC50 ± SEM (nM) Efficacy ± 
SEM (%) 
Adenosine 170 ± 29 44 ± 2 12,000 ± 670 *** 40 ± 6 ns 15,300 ± 6130*** 68 ± 8 ** 
NECA 10.5 ± 0.8 52 ± 2 109 ± 37 ** 51 ± 4 ns 7.21 ± 0.89 ns 59 ± 4 ns 
CGS21680 16.6 ± 0.9 49 ± 2 31,100 ± 7130*** 28 ± 7 * 27.1 ± 11.3 ns 64 ± 6 ns 
PSB-15826 53.5 ± 17.9 84 ± 4 > 100,000 b  n.d. 65.7 ± 6.2 ns 58 ± 2 ** 
BAY60-6583 > 100,000 b n.d.  195 ± 40 34 ± 3  22.9 ± 18.6 a - 9 ± 4 ns  
n.d., not determined. 
a IC50 value ± SEM. 
b no EC50 value could be determined since the agonist is inactive at the receptor. 
Results of two-tailed t-test: ns not significantly different from wildtype human A2AAR, * p < 0.05, 
** p<0.01, *** p<0.001.  
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2.5.4 Discussion  
Adenosine receptors (ARs) belong to the rhodopsin-like family (class A) of G protein-coupled 
receptors (GPCRs) and are among the most important pharmacological targets for drug 
development due to their involvement in most of the physiological and pathophysiological 
pathways [30]. Despite the increasing number of solved GPCR crystal structures, several 
aspects of the ligand-receptor modulation are unclear. Three-dimensional models based on the 
several A2A crystal structures and ligand docking studies showed that, among the four AR 
subtypes, A2A and A2BARs have the highest sequence conservation (identity of 59%), 
especially in the helices involving the binding pocket [55,77]. However, their response to the 
endogenous ligand, adenosine (1, Fig 5), and its nucleosidic derivatives considerably differ, 
these compounds have an higher affinity for the A2A subtype than for the A2BAR. The 
explanation of this discrepancy is still unknown but the investigation is in progress. In the last 
decade, it has become clear that not only the most conserved transmembrane domains 
(TMDs) but also the extracellular loops (ECLs) have important roles in receptor activation. 
The ECLs, in particular the ECL2, show low sequence homology even within GPCRs of the 
same subfamily, therefore this diversity might be one of the explanations of the receptor 
subtype specificity [57].  
Recently we generated a mutant receptor exchanging the ECL2 of the human A2BAR for the 
one of the human A2AAR [39]. We showed with radioligand binding and functional studies 
that the ECL2 in A2A and A2B subtypes contributes to ligand affinity and selectivity. The 
A2BAR is not activated by the A2A selective agonist CGS21680 while the loop mutant, 
containing the A2AAR ECL2, gains affinity for this compound. Functional experiments 
confirmed the increased activity of CGS21680 at the loop mutant as well. In addition we 
noticed that the ECL2 exchange also led to the stabilization of the receptor’s active 
conformation, since the maximal effect of all agonists was dramatically increased in the loop 
mutant as compared to the wt receptors.  
In order to have a comprehensive overview about the ECL2 in A2A and A2BAR subtypes, we 
exchanged the whole ECL2 of the human A2AAR to the one of the human A2BAR, obtaining 
the opposite chimera, the hA2A(ECL2 hA2B) receptor. CHO cells were stably transfected with 
either the wt hA2AAR, the wt hA2BAR or the loop mutant, using retroviral transfection. The 
expression level of the receptors was determined with ELISA, detecting the receptor 
population at the cell surface, and with homologous binding experiments, estimating the 
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number of receptor binding sites in the membrane preparation. The loop mutant receptor 
appears to be efficiently transported to the cell surface since the values obtained from the 
ELISA and the homologous binding were similar. The expression level of the loop mutant and 
the wt hA2BAR were similar and not significantly different to the wt hA2AAR, therefore the 
data obtained from the three cell lines were comparable to each other.  
Since previous studies suggested that the ECL2 is involved in the stabilization of certain 
receptor conformations [39,66], binding studies were performed with the A2A agonist, 
[3H]CGS21680, which label only the active state of the receptor, as well as with the 
antagonist, [3H]MSX-2, thus labeling both the active and inactive receptor population.  
The Ki values of the tested agonists determined in binding assay versus [3H]CGS21680 were 
in the expected rank-order of affinity for A2AAR but slighly higher than previously reported 
[30]. Former studies defined different reasons for these results. Firstly, this outcome depends 
on the low level of Gαs proteins present in mammalian cells relative to the overexpressed 
A2AAR, so only a low percentage of receptors couples to the G protein, resulting in the active 
state [78]. It was also demonstrated that the composition of the Gβ subunit changes the 
coupling ability of receptors to Gs proteins [79]. Our experimental conditions reflect the 
overexpression system, indeed the obtained Bmax values indicate that both wt A2AAR and the 
loop exchange mutant are higher expressed in CHO cells than in native tissues (Bmax: 480 ± 
110 and 799 ± 126 fmol/mg of protein for the wt A2AAR and the loop mutant, respectively) 
[80]. Therefore, the high Ki values obtained with [3H]CGS21680 are caused by the inability of 
a certain percentage of receptor to switch to the high-affinity agonist conformation.  
Using [3H]CGS21680, we found that compounds with a long substituent in position 2 of 
adenosine (CGS21680 and PSB-15826) showed a 3-fold and 12-fold loss in affinity at the 
loop mutant in comparison to the wt A2A receptor, respectively. Previous studies showed that 
long substituents in position 2 of adenosine lead to A2A selectivity [61], therefore we could 
confirm that the A2A ECL2 is involved in binding the long 2-substituent, as the recent A2AAR 
crystal structures demonstrated [54]. ECL2 also contributes to A2A selectivity of 2-substituted 
adenosine derivatives, like CGS21680 and PSB-15826. On the other hand, a 22-fold loss in 
affinity of adenosine was detected in comparison with the wt hA2AAR, while no significant 
changes were noticed for the structurally similar adenosine analog, NECA. An hypothesis 
might involve the meta-binding site found in the ECL2 of the human A2AAR by Moro et al. 
[81]. Since in the chimeric receptor the A2B ECL2 was present, adenosine might show less 
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affinity to the putative meta-binding site present in the ECL2. However, the ECL2 
replacement might have changed the conformation of the orthosteric binding site thereby 
reducing the interactions with adenosine. The differences found between adenosine and 
NECA might be due to the N-ethylcarboxamido group present in NECA which contributes to 
the stabilization of the ligand-receptor complex by additional interaction with the A2AAR.  
Binding studies versus the A2A antagonist [3H]MSX-2 were performed to analyze the 
involvement of the ECL2 in conformational changes. A biphasic behaviour describing the 
active and inactive receptor species was more marked in the hA2A(ECL2 hA2B) mutant than 
the wt hA2AAR. The ECL2 exchange seems to stabilize the active conformation of the 
receptor for compounds such as NECA and CGS21680, maybe the introduction of the A2B 
ECL2 has changed the twists of the transmembrane domains, promoting the active 
conformation. The same effect was not visible for the bulky 2-substituted PSB-15826, maybe 
because of different interactions with the ECL2. By comparing the active and inactive 
populations of receptors bound to different agonists, it was noticed that the longer the 
substituent in position 2 of adenosine the smaller the percentage of receptor in the active state 
(29% for PSB-15826, 58% for CGS21680 and 79% for NECA; Fig 10). The same tendency is 
observed at the loop mutant receptor.  
Functional studies highlighted the dramatic loss in potency (70-fold) for adenosine at the 
mutant receptor in comparison with the wt A2AAR, becoming similar to the wt A2BAR 
potency. This finding is consistent with the loss in affinity (22-fold) observed in binding 
studies. These results suggest that the ECL2 is important for the endogenous ligand 
recognition and for the subtype selectivity as well. The putative meta-binding site present in 
the A2A ECL2 might be lost in the loop exchange mutant.  
The other ligands (NECA, CGS21680 and PSB-15826) showed only little changes in potency 
at the loop mutant receptor if compared to the wt hA2AAR. A reduction in the maximal effect 
of PSB-15826 at the loop mutant is visible, probably due to lost interactions with the A2A 
ECL2 and the flexibility of the A2B ECL2. The A2A loop exchange did not influence neither 
the potency or the efficacy of the A2A agonists as much as the opposite chimera, hA2B(ECL2 
hA2A), showed in the previous study [39]. An hypothesis could be that the interactions formed 
between the agonists and the A2A ECL2 were replaced by similar residues present in the A2B 
ECL2. Some A2AAR crystal structures showed interaction with residues present in ECL2. 
Some of those residues are also present in the A2B ECL2 in similar positions, for example the 
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role of Glu169ECL2 of A2AAR could be replaced by Glu174ECL2 in A2BAR, since both residues 
are close to the TM5 and to the ECL3, and the role of Phe168ECL2 of A2A could be replaced by 
Phe173ECL2 in A2BAR. 
Since we were testing the ability of ECLs to recognize subtype-selective ligands, the partial 
A2BAR agonist BAY60-6583 was tested at the loop mutant as well. This compound slightly 
modulates the binding affinity of the A2A antagonist [3H]MSX-2 (30% of competitive 
replacement) but no competition is detected versus the A2A agonist [3H]CGS21680. 
Functional studies showed that the reduction of the loop mutant receptor’s basal activity 
induced by BAY60-6583 is not significant and the compound has no antagonistic activity 
against adenosine or NECA.  
In conclusion, we found that the ECL2 in A2A and A2B receptor is involved in subtype 
selectivity and ligand recognition. Adenosine lost affinity and potency at the loop mutant as 
compared to the wt A2AAR,  indicating that the ECL2 has a role in the binding of endogenous 
agonist and in the activation of the receptor. The presence of a putative meta-binding site in 
the ECL2 of the A2AAR could explain the lost in affinity displayed by adenosine at the loop 
mutant containing the A2BAR ECL2. Furthermore, the loop mutant receptor lost affinity for 
CGS21680 and PSB-15826 which are characterized by a long acidic 2-substituted group at the 
adenosine molecule. This confirms that the A2AAR ECL2 is involved in binding of the long 2-
substituent of adenosine derivatives as suggested previously [54,61].  
In addition, we verified that the ECL2 of the A2A and A2B AR is associated with 
conformational changes. In the A2B(ECL2 A2A) mutant, the loop exchange stabilized the 
active conformation increasing the efficacy of the AR agonists as compared to wt human 
A2BAR [39]. In the A2A(ECL2 A2B) mutant, the binding experiments with the A2A antagonist 
[3H]MSX-2 showed that the loop exchange stabilized the active conformation at NECA and 
CGS21680 as compared to the wt A2AAR. This stabilization might compensate the loss of the 
structured A2AAR ECL2 containing the meta-binding site and resulting in similar efficacies 
for those AR agonists as the wt A2AAR. The conformational stabilization was not observed 
for PSB-15826 which lost affinity at the active state of the loop mutant and its efficacy 
decreased in comparison to the wt A2AAR.  
These findings were in agreement with former studies indicating that the ECL2 is involved in 
conformational changes in several GPCRs, such as the ECL2 of the complement factor 5a 
(C5a) receptor was found to stabilizes its inactive conformation [66], in angiotensin II (Ang 
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II) type 1 receptor (AT1R) ECL2 is an important regulator of the functional states [82] and in 
the muscarinic M3 receptor the ECL2 stabilize its active conformation [83].  
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2.6 Part II: the cysteine mutant adenosine A2A receptors 
2.6.1 Potential role of disulfide bonds in the adenosine A2A receptor 
The relevance of disulfide bond formation for the function of the A2AAR was experimentally 
observed by treating A2A-expressing CHO cells with a reducing agent, dithiothreitol (DTT), 
followed by agonist-induced cAMP accumulation assay. As shown in Fig 13, reducing of the 
disulfide bonds accessible to DTT caused a rightward shift of the dose-response curves 
obtained by NECA or CGS21680 stimulation, respectively, in comparison with untreated 
cells. NECA-induced cAMP production was more affected than the CGS21680-induced 
accumulation. After DTT treatment, the NECA potency at the A2AAR was 100-fold lower 
(EC50 values: 6.81 ± 1.27 nM vs. 606 ± 12 nM) and the potency of CGS21680 was reduced by 
6-fold (EC50 values: 22.6 ± 3.6 nM vs. 119 ± 6 nM). 
 
Figure 13. Effect of DTT on the human A2AAR activity. cAMP accumulation induced by NECA (a) 
or CGS21680 (b) in CHO cells stably expressing the human A2AAR in presence and absence of DTT 
pretreatment (10 mM, 2 h, 37 °C). Data represent mean + SEM of two independent experiments 
performed in duplicates. Determined EC50 values for NECA: A2A without DTT: 6.81 + 1.27 nM; A2A 
with DTT: 606 + 12 nM***. EC50 values for CGS21680: A2A without DTT: 22.6 + 3.6 nM; A2A with 
DTT: 119 + 6 nM**. (Two-tailed t-test: ** p < 0.01 and *** p < 0.001). 
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2.6.2 Generation and characterization of mutant cell lines 
Since the initial DTT experiments suggested that disulfide bonds play an important role in 
A2AAR function, the next step was to generate A2A mutant receptors by site-directed 
mutagenesis, exchanging a single cysteine residue present in the ECL2 (C146, C159, or 
C166) for a serine residue. This led to the disruption of a single disulfide bond between ECL1 
and ECL2 in each cysteine mutant (C146S, C159S and C166S), see Fig 7. A forth A2A 
receptor mutant was generated by replacing both cysteine residues, that are not conserved in 
class A GPCRs, in the ECL2 (C146S-C159S) thereby disrupting two disulfide bonds at the 
same time.  
After the CHO cell lines that stably express the cysteine A2A mutant receptors had been 
established, their cell surface expression was compared to that of the wildtype (wt) A2AAR by 
enzyme-linked immunosorbent assay (ELISA; see Table 6). For this purpose, each receptor 
had been linked at the N terminus to an HA-tag, which had previously been shown not to 
interfere with receptor function or ligand binding [55,84]. In addition, cysteine mutant 
receptors were analyzed by homologous competition binding using CGS21680 versus the 
agonist radioligand [3H]CGS21680 and calculating Bmax and KD values (Table 6). Differently 
from the ELISA which was performed with intact cells to detect only the receptor surface 
expression, this method was performed with cell membranes thereby quantifying the density 
of receptors present in all membranes, including the intracellular ones. The mutant C159S A2A 
receptor showed a significant gain in affinity (3-fold) for CGS21680 and a higher cell surface 
expression level (227%) than the wt A2AAR (100%). Both, the single mutant C166S and the 
double mutant C146S-C159S receptors, displayed somewhat lower expression levels than the 
wt A2AAR as determined by ELISA (40% and 87% of the wt expression, respectively) and 
homologous binding experiments (48% and 74% of the wt expression, respectively). A 
different radioligand, [3H]NECA (3 nM), was used to determine KD and Bmax values of the 
C146S mutant, because of the narrow window between total binding and non-specific binding 
values obtained with the radioligand [3H]CGS21680. While the cell surface expression of the 
C146S mutant receptor was found to be significantly decreased in comparison to the wt 
A2AAR (23% of the wt expression determined by ELISA), the Bmax value was not 
significantly different from that of the wt receptor.  
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Table 6. Expression levels (Bmax) and KD values of the wt human A2A receptor and the A2A cysteine 
mutants. Data are obtained by homologous binding versus [3H]CGS21680 (5 nM; upper table) and 
[3H]NECA (3 nM; lower table). Data are means ± SEM of three independent experiments, unless 
otherwise noted. ELISA data are shown for comparison between the wt hA2AAR and the mutants.  
[3H]CGS21680 KD ± SEM (nM) Bmax ± SEM  
(fmol/mg of 
protein) 
ELISA (%) 
hA2A wt 127 ± 3 478 ± 70 100 ± 16 
hA2A C146S n.d. n.d. 23.0 ± 6.5 *** 
hA2A C166S 110 ± 4 b, ns  230 ± 38 a, **  40.1 ± 12.4 *** 
hA2A C159S 46.2 ± 6.5 a, ***  421 ± 51 ns 227 ± 4 *** 
hA2A C146S – C159S 124 ± 10 b, ns  352 ± 78 b, ns  87.4 ± 15.2 * 
[3H]NECA 
 
   
hA2A wt 6.33 ± 1.42 129 ± 13 100 ± 16 
hA2A C146S 25.8 ± 5.9 * 152 ± 17 ns 23.0 ± 6.5 *** 
n.d not determined, because of the low expression of the hA2A C146S mutant 
a n = 4 
b n = 5 
ns Not significantly different from wt hA2AAR (determined using the two tailed t-test) 
* p < 0.05 
** p < 0.01 
*** p < 0.001 
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2.6.3 Functional studies 
The function of the cysteine A2A mutant receptors was investigated by agonist-induced cAMP 
accumulation assays (Fig 14) and compared to that of the wt A2AAR as well as the 
homologous A2BAR. Structurally diverse agonists were tested: the endogenous agonist 
adenosine (1, Fig 5), its close analog NECA (2), the 2-substituted acidic agonist CGS21680 
(3), and the 2-substituted uncharged adenosine derivative PSB-15826 (5).  
The response of all cysteine mutant receptors to the endogenous agonist adenosine was 
significantly altered in comparison with the wt A2AAR (EC50 values and efficacies listed in 
Table 7). At three cysteine mutants adenosine displayed significantly reduced potency (22-
fold at C159S, 30-fold at C166S and 253-fold at C146S-C159S) while the C146S mutant 
receptor showed almost no activation by adenosine (maximal effects: 4 ± 1% vs 44 ± 3% of 
forskolin activation).  
Analyzing the receptors’ activation by other agonists, we noticed that the C166S mutant 
receptor showed only minor potency changes for the adenosine derivatives NECA, 
CGS21680 and PSB-15826 compared to the wt A2AAR (Table 7). The C146S mutant receptor 
could be moderately activated by NECA and CGS21680 (efficacies: 20% and 18% vs. 55% 
and 52%, respectively) while it showed no activation by the bulky 2-substituted PSB-15826. 
A gain in potency was found at the C159S mutant receptor for all adenosine derivatives (10-
fold for NECA, 6-fold for CGS21680 and 21-fold for PSB-15826).  
The activity of the double mutant C146S-C159S was more affected by smaller agonists 
(potency loss: 253-fold for adenosine and 87-fold for NECA) than large ones (similar to wt 
A2AAR EC50 values for CGS21680 and PSB-15826, Table 7). 
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Figure 14. Agonist-induced cAMP accumulation studies in CHO cells stably expressing the 
human wt A2AAR, wt A2BAR and A2A cysteine mutant receptors. Cells were stimulated with 
different concentrations of selected A2A agonists: (a) adenosine, (b) NECA, (c) PSB-15826 or (d) 
CGS21680. The disrupted disulfide bond is indicated in brackets. Data are normalized to forskolin 
(100 µM), set as 100%. Data represent mean ± SEM of at least three independent experiments 
performed in duplicates. EC50 values and maximal effects are listed in Table 7. 
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Table 7. EC50 values and efficacies of selected A2A agonists determined in cAMP accumulation assays at the wt hA2AAR, the wt hA2BAR and the A2A cysteine 
mutant receptors. Data are normalized to 100 µM forskolin, set as 100%, and represent mean ± SEM of three independent experiments, unless otherwise noted.  
compounds   hA2A wt hA2B wt hA2A C146S hA2A C166S hA2A C159S hA2A C146S – C159S 
EC50 ± SEM (nM) 170 ± 29 11,900 ± 670 *** n.d. 5110 ± 32 a, *** 3670 ± 719 ** 43,100 ± 8090 a, ** 
adenosine 
Efficacy ± SEM (%) 44 ± 3 40 ± 6 ns 4 ± 1 ** 33 ± 2 ns 38 ± 2 ns 85 ± 8 ** 
EC50 ± SEM (nM) 10.5 ± 0.8 109 ± 37 ** 1.43 ± 0.43 *** 31.4 ± 7.4 a, ns 1.27 ± 0.24 *** 870 ± 107 ** 
NECA 
Efficacy ± SEM (%) 55 ± 3 51 ± 4 ns 20 ± 1 ** 58 ± 3 ns 55 ± 2 ns 94 ± 4 ** 
EC50 ± SEM (nM) 16.6 ± 0.1 31,100 ± 7130 *** 0.653 ± 0.055 *** 25.9 ± 1.1 a, ** 3.05 ± 0.15 *** 7.16 ± 1.59 ** 
CGS21680 
Efficacy ± SEM (%) 52 ± 2 33 ± 7 ns 18 ± 1 * 62 ± 2 ns 56 ± 2 ns 71 ± 2 * 
EC50 ± SEM (nM) 62.0 ± 14.8 n.d. n.d. 75.0 ± 16.6 ns 2.41 ± 0.79 * 83.5 ± 4.1 ns 
PSB-15826 
Efficacy ± SEM (%) 79 ± 4 n.d. 2 ± 1 *** 56 ± 3 ** 53 ± 3 ** 101 ± 4 * 
n.d. not determined 
a n = 4 
ns    Not significantly different from wt hA2AAR (determined using the two tailed t-test) 
* p < 0.05 
** p < 0.01 
*** p < 0.001 
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2.6.4 Binding studies  
Competitive binding versus the radioligand [3H]CGS21680 (Fig 15) was used to determine 
the affinity of the cysteine A2A mutant receptors for the selected agonists.  
The increase in potency noticed in cAMP accumulation assays for the adenosine derivatives 
at the A2A C159S receptor was consistent with the relative gain in affinity found in 
comparison to the wt A2AAR (Ki values listed in Table 8). Adenosine was not tested in 
binding experiments since cell membrane preparations already contain endogenous adenosine 
and cannot be treated with adenosine deaminase, which would hydrolyze endogenous as well 
as added adenosine. A biphasic behaviour was observed for NECA binding at the C159S 
mutant receptor, where the low Ki value (4.92 ± 0.68 nM) was significantly decreased in 
comparison to the wt A2AAR (81.2 ± 11.4 nM).  
The A2A C166S mutant receptor characterized by a disruption of the “conserved” disulfide 
bond, showed similar affinity for the adenosine derivatives NECA and CGS21680 and a 
slight but significant reduction in affinity (1.7-fold) for PSB-15826 (see Table 8).  
The double mutant receptor C146S-C159S significantly lost affinity (30-fold) for the small 
ligand NECA while only a slight decrease (2-fold) was observed for PSB-15826 in 
comparison with the wt A2AAR.  
The agonist radioligand [3H]NECA has been used only for the A2A C146S mutant receptor 
and a significant loss in affinity was noticed for NECA itself in comparison to the wt A2AAR 
(Ki values: 7.06 ± 1.27 nM vs. 39.1 ± 1.3 nM, see Table 8).  
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Table 8. Affinities of selected ligands for the wt human A2AAR compared to the cysteine mutant 
receptors determined in radioligand binding studies versus [3H]CGS21680 (5 nM) or [3H]NECA (3 
nM). Ki values were calculated based on the KD values obtained in homologous competition 
experiments (see Table 6). Data are mean ± SEM of three independent experiments, otherwise noted. 
Ki ± SEM (nM) 
[3H]CGS21680 NECA Fold shiftd CGS21680 
Fold 
shiftd PSB-15826 
Fold 
shiftd 
hA2A wt 81.2 ± 11.4 a  130 ± 1 a  118 ± 1  
hA2A C166S 99.4 ± 15.2 ns 1.2 114 ± 4 b, ns 0.9 196 ± 1 *** 1.7 
hA2A C159S 
low c 4.92 ± 0.68 * 
high 467 ± 119 * 
one-site 20.2 ± 0.8 
0.1 
5.8 
0.3 
50.1 ± 0.7 b, *** 0.4 29.2 ± 3.6 a, *** 0.3 
hA2A C146S – C159S 2490 ± 3 b, *** 31 128 ± 10 a, ns 1.0 278 ± 8 a, *** 2.4 
[3H]NECA       
hA2A wt 7.06 ± 1.27   17.8 ± 3.5   43.5 ± 5.3  
hA2A C146S 39.1 ± 1.3 *** 5.5 19.5 ± 3.4 ns 1.1 33.9 ± 2.2 ns 0.8 
a n = 4 
b n = 5 
c low and high refer to the two Ki values of the biphasic curve of the C159S mutant, while one-site 
refer to the single Ki value calculated with one-site competition fit 
d The shift represents the ratio Ki (mutant): Ki (wt) 
ns Not significantly different from wt hA2AAR (determined using the two tailed t-test) 
* p < 0.05 
*** p < 0.001 
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Figure 15. Competition binding studies at the wildtype (wt) human A2AAR and the A2A cysteine 
mutants versus [3H]CGS21680 (5 nM; a, c, e) or [3H]NECA (3 nM; b, d, f) testing selected 
agonists, NECA (a, b), CGS21680 (c, d) and PSB-15826 (e, f). The affinity for the tested agonists at 
the hA2A C146S mutant receptor could be defined only through [3H]NECA binding, due to the low 
mutant expression. The disrupted disulfide bond is indicated in brackets. Data points represent means 
± SEM of at least three independent experiments performed in duplicates. The correspondent Ki values 
are listed in Table 8. 
44 
 
2.6.5 Binding mode and interactions  
To understand the significance of the potential extracellular disulfide bonds for receptor 
function, and to find possible explanations for the results obtained with the mutagenesis 
experiments, we explored the X-ray crystal structures available for A2AAR co-crystalized with 
the ligands used in this study.  
The recent structure co-crystallized with the agonist CGS21680 (4UHR.pdb) was considered 
as a reference, and the other two structures crystallized with the ligands NECA (2YDV.pdb) 
and adenosine (2YDO.pdb) were superimposed. For PSB-15826, a putative binding mode 
was predicted by docking the compound into the known orthosteric binding site of the A2AAR 
(Fig 16). The docking calculation was evaluated by redocking the co-crystallized ligand, 
CGS21680 which obtained an RMSD value of 0.90 Å. The output for PSB-15826 showed 
that the lowest binding energy binding pose was well correlated with the binding 
conformation of CGS21680.  
 
Figure 16. Binding modes of adenosine. Crystallographic binding poses of the agonist adenosine, 
(represented in stick, carbon atoms in yellow) in the active sites of A2AAR (represented in ribbon in 
grey color) with the important residues in the binding pocket (represented in stick, carbon atoms in 
green color) are shown. Oxygen atoms are colored in red, nitrogen atoms in blue, hydrogen in silver 
white and sulfur atoms in yellow. Figure credit to Dr. V. Namasivayam and PD Dr. A. Schiedel. 
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Similar to the binding interactions of adenosine (Fig 16 and 18a), NECA (Fig 17a and 18b) 
and CGS21680 (Fig 17b and 18c), the adenine moiety forms a π-π interaction with Phe168, a 
hydrophobic interaction with Leu249 and hydrogen bond interactions with the amino acids 
residues Asn253 and Glu169 (Fig 17c and Fig 18d). The 2-OH function of the ribose interacts 
with Ser277 and the 3-OH group possibly forms interactions with His278 (Fig 17c). The N-
ethylcarboxamido group of NECA and CGS21680 was replaced with a hydroxymethylene 
group in PSB-15826 which forms interactions with Thr88 (Fig 17c). In comparison, the N-
ethylcarboxamido group forms interactions with Thr88 and His250 (Fig 17b). The 2-(4-(4-
fluorophenyl)piperazin-1-yl)ethylthio group of PSB-15826 might form hydrophobic 
interactions with the residues Ile66 and Leu167 similar to the (2-
carboxyethyl)phenylethylamino group in CGS21680. On the other hand, the negatively 
charged carboxy group of CGS21680 and the fluorophenyl group of PSB-15826, which 
acquires a partial negative charge, might be similarly hydrated in the extracellular space (Fig 
18 c-d). This network might stabilize the receptor-ligand complex beyond the interactions 
with the core adenosine group into the orthosteric binding site of the receptor.  
 
 
 
Figure 17. Binding modes of agonists. Crystallographic binding poses of the agonist (a) NECA, (b) 
CGS21680 and (c) PSB-15826 in the binding pocket of A2AAR (represented as grey ribbon) are 
shown. All ligands are shows as sticks with carbons in yellow. The sidechains of important residues in 
the binding pocket are shown as sticks with carbons in cyan. The cysteine residues involved in 
disulfide bonds are shown as sticks and the carbon atoms are color coded as follows: Cys743.22-
Cys14645.30 blue, Cys712.69-Cys15945.43 orange and Cys773.25-Cys16645.50 green. Figure credit to Dr. V. 
Namasivayam and PD Dr. A. Schiedel.  
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Figure 18. 2D interaction diagram for agonists of A2AAR. The interaction diagrams of the selected 
agonists (a) adenosine, (b) NECA, (c) CGS21680, (d) PSB-15826 and human A2AAR are reported.  
 
2.6.6 Models of cysteine mutant adenosine A2A receptors 
Models of each cysteine mutant A2A receptor have been generated using the crystallographic 
structure of the human A2AAR bound to CGS21680 (4UHR.pdb) as reference. The disulfide 
bond I (Cys71-Cys159) was formed in the middle of the ECL2 and its disruption could 
increase the flexibility of the entire loop, in particular the two charged amino acids close to 
Cys159 such as Gln157 and Gln163, which might then form interactions with the distant 
residues in the receptor (Fig 19a). When the disulfide bond II (Cys74-Cys146) was disrupted 
(Fig 19b) by the C146S mutation, the Ser146 was found close to polar residues such as His75 
and Asn144 and possibly form intramolecular interactions. In the wildtype A2AAR, the 
Cys166 residue was found in proximity of two residues involved in ligand binding, Phe168 
and Glu169. The C166S mutation in A2AAR causing the disruption of the disulfide bond III 
(Cys77-Cys166) might cause a rearrangement of the two specified amino acids (Fig 19c).  
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Finally in the double mutant A2AAR, the disulfide bonds I and II disruption was characterized 
by a high flexibility of ECL1 and 2 (Fig 19d) influence the orthosteric binding pocket of the 
receptor. Several charged amino acids close to the mutated Cys146 and Cys159 such as 
Lys150 and Lys153, induces large flexible movement and accessible to form new 
interactions.   
 
 
Figure 19. Mutated models of A2AAR. All four models are shown with the ligand CGS21680 (stick 
representation with carbons in yellow). The sidechains of important residues in the orthosteric binding 
pocket are shown as sticks with carbons in cyan. The cysteine residues involved in disulfide bonds are 
shown as sticks and the carbon atoms are color coded as before (Cys743.22-Cys14645.30 blue, Cys712.69-
Cys15945.43 orange and Cys773.25-Cys16645.50 green). The mutated residues serine are shown in the 
respective color code as well. Amino acids which play an important role in the mutated receptors are 
highlighted as sticks with carbons in magenta and predicted interactions are circled with dotted lines. 
(a) Disruption of disulfide bond I (C159S). (b) Disruption of disulfide bond II (C146S). (c) Disruption 
of disulfide bond III (C166S). (d) Disruption of disulfide bonds I and II (C146S-C159S). Figure credit 
to Dr. V. Namasivayam and PD Dr. A. Schiedel. 
48 
 
2.6.7 Discussion 
Structural investigation of adenosine receptors (ARs) is critical for rational drug discovery. 
The four subtypes of ARs (A1, A2A, A2B and A3) respond to a single endogenous agonist, 
adenosine, and they are ubiquitously expressed in the human body, thereby involved in 
several pathological conditions [30]. The similarity in the orthosteric binding pockets 
interferes with the discovery of subtype selective drugs [77]. Therefore, crystal structures with 
different ligands bound to the ARs and mutagenesis studies are both essential for the 
investigation of structural and conformational dynamics.  
Due to their high flexibility and conformational diversity, the extracellular loops (ECLs) of 
the A2AAR have been resolved only in a few of the available crystal structures but the 
presence of disulfide bonds between ECLs is consistently identified in each of these X-ray 
structures [50,52,54]. Three disulfide bonds constrain the ECL1 and ECL2, Cys712.69-
Cys15945.43 (I), Cys743.22-Cys14645.30 (II) and Cys773.25-Cys16645.50 (III). The latter is 
conserved among most of the class A GPCRs [11]. The fourth intraloop disulfide bond is 
present within the ECL3 (Cys2596.61-Cys2626.64).  
The two closely related A2A and A2BAR subtypes are characterized by a high sequence 
identity (58%) however the endogenous ligand adenosine and its derivatives have higher 
affinity for A2AAR than for A2BAR. Contradictory data were also found regarding the 
essential cysteine residues and extracellular disulfide bonds present in the two AR subtypes. 
While crystal structures and a molecular modeling study indicated that four extracellular 
disulfide bonds are formed in A2AAR [49,50,52,54,69], mutagenesis studies on extracellular 
cysteine residues have been performed on the A2BAR subtype [55]. They demonstrated that 
for A2B subtype only the two conserved cysteine residues (Cys783.25-Cys17145.50) located at 
the extracellular end of transmembrane domain 3 (TMD3) and in the ECL2 form a disulfide 
bond which is essential for the ligand binding and receptor folding [55]. 
Several hypotheses might explain those discrepancies, such as the disulfide bonds solved in 
the A2AAR crystal structures are artefacts due to artifical conditions of the crystallization 
process. Another possibility includes that the cysteine residues found to be not essential for 
the function of A2BAR might possess a different role. Therefore, a focused investigation to 
evaluate the role of the extracellular cysteine residues in the A2AAR is critical.  
The relevance of A2AAR disulfide bonds for [3H]CGS21680 binding was first shown using 
reducing agents, such as tris(2-carboxyethyl)phosphine (TCEP) and dithiothreitol (DTT) 
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[85,86]. A recent mutagenesis approach suggested that the conserved disulfide bond in 
A2AAR is not essential for [3H]CGS21680 binding and for its plasma membrane expression 
[70] indicating that the mentioned disulfide bonds found in the A2AAR crystal structure might 
be an artefact. However, the mutagenesis study focused on ligand binding of cysteine residue 
A2AAR mutants utilizing one adenosine derivative, CGS21680, while functional data were not 
available. Our investigation addressed structural and functional issues involving the A2AAR 
extracellular cysteine residues and the corresponding disulfide bonds. 
Extracellular disulfide bonds are important for A2AAR function 
The first hint of the relevance of disulfide bonds for the function of A2AAR was observed by 
the loss in potency of NECA and CGS21680 in cAMP accumulation assay at the wt receptor 
after DTT pre-incubation. The treatment caused the disruption of multiple disulfide bonds 
present in the extracellular surface of the A2AAR, therefore, a precise understanding of the 
importance of single disulfide bonds in the stability and activation of the receptor was not 
feasible at that point.  
Role of single extracellular disulfide bonds in A2AAR 
In order to get a more complete view about the role of extracellular disulfide bonds of the 
A2AAR, we generated mutant A2A receptors in which cysteine residues were exchanged with 
serine (C146S, C159S, C166S and a double mutant C146S-C159S) focusing on ligand 
binding and receptor function with a variety of ligands (Fig 5). We tested A2AAR agonists 
with different substituents evaluating their effects on the mutant receptors: as first the 
endogenous ligand adenosine (1), then the derivatives NECA (2), the A2A selective 
CGS21680 (3) and a bulky 2-substituted derivative PSB-15826 (5), which is also selective for 
the A2AAR. When the CHO cell lines stably expressing the mutant receptors were established, 
two approaches were used to define their expression: by ELISA we characterized the amount 
of receptors transported to the cell surface and by ligand binding with cell membranes we 
defined the density of receptors in the preparation (Bmax value).  
The three extracellular disulfide bonds are critical for A2AAR activation by adenosine 
The involvement of the three disulfide bonds between the ECLs in A2AAR activation is one of 
the main foci of the current study. The results obtained with the adenosine-stimulated cAMP 
accumulation assay showed that all cysteine A2A mutant receptors lost potency as compared 
to the wt A2AAR, reaching EC50 values in the micromolar range, similar to the wt A2BAR. All 
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three disulfide bonds seem to be critical for the response of the A2AAR to the endogenous 
agonist.  
Disruption of disulfide bond I causes gain in affinity and function of A2AAR 
The C159S mutant receptor showed a significant increase in potency for the three adenosine 
derivatives NECA, CGS21680 and PSB-15826, but not for adenosine itself. This effect could 
be due to the higher expression level of this mutant in comparison to the wt A2AAR defined 
by ELISA, but the C159S might also be a gain-of-function mutation. It was previously 
demonstrated that mutations in the ECL2 could lead to constitutively active and gain-of-
function mutants in the close homolog A2BAR [44,46]. The A2A C159S mutant receptor also 
gained affinity for the adenosine derivatives NECA, CGS21680 and PSB-15826 with 4-fold, 
2.6-fold and 4-fold, respectively (Table 8). The disulfide bond Cys712.69-Cys15945.43 restricts 
the movement of the receptor and the charged amino acid residues Gln157 or Gln163, which 
are close to Cys159, were minimized for the natural ligand adenosine. However, for the 
C159S mutant receptor, the binding pocket might become wider than the wildtype pocket. 
Therefore, adenosine might stay longer in the meta binding site as compared to the orthosteric 
binding site due to stronger interactions (Fig 19a). Contrarily, for the larger agonists 
CGS21680 and PSB-15826 the breakage of the disulfide bridge results in flexible movement 
of the loop which probably form a cap which retains the compounds in the orthosteric binding 
site for a longer duration (Fig 19a). During this time, the residues in the loop region such as 
Lys150 or Lys153 might form interactions with the agonists CGS21680 and PSB-15826 
thereby increasing their affinity and potency with the receptor (Fig 19a). 
Disulfide bond II is critical for cell surface expression of A2AAR  
The mutation of Cys146 in A2AAR critically affected the cell surface expression of the 
receptor defined by ELISA, the identified data were supported by Naranjo et al. [70], and the 
agonist-induced cAMP accumulation assay displayed almost no activation at adenosine and 
PSB-15826 and extremely reduced efficacy at NECA and CGS21680. On the basis of the 
ELISA results, the reduced functionality of the C146S mutant receptor could be due to the 
low density of active receptors present at the cell surface. Binding studies versus [3H]NECA 
showed that the affinity of the C146S mutant receptor for CGS21680 did not change as 
compared to the wt A2AAR. However, competitive binding studies versus [3H]CGS21680 
have not been possible for this mutant. The mutation of Cys146 could have shifted the 
equilibrium towards the inactive state, lowering the percentage of active state receptors. 
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NECA, which has higher affinity for the active state than CGS21680, can label more 
efficiently the low percentage of active state receptors, while CGS21680 cannot label all of 
them (narrow window between the total binding and the non-specific binding). However, the 
expression level (Bmax value) of the C146S mutant detected with [3H]NECA is similar to the 
wt A2AAR, meaning that the amount of total binding binding sites in the membrane 
preparation is similar to the one of the wt receptor. We suggest that the disulfide bond 
Cys743.22-Cys14645.30 connecting the TMD3 and the ECL2 is critical for the receptor folding 
and its disruption might cause receptor aggregation and ER retention (Fig 19b), as it was 
proposed for other cysteine mutant GPCRs [63,87]. The small percentage of mutant receptors 
transported to the plasma membrane might have adopted a different stabilized conformation 
due to new interactions which are formed with the exchanged serine residue. The side chain 
of serine is sterically and electronically similar to the cysteine and can form a hydrogen bond 
with the nearby residue Asn144 or a salt bridge with His75 (Fig 19b). The competitive 
binding using [3H]NECA versus unlabeled adenosine derivatives (NECA, CGS21680 and 
PSB-15826) was not abolished, however the C146S mutant receptor lost affinity only for 
NECA. We hypothesize that during the ligand recognition process, the small molecule 
agonists, such as NECA and adenosine, could probably bind into a pocket in the the ECL2 
close to the disulfide bond Cys743.22-Cys14645.30. This so-called meta-binding site was 
described by Moro et al.  [81]. They investigated A2AARs using a new molecular dynamics 
simulation approach, supervised molecular dynamics (SuMD), with diverse adenosine 
receptor ligands and detected for adenosine and NECA a meta binding site in the loop region, 
to which the affinity of the ligands was almost as strong as for the orthosteric binding site. 
Thus, the disruption of the disulfide bond Cys743.22-Cys14645.30 could have an impact on the 
meta binding site and this can probably explain the loss in affinity for NECA which we found 
for the C146S mutant receptor (Fig 19b) [81]. In contrast, large agonists, such as CGS21680 
and PSB-15826, which are not likely to interact with the meta binding site, are not affected by 
the mutation of the cysteine residue (Table 8). They seem to bind directly to the orthosteric 
binding pocket.  
The GPCR-conserved disulfide bond (III) is not required for activation and binding of 
A2AAR by adenosine derivatives 
The cell surface expression of the C166S mutant receptor and its overall density in the 
membrane suspension was moderately lower than the level obtained for the wt A2AAR. In 
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addition to Cys743.22-Cys14645.30, the conserved disulfide bond Cys773.25-Cys16645.50 could 
also be involved in the stabilization of receptor folding. The weak loss of potency observed 
for NECA, CGS21680 and PSB-15826 is most likely due to the lower expression level of the 
mutant in comparison to the wt A2AAR. On the other hand, the endogenous agonist adenosine 
lost 30-fold potency at the C166S mutant receptor, which cannot be explained by different 
expression levels. It might therefore be due to the mutation resulting in the disruption of the 
disulfide bond. As shown in Fig 19c, the location of two of the residues important for the 
interaction with the adenine core of nucleosidic agonists, Phe168 and Glu169, might be 
affected by the loss of the disulfide bond when Cys166 is mutated, since it is very close. 
Thus, the conserved disulfide bond Cys773.25-Cys16645.50 appears to be essential for the 
proper activation of the receptor by the endogenous ligand adenosine, as much as the 
Cys712.69-Cys15945.43 and Cys743.22-Cys14645.30 disulfide bonds. Minor variations in affinity 
were observed between the C166S mutant receptor and the wt A2AAR for the adenosine 
derivatives NECA, CGS21680 and PSB-15826. The adenosine derivatives are characterized 
by substitutions to the adenine core which interact with the A2AAR binding site, stabilizing its 
conformation and are able to compensate the effect of the conserved disulfide bond 
disruption. In particular, the loss in potency for adenosine (30-fold) and for NECA (3-fold) 
comparing the C166S mutant and the wt A2AAR confirms that the N-ethylcarboxamido group 
largely contributes to the stabilization of the ligand-receptor complex. This finding is 
supported by the results obtained for CGS21680 which are comparable to the wt A2AAR. 
Despite the fact that PSB-15826 has no substitutions at the ribose ring, it slightly lost potency 
(1.2-fold) and affinity (1.7-fold) as compared to the wt A2AAR because the adenine 
substitution compensates with other interactions (Fig 19c).   
The 2-substitution length of adenosine derivatives affect affinity and activation of the 
double mutant receptor 
The double mutant receptor, in which the two suggested non-essential disulfide bonds 
(Cys712.69-Cys1595.20 and Cys743.22-Cys1464.67) were disrupted, has a similar expression as 
the wt A2AAR. Functional studies showed that the potency and efficacy of this mutant 
receptor are affected by the length of the substitution in position 2 at the adenine moiety of 
the ligand. Small ligands as adenosine and NECA showed a considerable loss in potency in 
the double mutant receptor (253- and 87-fold, respectively) as compared to the wt A2AAR. On 
the other hand, 2-substituted adenosine derivatives as CGS21680 and PSB-15826 only 
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showed minor changes in potency in comparison to the wt A2AAR. The affinity of the 
compounds at the double mutant receptor was affected as well. In the C146S-C159S mutant 
receptor, a considerable loss of affinity is shown for NECA (31-fold) in comparison to the wt 
A2AAR. Similar to functional studies, the long substituted CGS21680 and PSB-15826 
displayed only small variations in Ki values (Table 8). The disruption of two disulfide bonds 
in the double mutant receptor possibly results in highly flexible ECL1 and ECL2 (Fig 19d). 
The double disruption could influence the TMD2 and TMD3 of the receptor and furthermore, 
the residues in the orthosteric binding pocket. The high flexibility of the loop affects the 
interaction with the agonists in the binding site, as observed for adenosine and NECA. 
However, the flexible ECL2 of the double mutant receptor might be stabilized by the bulky 
substituent of CGS21680 and PSB-15826, resulting in similar potency and efficacy as the wt 
A2AAR. Probably, as explained for the C159S mutant, the charged amino acids residues 
Lys150 or Lys153 form interactions with CGS21680 and PSB-15826 and maintain similar 
potency and affinity to the wt A2AAR (Fig 19d).  
A higher efficacy was observed at the double mutant receptor for adenosine and NECA in 
comparison to the wt A2AAR. Small ligands might not be able to stabilize the flexible ECL2 
of the double mutant receptor so the equilibrium between receptor conformations is more 
oriented toward an active form increasing the maximal effect of the small compounds (85% 
and 94% vs. 44% and 55% for the wt A2AAR, respectively). A similar increased efficacy was 
observed in the loop exchange mutant hA2B(ECL2 hA2A) where the exchange of the ECL2 
between the two AR subtypes induces a stabilization of a receptor conformation that couples 
more efficiently to the Gs protein [39]. 
Conclusions 
Functional studies indicated that the three disulfide bonds between ECL1 and 2 are essential 
for the proper function of the A2AAR in response to the endogenous agonist adenosine. 
Inducing a simultaneous reduction of the extracellular disulfide bonds with DTT, we proved 
that the disulfide bond network is also relevant for the A2AAR response to adenosine 
derivatives (NECA and CGS21680). However, when the disulfide bonds are individually 
disrupted, the receptors compensate the loss of the covalent bridge by forming new 
interactions involving the exchanged serine residue. Another possibility includes the 
dynamics of disulfide bonds, as it was suggested for the P2Y12 receptor [63]. Crystallographic 
studies on P2Y12R were performed with agonist and antagonist, however, the conserved 
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disulfide bond is present only in the structure co-crystallized with the agonists 2MeSADP and 
2MeSATP [63,88]. Mutagenesis studies of the two conserved cysteine residues did not cause 
any affinity loss or receptor aggregation. On the other hand, a second extracellular disulfide 
bond was found in the structure (Cys17-Cys270) and its disruption caused receptor 
aggregation, meaning that this observed disulfide bond was essential for the receptor’s 
stability and conformation. Similar results were found in our study on A2AAR: the disruption 
of the conserved disulfide bond did not cause any dramatic changes in affinity and potency, 
except for adenosine, while the disruption of Cys743.22-Cys14645.30 caused decreased 
membrane transport.  
Another hypothesis could also be that the cysteine residues are involved in different 
interactions, i.e. direct ligand binding or allosteric disulfide bonds in oxidative stress 
condition or they could be regulated by the post-translation modification of the close 
asparagine residue Asn154, which can be glycosylated [55].  
In conclusion, all of the predicted disulfide bonds between ECL1 and 2 in A2AAR were found 
to be critical for the proper activation of the receptor when the endogenous agonist adenosine 
was used. The relevance of each cysteine residue in the ECL2 is ligand specific: while lower 
potencies at the mutant receptors were noticed for small agonists (adenosine and NECA), 
larger adenosine derivatives substituted in position 2 with a large residue (e.g. CGS21680) 
appear to be able to stabilize the flexible extracellular loops in the mutants that are lacking 
cysteine residues for disulfide formation and, therefore, they showed comparable potency for 
the mutant receptors. The conserved disulfide bond Cys773.25-Cys16645.50 is not essential for 
binding and activation of the receptor by adenosine derivatives while the Cys743.22-
Cys14645.30 is essential for the receptor folding and activation. Further studies are required to 
understand which could be the possible roles of extracellular cysteine residues in ARs.  
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3. Characterization of the G protein coupled-receptor GPR143 
3.1 Albinism  
Melanin-related agents in the retinal pigment epithelium (RPE) exert a strong influence on the 
development of neural retina, a cell layer containing photoreceptors, which is just at the back 
of the RPE. When melanin is reduced or absent, the neural retina develops abnormally. 
Mutations in multiple genes that decrease eye pigmentation all share the same developmental 
eye defects demonstrating that melanin-related agents are crucial for normal development of 
the visual system. The abnormalities are of great interest because they reveal how melanin-
related agents control specific aspects of the developing visual system [89].  
Albinism refers to a disease characterized by a group of inherited conditions, in particular 
little or no pigment in eyes, skin or hair. People affected by albinism inherited altered genes 
that do not make the usual amounts of melanin. There are different types of albinism and the 
amount of pigment in the eyes varies . 
Ocular albinism is one form of albinism which affects primarily the eyes. There are multiple 
forms of ocular albinism that are clinically similar (Table 9). The most common variety 
corresponds to the ocular albinism type I. 
 
Table 9. Description of the ocular albinism subtypes. The gene involved is listed together with the 
main information about the syndroms [90].    
Name Gene involved Description 
Ocular Albinism type I (OA1) GPR143 Also known as Nettleship-Falls syndrome, it is 
the most common variety of ocular albinism. 
OA1 is usually associated with nystagmus. 
Males show more readily observable 
symptoms. 
Ocular Albinism type II (OA2) CACNA1F Also known as Forsius-Eriksson syndrome or 
"Åland Island eye disease", mostly only affects 
males, though females are often carriers and 
can sometimes be symptomatic; it is frequently 
linked with protanopic dichromacy (a form of 
color blindness) and with night blindness 
(nyctalopia). 
Ocular Albinism with 
sensorineural deafness (OASD) 
? (Xp22.3) It is associated with loss of hearing. 
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3.2 Ocular Albinism type I 
Ocular Albinism type I (OA1) is an X-linked inherited disease characterized by severe 
reduction of visual acuity, nystagmus, strabismus, photophobia, iris translucentis, 
hypopigmentation of the retina, foveal hypoplasia and misrouting of the optic tracts, resulting 
in loss of stereoscopic vision [89]. OA1 is not caused by impairment of melanin production 
but by reduced number of melanosomes [91], organelles in which melanin is synthesized and 
stored in retinal pigment epithelium (RPE) and skin melanocytes. The skin pigmentation in 
OA1 patients is usually not affected or slightly reduced, however subcellular abnormalities, 
such as the presence of giant melanosomes (“macromelanosomes” shown in Fig 20), 
reduction of melasome number and alteration of melanosome motility, were found in both 
skin melanocytes and RPE [92,93]. The reason why the eyes are more affected than the skin 
in OA1 patients is still unclear however, several hypotheses about the role of GPR143 in the 
disease have been suggested.  
This form of albinism appears to be caused by a defect in melanosome biogenesis. 
Ultrastructural analysis of the RPE cells suggests that the giant melanosomes may form by 
abnormal growth of single melanosomes, rather than the fusion of several, shedding light on 
the pathogenesis of ocular albinism [94].  
 
Figure 20. Retinal pigment epithelium melanosomes from Oa1 knock-out mice. The ultrathin RPE 
sections from Oa1-/- (B) and their control B6/NCrl (A) mice show that knock-out mice have 
macromelanosomes in comparison with the control [95]. 
 
3.3 GPR143 receptor 
The protein responsible for ocular albinism type I is GPR143, product of the OA1 gene 
located on the distal short arm of the X chromosome [96]. Despite the low amino acid 
sequence conservation, GPR143 shares structural and functional similarities with different 
classes of G protein-coupled receptors (GPCRs; Schiaffino et al. 1999) but it still unclear to 
which family it belongs.  
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Furthermore, the receptor is highly expressed in pigmented cells such as melanocytes and 
RPE [96]. Unlike most of the GPCRs, GPR143 is not localized at the cell plasma membrane 
but is targeted to the membrane of melanosomes. The sorting mechanisms of GPR143 are still 
not clear but evidences show that it follows the lysosomal/melanosomal sorting pathway as 
other melanosomal proteins (e.g. tyrosinase, TYR, and tyrosinase-related protein 1, TRP1) 
[98]. Supporting this hypothesis, two sorting signals were found in the intracellular loop 3 and 
in the C-terminal tail of GPR143 which were demonstrated to be necessary and sufficient for 
its intracellular localization (Fig 21) [99]. These two sorting signals are recognized by non-
melanocytic cells as well, indeed GPR143 is localized at the membrane of late endosomes and 
lysosomes in transfected non-pigmented cells [99,102,103].  
 
 
Figure 21. 2D topology structure of GPR143 predicted by TMHMM Server [62,102]. The two 
sorting signals necessary and sufficient for GPR143 intracellular localization are highlighted (dileucin 
motif in the intracellular loop 3 and tryptophan-glutamic acid doublet in the C terminal tail) [99]. 
 
The endogenous GPR143 receptor was analyzed by Western blot (Fig 22) in healthy human 
melanocytes. It was extracted as a doublet of 45-48 kDa and a band migrating at 60 kDa 
corresponding to different patterns of glycosylation [100]. 
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Figure 22. Western blot showing GPR143 receptor as a doublet at 45-48 kDa and a large band at 
60 kDa. In the first well, the lysate of healthy human melanocytes was analyzed, while in the other 
samples three different oligonucleotides were tested to silence GPR143 expression [103].  
 
There are three potential N-glycosylation sites in the sequence of mouse GPR143 (asparagine 
residues: 101, 106 and 263), but only two sites are conserved in the human GPR143 sequence 
(asparagine residues: 106 and 263). N106 seems to be the only or the first site which is 
actually glycosylated but the possibility that the other two sites may be glycosylated or that 
the first site is necessary for the second site to undergo glycosylation is not excluded [104]. 
Additional post-translational modifications in addition to N-glycosylation are feasible.   
Several types of mutations were identified within the GPR143 gene in OA1 patients, 
including deletions, frameshifts, stop-codon insertion and a number of missense mutations. 
GPR143 mutants can be classified into two biochemical groups. The group I mutants 
displayed a glycosylation pattern completely overlapping the wildtype one and a 
cytoplasmatic vesicular distribution, more concentrated in the perinuclear area and spread 
toward the periphery. The group II mutants showed an altered glycosylation pattern, 
characterized by the absence of the 60 kDa glycosylated form. These GPR143 mutants appear 
unable to undergo complete processing in the Golgi apparatus which could affect the correct 
folding of the receptor. They exhibited a fine reticular distribution, with staining of the 
nuclear membrane, consistent with protein accumulation in the endoplasmatic reticulum (ER) 
[101,105].  
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The mutations belonging to the group I might affect important residues for the signaling 
activity of GPR143. In contrast, mutations of the group II (mainly concentrated within or 
close to the putative TM domain) appear to cause the retention of the GPR143 in the ER, 
preventing its proper glycosylation in the Golgi apparatus and its final targeting to the 
lysosomes/melanosomes [105].  
 
3.4 Subcellular localization debate 
In contrast to canonical GPCRs, GPR143 is not localized to the cell surface but it is 
exclusively detectable on the membrane of intracellular organelles. However some 
controversy exists on the precise subcellular localization of the protein.  
By double immunofluorescence in normal human melanocytes, the endogenous GPR143 was 
found to co-localize with the melanosomal matrix glycoprotein Pmel17 [97,106], which label 
melanosomes at early developmental stages [107]. The proteomic analysis of the purified 
early melanosome fraction obtained from the human melanoma line MNT1 confirmed that 
GPR143 is associated to these organelles [108]. In addition immunogold and 
immunoperoxidase assays in normal human melanocytes demonstrated that GPR143 is also 
present on melanosomes at later stages of maturation [97,100]. 
By contrast, studies on the mouse ortholog showed that the recombinant GPR143 linked to 
GFP in mouse melanocytes co-localized widely with LAMP1, lysosomal marker, but only 
modestly with tyrosinase-related protein 1 (TRP1), marker of mature melanosomes [104]. 
Then, upon density gradient fractionation of subcellular organelles, GPR143 was not found to 
peak at the dense fraction as tyrosinase and TRP1, suggesting that it is mostly an endo-
lysosomal protein, with minimal or no co-localization with melanosomes [104].  
The reason for these discrepancies might partially lie in the different techniques, markers and 
cell models utilized. In order to solve this issue, quantitative immunofluorescence and 
immunogold analyses of GPR143 distribution were performed in MNT1 cells, demonstrating 
that the receptor was similarly distributed along both the late endosomal/lysosomal and the 
melanosomal compartment [109]. 
Previous studies showed that GPR143 was ubiquitinated and this was essential for its 
targeting to the intraluminal vesicles of multivesicular bodies (MVBs) in non-melanocytic 
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and melanocytic cells. In pigmented cells, ubiquitination of GPR143 was likely to control the 
balance between down-regulation and delivery to melanosomes [110]. 
 
3.5 Intracellular signaling pathway and ligands 
The endogenous GPR143 was found to co-precipitate with the Gαi, Gαo and Gβ subunits of 
heterotrimeric G proteins in melanocytes extracts [97]. Similar results were obtained in COS7 
cells transfected with the wildtype GPR143, but not with the mutants carrying amino acid 
substitutions identified in OA1 patients [97]. In addition, the intracellular loop 3 and the C-
terminal tail of GPR143 were able to bind Gαi, Gαq/11 and Gβ by in vitro binding assay [97].  
An agonist-independent or constitutive activity of GPR143 was demonstrated expressing the 
receptor with its putative G protein partners in a heterologous system. When GPR143 was 
expressed in COS7 cells together with Gα15 (PLCβ-coupled G protein), the protein was able to 
induce a significant accumulation of inositol 1,4,5-trisphosphate compared to G proteins 
alone, GPR143 mutants and even unstimulated or ligand-activated canonical GPCRs [111].  
GPR143 phosphorylation and its interaction with β-arrestin protein were demonstrated by co-
localization and co-precipitation studies [111]. 
Topological orientation studies indicated that GPR143 had an odd number of transmembrane 
domains and the C terminal tail is oriented towards the cytoplasm. These findings underlined 
that putative ligands should bind from melanosome lumen [97,112]. 
In 2008 levodopa (L-DOPA) and dopamine (DOPA) were found to bind GPR143 at high 
concentrations (L-DOPA Kd 9.35 µM and DOPA Kd 2.39 µM) and activate the intracellular 
calcium release through Gq/11 protein coupling in transfected CHO cells [113].  
Since GPR143 was found to be expressed not only in pigmented cells but also in parts of the 
central nervous system (mainly in cerebral cortex and hypothalamus) and in some peripheral 
tissues (kidney, spleen and lung) [114], the role of DOPA and L-DOPA in the development of 
neural retina was investigated.  
Hiroshima et al. studied the role of L-DOPA on GPR143 in the central nervous system, 
showing that the compound has a lower affinity for GPR143 than described before (Kd 79.1 
µM) and does not cause calcium release in CHO cells but only in cells derived from RPE 
[115].  
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The association of GPR143 with L-DOPA and the role of its signaling is still an unclear issue 
however, recent evidences demonstrated that L-DOPA accumulated in RPE is critical for the 
proper development and differentation of cells in the neural retina [116]. Those findings could 
explain the perturbed neural cell generation in different albinism types, such as tyrosinase-
mutated albinism, in which the L-DOPA concentration in RPE is very low during the neural 
retinal development, or OA1, in which GPR143 is mutated and its signaling might be 
inhibited [117].  
 
3.6 Tyrosinase  
Tyrosinase is the key regulatory enzyme of melanogenesis, catalyzing three distinct reactions 
in the melanogenic pathway: oxydation of L-tyrosine to L-DOPA, dehydrogeneation of L-
DOPA to dopaquinone and dehydrogenetion of a dihydroxyindole (Fig 23).  
The structure of tyrosinase is highly conserved among different species and shows high 
homology with other tyrosinase-related proteins including tyrosinase-related protein 1 (TRP1) 
and tyrosinase-related protein 2 (TRP2). The N terminal domain of tyrosinase comprises a 
signal peptide (important for intracellular trafficking and processing), the EGF-like/cysteine-
rich domain, two histidine-rich regions binding coppers with a cysteine-rich region between 
them (important catalytic domain), the hydrophobic transmembrane domain and the 
cytoplasmatic tail (Fig 24). The cytoplasmatic tail contains the dileucin motif for the 
melanosomal sorting, indeed a missense mutation in the platinum allele of the murine 
tyrosinase, which produces a truncated protein lacking the cytoplasmatic dileucin motif, 
results in improper targeting of tyrosinase and the albino phonotype (mice are a shade darker 
than albino) [118].  
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Figure 23. Enzymatic activity of tyrosinase in the melanogenic pathway (adapted from [119]). 
Melanin is produced by the oxidation of the amino acid tyrosine, followed by polymerization. In the 
skin there are two types of melanin: eumelanin and pheomelanin. Eumelanin can be brown or black 
melanin, which chemically differ from each other in their pattern of polymeric bonds. Pheomelanins 
differs from eumelanins in that the oligomer structure incorporates benzothiazine and benzothiazole 
units that are produced, when the amino acid L-cysteine is present. 
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Figure 24. Scheme of tyrosinase structure with the most important domains: a signal peptide, the 
EGF-like/cysteine-rich domain, two histidine-rich regions binding coppers with a cysteine-rich region 
between them (catalytic domain), the hydrophobic transmembrane domain and the cytoplasmatic tail 
[120]. 
 
Newly synthesized tyrosinase has a molecular mass of 55-58 kDa. Proteolitic cleavage of the 
transmembrane portion of the enzyme generates two soluble molecular forms: a 53 kDa 
unmodified protein or a 65 kDa glycosylated tyrosinase, which may be active in the 
melanosome or secreted into the extracellular environment. After glycosylation (N- and O-
glycosylation) in the trans-Golgi complex, tyrosinase increases in size to 65-70 kDa or even 
80 kDa [121,122]. In melanocytes and melanoma cells tyrosinase exists in both membrane-
bound and soluble forms. Proteolytic cleavage of the membrane-bound enzyme near the C 
terminal tail produces a soluble form with equivalent activity [123].  
Defects in tyrosinase gene lead to the tyrosinase negative oculocutaneous albinism type I 
(OCA1). In addition to mutations in hot spots (copper binding domains), the entire coding 
sequence of the gene is susceptible to mutations. These include missense, non-sense, 
frameshift and splicing abnormalities. If translated, mutant tyrosinase proteins are routed for 
degradation by proteasomes (due to the retention of misfolded proteins in the ER), rather than 
allowed to pass to the Golgi apparatus for glycosylation and further transport to 
premelanosomes [121].  
L-DOPA seems to be involved in both tyrosinase and GPR143 signaling pathways and 
previous studies also showed that if GPR143 was silenced by iRNA (interference RNA), the 
melanin production in MNT-1 cells was modified in vitro [103].  
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3.7 GPR143 functions 
Hypotheses about the role of GPR143 in the melanogenesis process have been suggested but a 
clear model of the receptor mechanism of action is still required. Understanding the function 
of GPR143 and which pathways it regulates may be instrumental for investigating how 
neurogenesis is regulated during optic development.  
Several evidences demonstrated that macromelanosomes derive from an abnormal growth of 
single organelles, rather than from the fusion of different mature melanosomes [94]. Thus 
GPR143 seems to be involved in the regulation of melanosome biogenesis [104,124], 
functioning as stop signal for melanosome growth during melanogenesis. GPR143 mutations 
which affect its function would permit the continuous import of melanosomal proteins into 
melanosomes resulting in giant organelles because the downstream signaling pathway is 
compromised.  
Based on its topological orientation into the melanosomal membrane [97,112], GPR143 
ligands should bind from the organelle lumen and transduce information to the cytosol 
through activation of heterotrimeric G proteins. In this way, GPR143 could function as a 
“sensor” of melanosomal maturation inhibiting the organelle overgrowth [109].  
Another role assigned to GPR143 is the ability to control the melanosome transport inside the 
cell regulating the microtubules-mediated motility [93]. Since GPR143 could be sensitive to 
the melanosomal maturation, it could transduce this information in the cytosol and through a 
signalling cascade trigger the undeveloped organelles close to the perinuclear region for a 
complete maturation.  
In vivo studies with GPR143 and TYR double mutant mice demonstrated that GPR143 has a 
double function in two different stages of melanosome maturation: first, at early stages of 
organellogenesis GPR143 controls the rate of melanosome biogenesis (GPR143 mutation 
affects the number of melanosomes) and at final stages of melanosomal maturation (stage III 
and IV) GPR143 might regulate the organelle size, inhibiting the overgrowth [91]. This 
hypothesis was supported by the finding of a previously unknown function of GPR143: the 
regulation of transcription of genes involved in melanosome biogenesis [125]. GPR143 may 
regulate the expression of the microphthalmia-associated transcription factor (MITF), the key 
gene controlling the expression of several melanosomal proteins. In this way, GPR143 is 
included in a feedback loop since it was proved that MITF controls expression of GPR143 
itself [125,126].  
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Recently, an additional evidence clarified the role of GPR143 in the melanogenesis process: 
in Hela cells GPR143 signaling inhibits at the endosomal stage the lysosomal delivery of 
proteins and blocks the fusion of multivesicular bodies (MVBs) with lysosomes [127]. These 
findings are in agreement with the suggested role of GPR143 to be a sensor of melanosomal 
maturation, delaying the endosome-lysosome fusion in order to allow time for the delivery of 
melanin-synthetizing enzymes at later melanosome stages in order to synthetize and deposit 
melanin in Pmel-containing melanosomes. 
The connection between GPR143 and the melanosomal biogenesis and maturation was 
suggested by several studies in vitro and in vivo but the mechanism by which the receptor 
perceives the maturation of the organelle is still an unsolved question [91,104,109,124]. 
 
3.8 Aim of the project 
The role of GPR143 in the development of neural retina and in the Ocular albinism type I 
pathogenesis is still not clear. Several evidences obtained by in vitro experiments and in vivo 
observations suggested different hypotheses about GPR143 function but the reason why 
GPR143 mutations induce severe defects in the visual system while the skin is not affected is 
unknown.  
As first, our investigation focused on the role of GPR143 and its intracellular signaling 
cascade. Besides the suggested Gq/11 protein coupling after L-DOPA stimulation, GPR143 
was found to co-precipitate with Gαo, Gαi and Gβ subunits of heterotrimeric G proteins in 
melanocyte extracts [97,113]. In addition, a GPR143 constitutive activity and co-localization 
with β-arrestin 2 and 3 were detected in transfected COS7 cells [111]. The purpose of our 
study was to find a pharmacological tool suitable to analyze GPR143 function, such as a 
compound able to activate or inhibit the receptor signaling. Due to its intracellular 
localization, it is problematic for compounds with different sizes and hydrophobicity levels to 
reach GPR143. Thus, we generated a double mutant receptor exchanging the two sorting 
signals necessary for melanosomal/lysosomal localization to alanine residues [99] in order to 
have the receptor expressed at the cell plasma membrane. Beyond the establishment of CHO 
cell lines expressing the wildtype and mutant GPR143, L-DOPA was the first compound 
tested for the activation of calcium, β-arrestin and cAMP downstream signaling pathways. 
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Since the β-arrestin recruitment assay was suitable for high-throughput screening, two 
compound libraries were tested against GPR143 searching for selective and valuable ligands.   
The second part of the project was oriented toward GPR143 function as “sensor” of 
melanosomal maturation. The connection between GPR143 and the melanosomal biogenesis 
and maturation was suggested by several studies in vitro and in vivo but the mechanism by 
which the receptor perceives the maturation of the organelle is still an unsolved question 
[91,104,109,124]. The knowledge about the interaction between GPCRs and other proteins is 
getting more and more critical for the receptor folding, signaling and function [128]. Thus the 
purpose of our study was to investigate a hypothetical connection between GPR143 and 
tyrosinase, the main enzyme responsible for the melanin synthesis and thus for the 
melanosomal maturation. Taking advantage of the double mutant GPR143 expressed at the 
cell plasma membrane and through the optimization of several methodologies, such as 
immunoprecipitation, co-localization studies and Fluorescence Resonance Energy Transfer 
(FRET), we defined the physical interaction between GPR143 and tyrosinase in different cells 
systems. 
The work shown in the following result sections is included in two manuscripts: 
- De Filippo E., Manga P. and Schiedel A.C. (in preparation). Identification of novel 
GPR143 ligands useful as pharmacological tools. 
- De Filippo E., Schiedel A.C. and Manga P. (in preparation). GPR143-tyrosinase 
interaction as a measure of melanosome maturation. 
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3.9 Part I: GPR143 ligands as pharmacological tools to analyze receptor function 
3.9.1 Characterization of wildtype and mutant GPR143 in CHO cells 
The starting point of our research was to generate a cell-based system expressing GPR143 
suitable for screening of compound libraries. The GPR143 intracellular localization and its 
topological orientation in the lysosomal/melanosomal membrane constituted a challenging 
issue for this purpose. The GPR143 amino acid sequence contains two sorting signals 
responsible for its intracellular localization and recognized by non-melanocytic cells as well 
[99]. Exchanging these two sequences with alanine residues (L223A-L224A and W329A-
E330A), we generated a double mutant GPR143 which we assumed was transported at the 
cell plasma membrane and whose putative binding site was oriented toward the extracellular 
space.  
GPR143 was found to co-localize and co-precipitate with β-arrestin, which is involved in 
agonist-mediated desensitization and signaling transduction of GPCRs. Thus, we established a 
β-arrestin cell line expressing either the wildtype (wt) or the mutant GPR143 in order to set 
up a β-arrestin recruitment assay, which was also suitable for high-throughput screening.  
CHO cells were used as in vitro system for the expression of GPR143 and for the 
establishment of the β-arrestin recruitment assay, since these cells do not endogenously 
express the receptor of interest and untrasfected CHO cells can be used to control the 
specificity of the ligand targeting.  
The C terminus of wt and mutant GPR143 were linked to a ProLink (PL) tag, which is a β-
galactosidase fragment, and the obtained constructs were transfected in CHO cells already 
containing the β-arrestin protein linked to the second β-galactosidase fragment, Enzyme 
Acceptor (EA) fragment.  
Several plasmids were available from DiscoverX to link the GPCR of interest to the ProLink 
tag, such as PL1, PL2, ARMS1 and ARMS2. The ProLink2 (PL2) tag has higher affinity for 
EA than the original ProLink (PL1) tag (~3-fold greater) and is useful for weak protein-
protein interactions. G-protein Receptor Kinase (GRK) phosphorylates GPCRs; facilitating 
recruitment of arrestins. The Arrestin Recruitment Modifying Sequence (ARMS) is a G 
protein receptor kinase (GRK) consensus phosphorylation site deduced from analysis of 
GPCRs which generate a high signal-background in the assay. We subcloned the wildtype and 
mutant GPR143 in the four vectors and transfected them in CHO cells. The expression of the 
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mutant receptor was firsly quantified in the four cell lines by RT-PCR using two set of 
primers designed to bind within the cDNA sequence of GPR143. The aim was to compare the 
relative copy number of receptor between four established cell lines, using as control the 
house keeping gene β actin.  
The relative quantification of the samples was normalized to the control, set as 1 (Fig 25a). 
The highest expression of the mutant GPR143 was found in ARMS2 and ProLink2 (∼20 and 
15 fold higher than the control). 
Before the compound test, we quantified the basal activity of the cell lines expressing 
GPR143 in the β-arrestin recruitment assay. We observed an higher recruitment of β-arrestin 
without any compound stimulation as compared to untransfected CHO cells (Fig 25b). Cells 
expressing GPR143 in ProLink2 and ARMS2 plasmids showed the highest basal activity for 
wildtype and mutant GPR143. This constitutive activity was correlated with the relative 
expression of the receptor measured by RT-PCR.  
 
 
Figure 25. GPR143 expression in CHO cells transfected with different ProLink vectors. (a) 
Relative quantification of mutant GPR143 expression in stable transfected β-arrestin CHO cells by 
qPCR. The expression was normalized to the control, untransfected β-arrestin CHO cells. Two sets of 
primers were tested: H1-H2 shown in blue and H3-H4 shown in yellow (n=2). (b) Basal activity of 
CHO β-arrestin cell lines established with four ProLink vectors expressing GPR143 wildtype or 
double mutant. The cell lines with the higher constitutive activity in comparison to the control were 
the ones transfected with ProLink2 (green) and ARMS2 (blue) plasmids (n=2).  
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The CHO cells transfected with the ProLink2 and ARMS2 plasmids had the higher GPR143 
expression among the four cell lines however, the modified ProLink tag of ARMS2 might 
increase aspecific signals. Thus, we decided to use the CHO cells transfected with the 
ProLink2 for further experiments. 
Using an antibody anti-PL and a plasma membrane marker (E-cadherin), we detected the 
subcellular localization of the wt and mutant GPR143 in the stably transfected β-arrestin 
CHO cell lines (Fig 26). While the wt receptor is intracellularly expressed in the perinuclear 
region and in cytoplasmatic vesicles, the mutant GPR143 is also present at the cell surface co-
localizing with the plasma membrane marker.  
 
 
Figure 26. Characterization of CHO β  arrestin cells expressing wildtype (wt) or mutant 
GPR143. The subcellular localization of GPR143 was detected by immunofluorescence. Cells were 
fixed and stained with monoclonal anti-ProLink antibody (against PL-tagged GPR143) and polyclonal 
anti-cadherin antibody (plasma membrane marker). Scale bars represent 10 µm.  
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3.9.2 GPR143 stimulation with levodopa  
The β-arrestin CHO cell lines expressing the wt or mutant GPR143 were used to investigate 
the potential levodopa (L-DOPA) activation of different signaling pathways. As previously 
described, we noticed that CHO cell lines expressing wt and mutant GPR143 when not 
stimulated showed a high basal activation in β-arrestin recruitment (Fig 27a) in comparison 
with untransfected β-arrestin CHO cells. Stimulation of GPR143 with L-DOPA (10 µM) 
induced only a minor increase in β-arrestin recruitment as compared to the control and the 
calculated signal-to-noise ratio was 1.12 for the mutant GPR143 and 1.25 for the wt GPR143. 
The DiscoverX company, who designed the β-arrestin recruitment assay, suggested that a 
compound which stimulates a receptor obtaining a signal-to-noise ratio higher than 3 can be 
considered as a valuable agonist. A larger range of L-DOPA concentrations (until 100 µM) 
was tested on the β-arrestin assay to obtain a dose-response curve however, any tendency or 
major gain in signaling response was detected (data not shown).  
The intracellular calcium release associated with GPR143 Gq/11 protein coupling was also 
measured after L-DOPA stimulation. Any increase in intracellular calcium was observed in 
CHO cells expressing wt or mutant GPR143 after 10 µM L-DOPA treatment as compared to 
the control (Fig 27b). Finally, the signaling pathways associated with Gi and Gs protein 
coupling were assessed. If L-DOPA would induce the coupling of GPR143 with Gi protein, a 
reduction in intracellular cAMP concentration would be expected however, no significant 
difference was measured after L-DOPA stimulation in comparison to the cAMP accumulation 
after forskolin treatment (Fig 27c). On the contrary, the coupling of GPR143 to Gs protein 
after L-DOPA stimulation would cause an increase of intracellular cAMP accumulation 
however, L-DOPA treatment of mutant GPR143 expressing cells did not induce any 
increment in cAMP concentration (Fig. 27c). In summary, L-DOPA cannot be considered a 
valuable pharmacological tool to study GPR143 function since the stimulation of the receptor 
by L-DOPA did not induce a significant activation of a precise signaling pathway. 
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Figure 27. Effect of L-DOPA on CHO cells expressing GPR143. (a) β arrestin assay: L-DOPA was 
tested at  10 µM final concentration on CHO cells expressing the wildtype or the mutant GPR143 and 
buffer was used as control. Experiments were performed in duplicates. (b) Calcium mobilization 
assay: data were normalized to the positive control (100 µM ATP), set as 100%, and the buffer control 
was set at 0%. Experiments were performed in triplicates. (c) cAMP accumulation assay: data were 
normalized to the positive control (100 µM forskolin), set as 100%, and to the negative control, buffer, 
set as 0%. Experiments were performed in triplicates. Data are mean ± SEM of three independent 
experiments. Two-tailed t-test: ns not significantly different from the control, * p < 0.05, ** p < 0.01 and 
*** p < 0.001. 
 
3.9.3 Compound library screening  
The β-arrestin recruitment assay optimized for GPR143 was used as high-throughput 
screening technique to test the Tocris and Drug library which taken together included about 
1800 compounds. The goal of the screening was to find a pharmacological tool to investigate 
GPR143 function. Due to the high basal activity observed in CHO cells expressing GPR143, 
the investigation of compounds either increasing or decreasing the receptor activation was 
feasible. Each compound of the libraries was tested at 10 µM final concentration and the 
corresponding signal-to-noise ratio was calculated (Fig 28). As comparison dopamine 
(DOPA) and L-DOPA values were added to the plot (black and magenta spots, respectively, 
Fig 28a). Any compound reached a signal-to-noise ratio equal or greater than 3 and the 
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compounds with the highest ratio (≥ 1.5) produced non-reproducible values. On the other 
hand, about 40 compounds reached a signal-to-noise ratio equal or lower than 0.6 which was 
the threshold suggested by DiscoverX company for potential antagonists or inverse agonists. 
It was possible to confirm three hits compounds from the Drug library as potential inhibitors 
of GPR143 activity due to reproducible and consistent values (highlighted in Fig 28b, 
pimozide in red, niclosamide in green and ethacridine lactate in blue). Additionally, the three 
compounds were tested against a different GPCR, the rat adenine receptor, with high 
constitutive activity and they did not alter its function (Table 10). The described hits are drugs 
currently on the market: pimozide, an antipsychotic drug, niclosamide and ethacridine lactate, 
antiseptic compounds (Table 10). Dose-response curves were obtained with different 
compound concentrations using the β-arrestin assay (Fig 29). The compound potencies were 
in low micromolar range: 2.72 ± 1.17 µM for pimozide, 3.40 ± 1.11 µM for niclosamide and 
26.1 ± 1.03 µM for ethacridine lactate.  
 
Figure 28. High-throughput screening via β arrestin assay of (a) Tocris and (b) Drug libraries. 
CHO cells expressing the mutant GPR143 were used. Each point represents a single compound (n=1) 
tested at 10 µM final concentration. Plotted values correspond to the signal-to-noise ratio (compound 
signal/baseline). Compounds are considered potential GPR143 agonists  if the signal-to-noise ratio is 
higher than 3.0 and potential inverse agonists if it is lower than ≤ 0.6. (a) Data corresponding to L-
DOPA and DOPA (10 µM) are shown in black and magenta, respectively. (b) Reproducible hit 
compounds are highlighted in red (pimozide), green (niclosamide) and blue (ethacridine lactate). 
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Table 10. Hit compounds description. The structure and the principal effects of the hit compounds 
from the Drug library screening are listed. The signal-to-noise ratio of the compounds tested at 10 µM 
final concentration on CHO cells expressing the human mutant GPR143 is specified. As control the 
compounds have been tested on CHO cells expressing the rat adenine receptor, which has an high 
basal activity as well. Data correspond to mean ± SEM of three independent experiments performed in 
duplicates.  
signal-to-noise ratio ± SEM 
compound 
name compound structure 
compound 
description 
human 
GPR143 
CHO cells 
 
rat adenine 
CHO cells 
 
Pimozide 
 
an antipsychotic 
drug used for 
schizophrenia and 
chronic psychosis, 
Tourette syndrome, 
resistant tics and 
paranoid personality 
disorder 
 
0.6 ± 0.1 
 
0.9 ± 0.1 
 
Niclosamide 
 
An antiseptic in the 
anthelmintic family 
especially effective 
against cestodes that 
infect humans  
 
0.6 ± 0.1 
 
1.0 ± 0.1 
 
Ethacridine 
lactate 
 
an aromatic organic 
compound based on 
acridine. Its primary 
use is as an 
antiseptic in 
solutions of 0.1%. It 
is also used as an 
agent for second 
trimester abortion. 
0.6 ± 0.1 
 
0.9 ± 0.1 
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Figure 29. Dose-response curves of hit compounds in β-arrestin assays. CHO cells expressing the 
mutant GPR143 were stimulated with different concentrations of selected compounds: pimozide (red), 
niclosamide (green) and ethacridine lactate (blue). Data were baseline-corrected (signal-baseline) and 
correspond to mean ± SEM of three independent experiments performed in duplicates. EC50 values are 
shown in the legend for each compound.  
 
3.9.4 Validation of hit compounds 
Since the effect of the three hit compounds from the library screening were specific for 
GPR143 (expressed in CHO cells), we tested them in an endogenous cell system, such as 
melan-a cells. In order to detect and measure pigmentation changes, cells were treated with 
compounds for three to five days and a previous cell viability assay was necessary to set the 
proper range of non-toxic compound concentrations.  
After three days of cell treatment, pimozide was toxic at higher concentrations than 10 µM, 
while niclosamide showed 40% of cell viability at 1 µM. Ethacridine lactate displayed 
toxicity at concentrations higher than 100 µM (Fig 30a).  
The melanin assay was performed treating melan-a cells for five days with different  
compound concentrations. Propylthiouracil (PTU), a tyrosinase inhibitor, and 3-isobutyl-1-
methylxanthine (IBMX), a phosphodiesterase inhibitor, were used as controls (Fig 30b). 
Niclosamide and pimozide treatment dramatically reduced cell pigmentation thus, 
niclosamide at 0.5 µM reached 6% of the control melanin amount while pimozide decreased 
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the melanin content of 88% in comparison with DMSO. Ethacridine lactate induced a 39% 
reduction in pigmentation at 1 µM and 85% at 5 µM as compared to the control however, at 
the highest concentration (7.5 µM) the melanin accumulated in the cells was similar to the 
control.  
 
 
 
Figure 30. Treatment of melan-a cells with the hit compounds. (a) MTT assay for cell viability. 
Melan-a cells were treated with different concentrations of pimozide (in red), niclosamide (in green) 
and ethacridine lactate (in blue) for 72 hr and then the cell viability was measured by MTT assay. Data 
were normalized to the cell treatment with vehicles (DMSO or ethanol), set as 100%. Data represent 
one of four independent experiments performed in quadruplicates. (b) Melanin assay. Melan-a cells 
were treated with different concentrations of hit compounds (see Fig 30a) and then the amount of 
melanin produced was isolated and quantified. Data were normalized to the cell treatment with 
vehicles (DMSO and ethanol), set to 1. Propylthiouracil (PTU) and 3-isobutyl-1-methylxanthine 
(IBMX) were used as controls to decrease and increase, respectively, the pigmentation of the cells. 
Data correspond to mean ± SEM from triplicate samples from one of five representative experiments.    
 
3.9.5 Tyrosinase activity 
In order to verify the target specificity of the hit compounds, the tyrosinase activation was 
analyzed in melan-a cell lysates. The tyrosine hydroxylase activity of tyrosinase was first 
examined in lysates of untreated melan-a cells (Fig 31a) incubated with different 
concentrations of the three hit compounds (50 and 100 µM). The purpose was to check the 
direct interaction of the compounds with tyrosinase, whether the reduction in pigmentation 
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observed in the melanin assays was caused by direct tyrosinase inhibition. As control, 
increasing concentrations of unlabeled L-tyrosine were used to compete with [3H]L-tyrosine. 
The tyrosinase activity in melan-a lysates treated with pimozide, niclosamide and ethacridine 
lactate was comparable to the vehicle one, indicating that the compounds do not directly 
inhibit the tyrosine hydroxylase activity (Fig 31a).  
Finally, the tyrosinase function was verified in lysates derived by melan-a cells treated for 
five days with the compounds and used in melanin assay (Fig 31b). A significant inhibition of 
tyrosinase activity was observed in melan-a cell treated with niclosamide as compared to the 
vehicle (ethanol). The enzyme activation in melan-a cells after pimozide treatment was 
similar to the DMSO control. Ethacridine lactate induced a reduction in tyrosinase activity 
only at the highest concentrations (5 and 7.5 µM). Niclosamide and ethacridine lactate 
seemed to indirectly affect tyrosine hydroxylase activity, which could be a potential reason 
why the pigmentation was reduced in melan-a cells. 
 
Figure 31. Effect of hit compound treatment on tyrosinase activity. (a) Tyrosinase assay 
performed treating melan-a cell lysates with different concentrations (50 and 100 µM) of hit 
compounds: pimozide, niclosamide and ethacridine lactate. Data were normalized to the untreated 
melan-a lysates (L-tyr 0 µM), set as 100%. Positive controls correspond to L-tyrosine treatments (150 
and 300 µM), since unlabeled L-tyrosine competes with [3H]L-tyrosine and the release of radioactive 
water decreases. The vehicles (DMSO and ethanol) were tested as control. (b) Tyrosinase assay 
performed with melan-a cell lysates from melanin assay. Melan-a cells were treated with different 
concentrations of hit compounds (see Fig 29b) for 5 days. The melanin was isolated from the cell 
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lysates, which were tested for tyrosinase activity. L-tyrosine (150 and 300 µM) and the vehicles 
(DMSO and ethanol) were used as controls. The tyrosinase activity of untreated melan-a cells was set 
as 100%. Experiments were performed in triplicates. Data are mean ± SEM of one experiment. Two-
tailed t-test: ns not significantly different from the control, * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
3.9.6 Discussion 
Ocular Albinism type I (OA1) is a X-linked form of albinism characterized by optical 
anomalies typical of albinism however, the cutaneous changes in pigmentation are usually 
mild or absent [129]. Despite the fact that the skin of OA1 patients seems not to be affected, 
histological analysis showed that subcellular abnormalities are present in both skin 
melanocytes and retinal pigment epithelium (RPE) [92]. The RPE appears hypopigmented 
because melanin is concentrated in few giant melanosomes instead of being homogenously 
dispersed in the cell and also the number of melanosomes is reduced [91].  
GPR143 is the protein product of the Oa1 gene and its mutations were found to be responsible 
for OA1 development [96]. GPR143 is mainly expressed in pigmented cells of the eye and 
skin however, recently its expression was also found in the central nervous system and in 
peripheric tissues [114]. Two sorting signals are present in GPR143 coding sequence which 
are necessary and sufficient for its intracellular localization [99]. GPR143 is localized to the 
membrane of melanosomes in pigmented cells and on lysosomes and early endosomes in non-
melanocytic cells [99]. The pathophysiological role of GPR143 in pigmented cells is still 
unclear nevertheless, considering the subcellular consequences of GPR143 mutation, the 
suggested function for the receptor is the regulation of melanogenesis rate and melanosome 
maturation [104,124]. GPR143 shares structural and functional similarities with G protein-
coupled receptors (GPCRs; Schiaffino et al. 1999) and a characteristic feature all GPCRs have 
in common is the coupling with heterotrimeric G proteins. Different types of G proteins and 
effectors were found to co-precipitate and co-localize with GPR143 in melanocytes, such as 
β-arrestin, Gαo, Gαi and Gβ subunits [97,113] and so far only levodopa, L-DOPA, was 
proposed to be the GPR143 endogenous agonist activating the the Gq/11 protein associated 
pathway [113].  
The aim of our investigation was to find a valuable pharmacological tool to study the function 
of GPR143 and clarify its role in the OA1 pathogenesis. The first step consisted in the 
validation of L-DOPA as GPR143 agonist. Exchanging the two sorting signal sequences into 
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alanine residues, we generated a double mutant GPR143 expressed at the cell plasma 
membrane and accessible by compounds from the extracellular space.  
We established CHO cell lines expressing either the wildtype (wt) or the mutant GPR143 and 
optimized specific cell-based assays to test the activation of GPR143 through different 
downstream signaling pathways, such as the β-arrestin recruitment assay, calcium 
mobilization assay and cAMP accumulation assay. Performing the β-arrestin recruitment 
assay we observed that the β-arrestin CHO cell lines expressing GPR143 displayed a high 
constitutive activation in comparison with the untransfected β-arrestin CHO cells, as 
previously suggested by Innamorati et al, 2006.  
L-DOPA was tested in the β-arrestin recruitment assay against the wt and the mutant GPR143 
and only a slight increase in activation was observed at 10 µM final concentration. The 
DiscoverX company, who designed the β-arrestin recruitment assay, suggested that a valuable 
agonist tested at 10 µM should have a signal-to-noise ratio equal or greater than 3. L-DOPA 
displayed a signal-to-noise ratio of 1.12 for the mutant GPR143 and 1.25 for the wt GPR143. 
Since the compound was previously reported to have low affinity for the receptor (Kd 9.35 
µM [113] and Kd 79.1 µM [115]), higher L-DOPA concentrations (until 100 µM) were tested 
however, the signal-to-noise ratio did not increase. L-DOPA was tested on GPR143 
expressing CHO cells for the activation of calcium signaling pathway through Gq/11 protein 
coupling and for cAMP accumulation pathways through Gi and Gs protein coupling however 
no significant differences were observed from the controls.  
A recent study showed that L-DOPA could not induce intracellular calcium increase in CHO 
cells transfected with GPR143, differently from the previous study by Lopez et al. (2008), 
however calcium responses to L-DOPA were visible in ARPE-19 cells, derived from RPE 
which endogenously express GPR143 [115]. We observed that L-DOPA slightly induced β-
arrestin recruitment in GPR143 expressing CHO cells but the calcium response was not 
detected, supporting the former findings [115]. An hypothesis could be that the partecipation 
of a third factor is necessary for the activation of GPR143 by L-DOPA and this additional 
component is present only in pigmented cells. An alternative might be that the observed 
calcium release in ARPE-19 cells after L-DOPA treatment is not a GPR143 specific effect, 
since some dopamine receptor subtypes are endogenously expressed in those cells, such as D1 
and D5 subtypes, and their activation induces intracellular calcium increase [130,131]. Recent 
studies indicated that L-DOPA produced by RPE has a role in retinal development through 
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the activation of dopamine receptors present on neural retina cells however, the hypothetical 
L-DOPA targeting of dopamine receptors on RPE has never been approached yet [116]. RPE 
cells differentiate already during the first days of eye formation [89] and during this time 
tyrosinase produce L-DOPA, which is then secreted and taken up by retina neurons. The 
dopamine produced by L-DOPA in immature retina cells induce activation of dopamine 
receptors and play a role in retinal differentiation since early stages of development. A more 
focused investigation needs to address the link between GPR143 activation by L-DOPA and 
L-DOPA targeting of dopamine receptors in RPE and neural retina.  
The β-arrestin recruitment assay resulted the best technique to analyze the function of 
GPR143 since it showed a slight activation of GPR143 after L-DOPA treatment and a 
GPR143 constitutive activity which was previously observed [111]. The β-arrestin 
recruitment assay was suitable for high-throughput screening thus, we decided to screen two 
compound libraries in order to find more valuable ligands for GPR143. In addition the 
receptor basal activity displayed in the assay opened the opportunity to investigate not only 
potential agonists but also potential inverse agonists which decrease the activity of the 
receptor. The wt and mutant GPR143 exhibited similar behaviour when L-DOPA was tested 
in the β-arrestin recruitment assay and calcium mobilization assay, as they both showed high 
basal activity and comparable signal-to-noise ratios. For this reason we decided to test the 
compounds against the mutant GPR143, which is accessible to all compounds indipendently 
to their size and hydrophobicity level.  
Two compound libraries were screened against GPR143: the Tocris library, which contains a 
collection of small molecules biologically active at most of the important biological targets 
(GPCRs, ion channels, kinases, transporters) and the drug library including important drugs 
available on the market. The screening resulted in three reproducible hit compounds, which 
decreased the constitutive activation of GPR143 with a signal-to-noise ratio close to 0.6, as 
was suggested by the DiscoverX company for potential antagonists or inverse agonists.  
The hit compounds were drugs currently on the market and their potency at GPR143 were in 
the low micromolar range. The hit compounds were pimozide, an antipsychotic drug active on 
dopamine receptors [132], niclosamide, an oral antihelminthic drug lately discovered to be 
active against cancer cells [133], and ethacridine lactate, antiseptic and abortifacient. The 
specificity of the compound effects observed in the β-arrestin recruitment against GPR143 
was proven by testing them against CHO cells expressing a GPCR with high constitutive 
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activity, the rat adenin receptor. The compound treatment did not induce any decrease in β-
arrestin recruitment on rat adenin receptor expressing cells, indicating that the displayed 
effect on GPR143 is specific for the receptor.  
In order to investigate the effect of the compounds in pigmented cells endogenously 
expressing GPR143, melan-a cells derived from murine melanocytes were tested with 
different concentrations of compounds and then the accumulated melanin content was 
quantified. The cell viability assay indicated the nontoxic concentration range of each 
compound for a long-term (three days) cell treatment. The results of the melanin assay 
showed that the treatment with the three hit compounds induced a dose-dependent reduction 
in melan-a cell pigmentation.  
The melanin synthesis in melanocytes and RPE is controlled by tyrosinase, an enzyme 
responsible for the tyrosine hydroxylation in L-DOPA and its oxidation to dopaquinone. 
Thus, we checked if the reduction in melan-a cell pigmentation was due to the inhibition of 
tyrosinase activity by the compounds. Treating melan-a lysates with different concentrations 
of compounds, we observed that the three compounds did not directly inhibit tyrosinase thus, 
the enzyme activity was comparable to the vehicle treatments. On the other hand, analyzing 
the melan-a lysates derived from compound treatment for the melanin assay, a strong 
inhibition of tyrosinase activity was displayed by niclosamide and ethacridine lactate. These 
two compounds did not directly influence tyrosinase but the pigmentation reduction was due 
to an inhibitory effect on the enzyme. On the contrary, the reduction in pigmentation in 
melan-a cells derived by pimozide treatment was not due to the inhibition of tyrosinase 
activity. Since we proved that pimozide was selectively inhibiting GPR143 constitutive 
activity, this compound might be able to inactivate GPR143 inducing a reduction in 
melanocyte pigmentation.  
In a previous study GPR143 was inactivated by interference RNA in pigmented MNT-1 cells 
and the melanosome morphology and composition was analyzed when GPR143 expression 
was silenced [103]. It was found that the number of mature melanosomes and melanin content 
was reduced of 50% as compared to the control cells. After 5 days of GPR143 silencing, 
abnormal enlarged pigmented structures appeared in the cells however the pigmentation and 
the number of melanosomes did not increase [103]. We suggest that pimozide decrease 
GPR143 function and this condition could resemble the cell phenotype of OA1, in which 
GPR143 is mutated and non-functional. An alternative explanation is that pimozide targets 
81 
 
dopamine receptors on melanocytes, since this compound has high affinity for different 
dopamine receptor subtypes such as D2, D3 and D4 [134]. A few studies demonstrated that 
melanocytes and RPE express dopamine receptors and dopamine agonists could decrease 
tyrosinase activity in hair follicular melanocytes reducing the pigmentation of the cultured 
cells [135,136]. The possibility that pimozide targets a different receptor than GPR143 in 
melan-a cells and activates a signaling pathway causing the melanin content reduction cannot 
be excluded. However, we proved that tyrosinase activity was not inhibited when cells were 
treated with pimozide indicating that the reduction in pigmentation is not due to direct 
tyrosinase regulation.  
In summary, the β-arrestin recruitment assay was a cell-based technique optimized to analyze 
the GPR143 function and was used to confirm its high constitutive activation. L-DOPA 
slightly increased the GPR143 activity but it cannot be considered a valuable pharmacological 
tool to investigate the receptor’s role as its signal-to-noise ratio is close to the control one. 
Further studies are necessary to address the specificity of the L-DOPA target in the RPE 
clarifying its role in the neural retina development. In addition, the compound library 
screening resulted in three hits which were able to decrease GPR143 constitutive activity and 
might be used as scaffolds to develop GPR143 high affinity ligands. One of these hit 
compounds, pimozide, is a promising candidate to study GPR143 function in an endogenous 
system since it is able to reduce the pigmentation of melanocytes without interfering with 
tyrosinase activity. We proved that pimozide can selectively decrease GPR143 basal activity 
in CHO cells, however the underlying mechanism of action in an endogenous cell system 
needs to be investigated. 
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3.10 Part II: investigation of GPR143-tyrosinase interaction 
3.10.1 Characterization of GPR143 in COS7 and melan-a cells 
With mutations in the amino acid sequence of the sorting signals (L223A-L224A and 
W329A-E330A) we generated a double mutant GPR143 receptor which does not follow the 
lysosomal/melanosomal sorting pathway and it can be transported to the plasma membrane of 
COS7 cells. The cell surface expression of the mutant GPR143 can be helpful to singularly 
investigate its role in pigmented and non-pigmented cells.  
The wildtype (wt) and mutant GPR143 were transiently expressed in COS7 cells and 
characterized by immunostaining and western blot. The wt GPR143 was intracellularly 
expressed, localized in vesicles close to the perinuclear region (Fig 32a, upper panels), while 
the mutant GPR143 was more distributed in vesicles in cell perifery and it colocalized with 
cadherin at the cell plasma membrane (Fig 32a, lower panels).  
The Western Blot analysis performed with lysates of GPR143 transiently transfected COS7 
cells showed the proper glycosylation pattern of the receptor [100] which consisted of a 
doublet of 45 and 48 kDa and a thicker band at 60 kDa (Fig 32b).  
 
Figure 32. Characterization of COS7 cells expressing wildtype (wt) or double mutant GPR143. 
(a) Subcellular localization of wt and mutant GPR143 detected by immunofluorescence. Transfected 
COS7 cells were fixed and stained with monoclonal anti-ProLink antibody (against PL tagged-
GPR143), polyclonal anti-cadherin antibody (plasma membrane marker) and DAPI (nuclei). Scale 
bars represent 20 µm. (b) Immunoblot of protein extracts from transfected COS7 cell. The anti-
ProLink antibody was used to detect GPR143. Each lane was loaded with 30 µg of total amount of 
protein.  
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Furthermore, the glycosylation of GPR143 was analyzed with Peptide-N-Glycosidase F 
(PNGase F) and endoglycosidase H (Endo H) in order to report the extent of oligosaccharide 
processing in the exogenous cell system. While PNGase F treatment caused the loss of the 60 
kDa band, Endo H did not cause any oligosaccaride cleavage (Fig 33) meaning that the 60 
kDa band corresponds to a complex oligosaccharide, which is processed in the Golgi 
apparatus. This finding confirmed that GPR143 was carried through the endoplasmic 
reticulum (ER) to the Golgi and then sorted to the proper subcellular organelles.  
 
 
 
Figure 33. Glycosylation study of GPR143 expressed in COS7 cells. The wildtype and mutant 
GPR143 were treated with different endoglycosidases (Endo H and PNGase F) reacting at different 
levels of the glycosylation pattern. GPR143 was subjected to complex glycosylation in the Golgi 
apparatus and to different post-translational modifications apart from N-glycosylation. Each lane of 
the SDS-PAGE was loaded with 50 µg of total protein amount from the lysate, after treatment with the 
corresponding enzyme.  
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3.10.2 Colocalization of GPR143 and tyrosinase in COS7 and melan-a cells 
Tyrosinase contains sorting signals in the C-terminal tail responsible for its lysosomal 
localization in heterologous systems [118], thus we investigated the colocalization in COS7 
cells of tyrosinase and GPR143, as both proteins should follow the lysosomal sorting pathway 
in non-melanocytic cells.  
When the wt GPR143 was expressed together with tyrosinase, colocalization was detectable 
in the perinuclear region of the cell, where ER and Golgi apparatus are located, and only in a 
few vesicles in the cell perifery (Fig 34a). On the other hand, in double transfected COS7 
cells where the mutant GPR143 was present and localized at the cell surface, tyrosinase was 
also partially localized at the plasma membrane overlapping with the mutant GPR143 (Figure 
2a, lower panels).  
The validation of the observed colocalization between tyrosinase and GPR143 was performed 
in a pigmented cell system, melan-a cells, a mouse melanocyte cell line. Since the amino acid 
sequence alignments displayed high identity and similarity between human and mouse 
GPR143 and tyrosinase (Appendix 1, also shown in [109]), melan-a cells were transfected 
with GPR143-YFP and its colocalization with the mouse endogenous tyrosinase was 
investigated. The localization of the two proteins in melan-a cells was similar to the one in 
COS7 cells. The wt GPR143 was localized in vesicles in the cell perifery which appeared 
different but often close to the vesicles containing the endogenous tyrosinase (Fig 34b). The 
mutant GPR143 and the endogenous tyrosinase were localized at the plasma membrane in 
melan-a cells and the vesicles containing tyrosinase were mostly grouped at the cell perifery 
close to the cell surface (Fig 34b).   
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Figure 34. Colocalization of GPR143 and tyrosinase by immunofluorescence in COS7 (a) and 
melan-a (b) cells. (a) COS7 cells were double transfected with GPR143 (wt or mutant) and TYR-
EGFP, fixed and stained with monoclonal anti-ProLink antibody (against PL tagged-GPR143) and 
DAPI (nuclei). (b) Melan-a cells transfected with GPR143-EYFP (wt or mutant) were fixed and 
stained with αPEP7 (against endogenous tyrosinase). Magnification of plasma membrane regions are 
shown as insets. Scale bars represent 20 µm.  
 
3.10.3 Immunoprecipitation of GPR143 and tyrosinase 
Since the previous colocalization studies suggested a direct interaction between GPR143 and 
tyrosinase, the hypothetical physical interaction between these two proteins was investigated 
by immunoprecipitation (IP) in lysates of transfected cells. In double transfected COS7 cells 
GPR143-PL was pulled down by the anti-ProLink antibody and the fractions derived by the 
IP (washing and elution) were analized by Western Blot detecting either GPR143 or 
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tyrosinase (Fig 35a). The lysate fractions were loaded in the SDS-PAGE as control since they 
were not incubated with the antibody. 
GPR143 was identified in the lysates of the double transfected COS7 cells (two bands of 50-
60 kDa) but not in untransfected cells. The GPR143 lower band is overlapping with one of the 
anti-ProLink antibody bands (∼50 kDa) corresponding to the heavy antibody chain, visible in 
the untransfected COS7 cells as well, however the higher GPR143 band is clearly detectable 
in both washing and elution fractions.  
Tyrosinase was detected in the blot by a different species antibody. Thus, the antibody chains 
were not visible. The bands corresponding to different glycosylation patterns of tyrosinase 
(70-84 kDa + EGFP 27 kDa) were detected in the lysate and elution fractions of the double 
transfected COS7 cells, indicating that the enzyme was interacting and pulled down together 
with GPR143.  
Comparable results were obtained pulling down tyrosinase using the anti-GFP antibody in 
double transfected COS7 cells (Appendix 2). Both wt and mutant GPR143 were able to 
interact with tyrosinase since no differences were detected between the two transfected cell 
lines. 
Furthermore, IP studies were also performed in melan-a cells transfected with GPR143-EYFP 
pulling down the mouse endogenous tyrosinase with α-PEP7 (Fig 35b). A broad band 
representing tyrosinase was detected above 75 kDa and it was present in the lysates and 
elutions of all samples, including the untransfected melan-a cells.  
A doublet corresponding to GPR143 (45-60 kDa + EYFP 27 kDa) was observed below 75 
kDa in the lysates and elutions of the transfected melan-a cells, confirming the interaction 
between GPR143 and endogenous tyrosinase.  
The α-PEP7 was loaded as control in GPR143- and tyrosinase-detecting blots since the 
samples were treated differently (for GPR143: 37 °C 30 min and for tyrosinase: boiled 2 min) 
and as consequence the antibody chains were running differently in the SDS-PAGE 
(Appendix 2). GAPDH was detected to check the specificity of the IP and the amount of 
protein loaded for each fraction. The protein amount was similar for the three cell lines 
(slightly lower in untransfected cells) and the absence of GAPDH in the elution indicates that 
the precipitation is specific for GPR143 and tyrosinase (Appendix 2). 
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Figure 35. Western blotting detection of proteins obtained through immunoprecipitation (IP). 
(a) Immunoblots of IP performed with anti-ProLink antibody in COS7 cell lysates transfected with 
GPR143-PL (wt or mutant) and TYR-EGFP. Untransfected COS7 cells lysates were used as control. 
Each lane was loaded with 30 µl of total volume. The upper blot was stained with the monoclonal anti-
ProLink antibody against the PL tagged-GPR143 and the lower blot with polyclonal anti-GFP 
antibody against the EGFP tagged-TYR. (b) Immunoblots of IP performed with αPEP7 antibody in 
melan-a cells trasfected with GPR143-EYFP (wt or mutant). Untransfected melan-a cells were used as 
control. Each lane was loaded with equal volume of solution (∼ 30 µl). The upper blot was stained 
with αPEP7 (against endogenous tyrosinase) and the lower blot with the monoclonal anti-GFP 
antibody against the EYFP tagged-GPR143. As additional controls, GAPDH was detected in each 
fraction and the antibody used for precipitation (αPEP7) was loaded in each blot.  
 
3.10.4 Fluorescence Resonance Energy Transfer (FRET) 
FRET is a technique which allows insight into protein interaction thus we established a cell 
system to study the direct interaction of GPR143 and tyrosinase. We linked EYFP and ECFP 
to the C-terminal end of GPR143 and TYR, respectively, generating GPR143-EYFP and 
TYR-ECFP fusion proteins. Since previous evidences showed that GPR143 is a 7-
transmembrane protein [112] and tyrosinase is a single membrane-spanning enzyme, both 
characterized by the N-terminal end oriented toward the cytosol, the fluorescent proteins 
(EYFP and ECFP) should be located on the same side of the phospholipidic membrane. The 
constructs were transiently transfected together or singularly in COS7 cells and the cells were 
analyzed by confocal microscopy after fixation.  
Sensitized emission is one method to evaluate FRET efficiency in which the excitation of the 
donor fluorophore (ECFP) leads to the emission of the acceptor molecule (EYFP), if the 
proteins are close enough (1-10 nm) for the energy transfer to occur (Fig 36a). Images of the 
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transfected cells were simultaneously acquired in the three channels (YFP, CFP and FRET), 
as Figure 37 shows. The Nikon A1 software was used to calculate the correction parameters 
(see the formulas in Methods section) by means of single transfected COS7 cells (wt or 
mutant GPR143-EYFP or TYR-ECFP, see Fig 38) and the FRET efficiency value of each 
point in a point-to-point manner, thus the FRET efficiency distribution view was obtained 
(last right panels, Fig 37). The transition from purple to red indicates the increase in FRET 
efficiency from 0 to 100% which corresponds to the intensity of protein interaction. When the 
wt GPR143 was expressed together with tyrosinase, the FRET signal was observed in several 
vesicles in the cell perifery, in addition to the perinuclear region (Fig 37). On the other hand, 
the FRET signal was found at the cell plasma membrane when tyrosinase was co-expressed 
with the mutant GPR143. In this case the FRET efficiency in some regions of the plasma 
membrane was spanning between 20 and 100% (white arrows in Fig 37). 
 
Figure 36. Fluorescence Resonance Energy Transfer (FRET) detection methods. (a) The 
sensitized emission FRET consists in the excitation of the single donor fluorophore (i.e. CFP) and in 
the detection of the acceptor (YFP) emission. If the two proteins are not close enough (< 10 nm) to 
each other, FRET does not occur. (b) The acceptor photobleaching methods consists in bleaching the 
acceptor using an high intensity laser and monitor the donor emission spectrum. If the FRET occurs, 
bleaching the acceptor results in an increased donor emission. 
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Figure 37. FRET images of COS7 cells trasfected with GPR143-EYFP (wt or mutant) and TYR-
ECFP. Sensitized emission method was used to detect interaction of GPR143 (YFP channel) and TYR 
(CFP channel). FRET signal, corrected by CoA and CoB parameters, and FRET efficiency (color scale 
on the far right) are shown. White arrows indicate the plasma membrane regions where FRET signal is 
localized. Controls are shown in Fig 38. Scale bars represent 20 µm.  
 
 
To further validate the interaction of GPR143 and tyrosinase we used the acceptor 
photobleaching method, a simple and quantitative FRET technique which measures the donor 
“de-quencing” in presence of an acceptor (Fig 36b). During FRET the donor fluorescence is 
channeled to the acceptor, thus it is partially quenced. Photobleaching the acceptor 
irreversibly eliminates the quencing effect and the level of donor fluorescence increases. The 
FRET efficiency can be measured substracting the donor fluorescence before to after the 
acceptor bleaching and normalizing this value to the donor intensity after the bleaching (see 
Methods section). The photobleaching of the acceptor was delimited to some regions of 
interest (ROI) which correspond to some vesicles in the cell perifery where the wt GPR143 
and TYR were present and parts of the plasma membrane where the mutant GPR143 and 
TYR colocalize. 
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Figure 38. Control FRET images of COS7 cells transfected either with (a) ECFP-EYFP fusion 
protein or (b) TYR-ECFP or (c) wt GPR143-EYFP or (d) mutant GPR143-EYFP. Sensitized 
emission method was used to detect interaction of GPR143 (YFP channel) and TYR (CFP channel). 
FRET signal, corrected by CoA and CoB parameters, and FRET efficiency (color scale on the far 
right) are shown. Scale bars represent 20 µm.  
 
Images were captured before and after the photobleaching, displaying the fluorescence in the 
CFP and YFP channels (Fig 39). The fluorescence of the ROI were used to calculate the ratio 
of emission intensity after to before the photobleaching and the FRET efficiency (Fig 40). 
The intensity of the ECFP emission increased when GPR143-EYFP and TYR-ECFP were 
expressed together indicating that the pair of fluorophores were involved in a resonance 
energy transfer before the acceptor photobleaching (Fig 40a). The FRET efficacy of the 
double transfected COS7 cells resulted 21.8 ± 4.5% for the wt GPR143 with TYR and 16.3 ± 
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3.4% for the mutant GPR143 with TYR (Fig 40b), which was significantly different from the 
negative controls (single transfected COS7 cells) and comparable to the positive control 
(ECFP-EYFP fusion protein: 28.4 ± 4.4%).  
Taken together we were able to show with IP and two different methods that GPR143 and 
TYR are directly interacting with each other in several regions and this interaction depends on 
the localization of GPR143.  
 
 
Figure 39. FRET acceptor photobleaching in COS7 cells trasfected with GPR143-EYFP (wt or 
mutant) and TYR-ECFP. The EYFP photobleaching was performed and detected in delimited 
regions (highlighted and zoomed in the pictures). Images of GPR143 (YFP channel) and TYR (CFP 
channel) fluorescence are shown before and immediately after the acceptor photobleaching. Scale bars 
represent 20 µm.  
 
92 
 
 
Figure 40. Quantification analysis of FRET acceptor photobleaching in COS7 cells expressing 
GPR143-EYFP (wt or mutant) and TYR-ECFP. (a) Ratio of emission intensity after bleaching to 
that before bleaching is plotted for both the CFP and YFP channels. Single transfected COS7 cells and 
the fusion protein ECFP-EYFP are used as controls. Data represent means ± SEM of four (double 
transfected cells) or two (controls) different cells (two independent experiments). For wt GPR143, the 
photobleaching and the relative quantification was performed in limited intracellular spots, while for 
mutant GPR143, small portions of plasma membrane were photobleached and analyzed (see ROI in 
Fig 39). (b) FRET efficiency was quantified for COS7 cells double transfected with GPR143-EYFP 
(wt or mutant) and TYR-ECFP. Single transfected cells and ECFP-EYFP fusion protein were tested as 
controls. Results are expressed as means ± SEM of four (double transfected cells) or two (controls) 
different cells (two independent experiments). The unpaired t-test was performed: * p<0.05, ns not 
significantly different from the control. Efficacy values refer to the limited regions described in Fig 
39a.  
 
3.10.5 Discussion 
GPR143 is a peculiar G protein-coupled receptor (GPCR) with an undisclosed function in 
pigmented cells whose mutation was found to be responsible for a X-linked form of albinism, 
the Ocular Albinism type I (OA1) [129]. Hypotheses about GPR143 function include to be a 
sensor of melanosome maturation and to delay the fusion of multivesicular bodies (MVBs) to 
lysosomes [104,127]. The mechanism used by GPR143 to recognize the melanosome 
maturation is still an unsolved question, however the suggested purpose of the lysosomal 
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fusion delay was the delivery of melanosomal proteins and this hypothesis gave us an 
indication for further studies. Since in the last decade the interaction between GPCRs and 
proteins was found to be important for their regulation and function [128], our investigation 
focused on the association between GPR143 and tyrosinase, the leading enzyme responsible 
for the melanosome maturation. Previous evidences showed that the function of tyrosinase is 
not influenced by GPR143 mutation, indeed in GPR143 knockout mice tyrosinase is 
expressed and functional in macromelanosomes [91]. However when tyrosinase is knocked 
out or not transported to the melanosomes (membrane-associated transporter protein, Matp, 
knockout mice), macromelanosomes are not formed and GPR143 stops the maturation of the 
organelles in stage II [91]. Those findings underline a possible connection between GPR143 
and tyrosinase or tyrosinase products.   
We first generated a double mutant GPR143 replacing the two sorting signals necessary for its 
intracellular localization with alanine residues [99]. The wildtype (wt) and the mutant 
GPR143 were transiently expressed in COS7 cells and for this purpose the proper DNA 
concentration was researched in order not to overexpress the proteins, indeed in a former 
study the wt GPR143 was found at the plasma membrane in COS7 cells due to high over 
expression [111]. The characterization of the receptors showed that the wt receptor is 
intracellularly localized in the ER, Golgi apparatus and in vesicles which correspond to 
endosomes and lysosomes (data not shown), in agreement with previous studies [97,101]. On 
the other hand, the mutant GPR143 was mainly expressed at the cell plasma membrane. The 
glycosylation study revealed that both wt and mutant receptors were properly processed in the 
Golgi apparatus and were subjected to highly complex post-translation modifications.  
Colocalization studies in transfected COS7 and melan-a cells showed that wt GPR143 and 
tyrosinase converged in some spots but they are mainly localized in close proximity vesicles. 
However, mutant GPR143 and tyrosinase were found to colocalize at the plasma membrane 
and in vesicles close to cell surface. The accuracy of the results was confirmed in melan-a 
cells, where the endogenous mouse tyrosinase was found to colocalize with the mutant 
GPR143.  
Different arguments about the role of GPR143 in tyrosinase transport could derive from these 
findings. An hypothesis might be that GPR143 triggers the delivery of tyrosinase to the 
membrane where it is located, thus if mutant GPR143 localizes at the plasma membrane, 
tyrosinase is delivered to the same compartment. A similar interpretation was already 
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suggested by Cortese et al. (2005) who proposed that GPR143 controls the membrane 
delivery to melanosomes. However, this explanation is not in agreement with some evidences 
observed in pigmented cells of OA1 patients, in which tyrosinase is delivered to melanosomes 
even if GPR143 is not functional or retent in the ER, creating macromelanosomes full of 
melanin [91]. On the other hand, considering that melanosomal and lysosomal markers are 
mixed in the same vesicles when GPR143 is knockout and the two pathways are not separated 
[103], tyrosinase could be delivered to the lysosomes and produce macro-organelles 
containing melanin. A different interpretation for our findings could involve the direct 
interaction of GPR143 with tyrosinase. Thus, mutant GPR143 might transport the enzyme 
from the Golgi apparatus through vesicles to the plasma membrane.  
As further step, the hypothetical direct interaction between GPR143 and tyrosinase was 
investigated. The immunoprecipitation studies in COS7 and melan-a cells showed that the 
two proteins are pulled down together from the cell lysates using antibodies either against 
GPR143 or tyrosinase. The double mutation in GPR143 does not influence the interaction 
with tyrosinase. The physical interaction of GPR143 and tyrosinase was supported by two 
different FRET techniques which demonstrated the close promity of the two proteins in 
several intracellular vesicles in COS7 cells, where the wt GPR143 was transfected, and at the 
plasma membrane, when the mutant GPR143 was present. The FRET efficiency obtained by 
analyzing the interaction of GPR143 and tyrosinase was comparable with the signal obtained 
by the fluorophores fusion protein. In addition, the obtained values of FRET efficacy are in 
the same order of significance of values showed in other studies involving the same 
fluorophore pair (ECFP-EYFP) [137–139], thus they can be considered accurate and reliable. 
Cortese et al. demonstrated that at early stages of melanogenesis (stage I-II) GPR143 controls 
the rate of melanosome biogenesis while at final stages of maturation (stage III-IV) it 
regulates the organelle size and protein content [91]. Considering the results of our 
investigation and the information gained so far about GPR143 regulation, we propose an 
hypothetical model for the biological relevance of the receptor in pigmented cells (Fig 41). 
GPR143, after being processed in the Golgi apparatus, is transported to the early endosomes 
which evolve in premelanosomes due to an enrichment of melanosomal proteins [107]. 
Controlling the early segregation of the melanosomal and lysosomal pathway [127], GPR143 
might regulate the rate of melanosomal biogenesis (Fig 41a). At later stages of melanosomal 
biogenesis GPR143 controls the maturation of the organelles through either perceiving the 
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presence of tyrosinase or controlling the delivery of melanin-related proteins (MRP), 
including tyrosinase, to the organelles (Fig 41a). When MRP are delivered to the 
melanosomes, the melanin synthesis begins and the maturation occurs. GPR143 might 
interact with tyrosinase and its downstream signaling changes, blocking the delivery of MRP 
to the mature organelles which are released to the cell perifery (Fig 41a). Then, GPR143 can 
be ubiquitinated and recycled [110]. Melanin-containing melanosomes are resistant to 
lysosome fusion [103,140] thus, the activity of GPR143 would not be required anymore. 
The GPR143 regulation of early stages of melanogenesis could be associated to the receptor 
constitutive activity and its binding to the Gαi3 subunit (Fig 41a), since the introduction of a 
constitutively active Gαi3 protein in GPR143 knockout mice corrected the abnormal rate of 
melanosomal biogenesis [141]. Additional factors have been associated to the downstream 
pathway of GPR143, such as β-arrestin [111] which might regulate GPR143 signaling after 
the perception of melanosome maturation (Fig 41a). Over a decade ago, it was demonstrated 
that GPCRs are involved in biased signaling through arrestin proteins which activate a G 
protein-independent signaling pathway [142]. Therefore, later stages of melanosome 
maturation could be regulated by the arrestin recruitment after GPR143 binding to tyrosinase, 
which could switch off its basal activity (Fig 41a). 
Most of OA1-associated mutations lead to ER retention of GPR143 while some others 
produce an unfunctional receptor [105]. When GPR143 is not functional (Fig 41b), the 
lysosomal and melanosomal pathways in pigmented cells are not segregated [103] which 
might be caused by an enhanced fusion of immature melanosomes and lysosomes due to the 
absence of GPR143 [103,127]. Part of these endosomes containing melanosomal and 
lysosomal markers, including an non-functional GPR143, could be targeted by the vesicles 
delivering MRP, such as tyrosinase and TRP1 (Fig 41b). GPR143 might not perceive the 
maturation of the organelles, due to loss in signaling function after tyrosinase interaction and 
the presence of lysosomal markers on the melanosomes induces a continuous delivery of 
MRP generating macromelanosomes.  
In summary, we provided evidence of a direct interaction between GPR143 and tyrosinase 
through different methods. The colocalization of these two proteins in COS7 and melan-a 
cells and the FRET studies showed that the subcellular localization of TYR partially depends 
on GPR143. In addition, the physical interaction between GPR143 and TYR was suggested 
by IP studies in COS7 and melan-a cells. The results of our investigation improve the view 
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about GPR143 mechanism of action and open the scenario to new possible prospects about 
the role of GPR143 in the melanosomal biogenesis. These findings have important 
implications in the clarification of the physiopathology of Ocular Albinism type I, since 
GPR143 mutations were found to be responsible for the disease but the receptor role in the 
ocular and neurodevelopmental process is still unsolved.  
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Figure 41. Proposed hypothetical model for the role of GPR143 in the regulation of melanosome 
biogenesis. (a) GPR143 first has a role at early stages of the organellogenesis controlling the rate of 
melanosomal biogenesis, inhibiting the fusion with lysosomes and holding the organelles in the 
perinuclear region through microtubules (MT) action. Then, GPR143 might control the delivery of 
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tyrosinase-containing vesicles to melanosomes (1) or perceive the maturation of the melanosomes 
through interaction with tyrosinase (2). EE early endosomes, LE late endosomes, MVB multivesicular 
body, TYR tyrosinase, TRP1 tyrosinase-related protein 1, TGN trans-Golgi network, stages I-IV refer 
to the maturation steps of melanosomes. (b) Mutations in GPR143 are associated with Ocular 
Albinism type I and could cause (1) GPR143 ER retention or (2) a functional problem in its signaling. 
In any of the two cases, there might be not a complete segregation between lysosomal and 
melanosomal pathway with marker mixing. The melanosomes are dispersed in the cell perifery, a 
reduced number of stage II melanosomes are present and the delivery of melanin-related proteins to 
melanosomes is continuous since the sensor of the organelle maturation, GPR143, is not functional. 
“GPR143 dm” refers to disease mutations in GPR143.  
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4. Summary 
The present thesis deals with the characterization of G protein-coupled receptors (GPCRs) 
and their interaction with modulators on a molecular level. We focused on the structural and 
functional investigation of different types of GPCRs: the well known, previously crystallized 
adenosine A2A receptor and its closely related, but much less investigated relative, the 
adenosine A2B receptor, both of which are promising drug targets, and the underexplored 
orphan receptor GPR143, an intracellular GPCR which is involved in Ocular Albinism type I. 
Our goal was to study the impact of structural changes of GPCRs on ligand binding, 
signaling, and ligand selectivity as well as their allosteric modulation by interaction with other 
proteins. The results of our studies do not only expand the knowledge of basic biological 
processes, but they will also contribute to design of potent and selective receptor ligands 
which have potential as novel therapeutics. The most important results are summarized below. 
1. Adenosine receptors 
The human A2A and A2B adenosine receptors (ARs) are the closest homologs among the four 
AR subtypes. However, the endogenous ligand adenosine and its derivatives NECA and 
CGS21680 show significantly higher affinity for A2AAR than for the A2BAR subtype. The 
largest differences in sequences were found in the loop regions, especially in the extracellular 
loop 2 (ECL2). We created a chimeric receptor exchanging the ECL2 of the human A2AAR 
for the one of the human A2BAR generating the hA2A(ECL2-hA2B) mutant receptor. Ligand 
binding and receptor activation of the loop mutant receptor was compared to that of the 
wildtype (wt) human A2A and A2BAR. 
• We found that the ECL2 in A2A and A2B receptors is involved in ligand recognition and 
subtype selectivity. Adenosine lost its affinity (22-fold) and potency in cAMP 
accumulation studies (70-fold) at the loop mutant (hA2A(ECL2-hA2B)) as compared to the 
wt A2AAR, indicating that the ECL2 plays an important role in the binding of and 
interaction with the endogenous agonist adenosine (Fig 42).  
• Competitive binding studies versus [3H]CGS21680 showed that compounds with an 
extended substituent in the 2-position of adenosine (CGS21680 and PSB-15826) 
displayed a loss in affinity at the loop mutant in comparison with the wt A2A receptor. 
Therefore we could confirm that the A2A ECL2 is involved in binding of large 
2-substituents of adenosine derivatives.  
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Figure 42. Adenosine binding (a) and activation (b) at the wildtype human A2AAR and 
hA2A(ECL2-hA2B) receptor. (a) Competition binding studies versus [3H]CGS21680 using adenosine. 
(b) Adenosine-induced cAMP accumulation assay at CHO cells stably expressing wild type A2AAR, 
wildtype A2BAR and hA2A(ECL2 hA2B) receptor.  
• In addition, we verified that the ECL2 of the A2A and A2BAR is associated with 
conformational changes. Binding studies versus the A2A antagonist [3H]MSX-2 revealed 
a marked biphasic behaviour corresponding to the active and inactive receptor species in 
the hA2A(ECL2-hA2B) mutant. The ECL2 exchange appeared to stabilize the active 
conformation of the receptor for agonists such as NECA and CGS21680.  
 
The investigation of the role of extracellular cysteine residues of the human A2AAR for ligand 
binding and receptor activation constituted a further part of this study. Cysteine mutant 
receptors were generated (Cys146Ser, Cys159Ser, Cys166Ser and Cys146Ser-Cys159Ser) 
and various agonists including the endogenous ligand adenosine were tested. The results 
obtained in binding and functional studies were supported by molecular modeling based on 
recently published crystal structures. 
• The three disulfide bonds between ECL1 and 2 (Cys712.69-Cys15945.43, Cys743.22-
Cys14645.30 Cys773.25-Cys16645.50) were found to be essential for the proper activation of 
the A2AAR in response to the endogenous agonist adenosine since all cysteine A2A mutant 
receptors displayed significantly reduced potency for adenosine as compared to the wt 
A2AAR, reaching EC50 values in the micromolar range, similar to those determined for 
the wt A2BAR. 
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• The C159S mutant receptor showed a significant increase in potency for the three 
adenosine derivatives NECA, CGS21680 and PSB-15826 which could be due to the 
higher expression level of this mutant in comparison to the wt A2AAR or to the gain in 
affinity for the adenosine derivatives (in contrast to adenosine itself) at the loop mutant 
receptor. Disruption of the disulfide bond I (Cys712.69-Cys15945.43) generated a mutant 
receptor characterized by higher affinity and potency for adenosine derivatives than the 
wt A2AAR as it was already observed in ECL2 mutant of the close homolog, the A2BAR 
(Peeters et al. (2012) and (2014)). 
• The mutation of Cys146 in the A2AAR critically affected the cell surface expression of 
the receptor shown by ELISA. We suggest that the disulfide bond II (Cys743.22-
Cys14645.30) is critical for receptor folding, and its disruption might cause its ER retention 
(Fig 43).  
• The disulfide bond III (Cys773.25-Cys16645.50) conserved in most class A GPCRs appears 
to be essential for the proper activation of the receptor by the endogenous ligand 
adenosine. However, only minor variations in affinity and potency were observed at the 
C166S mutant for adenosine derivatives NECA, CGS21680 and PSB-15826 as compared 
to the wt A2AAR (Fig 43). This indicates that the GPCR-conserved disulfide bond is not 
required for A2AAR activation by adenosine derivatives. 
 
Figure 43. Binding of adenosine at the A2AAR. The disulfide bonds have been numbered from I to 
III based according to increasing numbers of the cysteine residues. A summary of the main findings is 
shown. 
102 
 
• The length of the 2-substituent of the adenosine derivatives affected their binding and 
activation at the double mutant receptor, in which the two non-conserved disulfide bonds 
I and II (Cys712.69-Cys1595.20 and Cys743.22-Cys1464.67) were disrupted. Small ligands 
such as adenosine and NECA showed a considerable loss in affinity and potency in the 
double mutant receptor as compared to the wt A2AAR. On the other hand, the 
2-substituted adenosine derivatives CGS21680 and PSB-15826 only showed minor 
changes in receptor binding and activation in comparison to the wt A2AAR (Fig 43). The 
flexible ECL2 of the double mutant receptor is stabilized by the bulky substituents of 
CGS21680 and PSB-15826, resulting in similar potency and efficacy than for the wt 
A2AAR. 
 
2. Ocular Albinism type I and GPR143 
Despite its recent “de-orphanization”, the role of GPR143 in the development of neural retina 
and in the Ocular Albinism type I pathogenesis is still unclear. Our investigation focused on 
the function of GPR143 and its intracellular signaling cascade, and the purpose of our study 
was to identify pharmacological tools suitable to analyze GPR143 function, i.e. compounds 
able to activate or inhibit receptor signaling.  
• GPR143 is an intracellular receptor, and thus we generated a double mutant GPR143 
receptor which is expressed in the plasma membrane. Then we established CHO cell lines 
expressing either the wildtype (wt) or the mutant GPR143 to perform pharmacological 
studies.  
• Levodopa (L-DOPA) was proposed to be the endogenous GPR143 agonist by Lopez et al. 
(2008). We tested it using an engineered CHO cell line allowing to monitor agonist-
induced β-arrestin recruitment with a luminescence readout based on a β-galactosidase 
complementation assay (DiscoveRx company). We found that the cell line showed high 
basal activation, and L-DOPA displayed only a small effect with a low signal-to-noise 
ratio. L-DOPA was also tested for activation of the calcium signaling pathway through 
Gq/11 protein coupling and for cAMP accumulation pathways through Gi and Gs protein 
coupling, however no significant differences from controls were observed. GPR143 
might be already completely activated in the artificial cell system indicating a high 
constitutive activity. Thus, L-DOPA could not induce a further significant activation of 
the receptor. Since GPR143 activation by L-DOPA previously had only been observed in 
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ARPE-19 cells derived from retinal pigment epithelium which endogenously express 
GPR143, a second hypothesis could be that the participation of a third factor is required 
for activation of GPR143 by L-DOPA, and this additional component may be only 
present in pigmented cells. An alternative might be that the observed calcium release in 
ARPE-19 cells after L-DOPA treatment is not a GPR143-specific effect, but mediated by 
other natively expressed receptors that may be directly or indirectly activated by L-
DOPA.  
• In order to find more valuable tools to analyze GPR143 function, we screened two 
compound libraries using the β-arrestin recruitment assay. The screening campaign 
resulted in three reproducible hit compounds, which decreased GPR143 activation with 
potencies in the low micromolar concentration range (Fig 44). 
• Pimozide, an antipsychotic drug active on dopamine receptors (Fig 44), was found to be a 
promising candidate to study GPR143 function in an endogenous system since it 
selectively reduced GPR143 basal activity and decreased melanocyte pigmentation 
without interfering with tyrosinase activity. Pimozide might be used as a scaffold for 
optimization to develop high affinity GPR143 ligands.  
 
Figure 44. High throughput screening of the Tocris compound library by β-arrestin recruitment 
assay. Each point represents a single compound tested at 10 µM final concentration. The reproducible 
hit compound, pimozide, which decreases GPR143 constitutive activity is indicated in green. 
As a second part of the project, the connection between GPR143 and melanosomal maturation 
was investigated through studying the possible interaction between GPR143 and tyrosinase, 
the main enzyme responsible for the melanin synthesis and thus for melanosomal maturation.  
104 
 
• Colocalization studies in transfected COS7 and melan-a cells showed that when the wt 
GPR143 and tyrosinase are expressed together, they are mainly localized in vesicles in 
close proximity. However, tyrosinase was found to colocalize at the cell plasma 
membrane with the mutant GPR143 receptor (Fig 45). 
 
Figure 45. Colocalization studies of tyrosinase and wildtype or mutant GPR143. Melan-a cells 
were transfected with GPR143, fixed and the localization of endogenous tyrosinase and GPR143 was 
detected by staining with antibodies. Scale bars = 20 µm. 
• The interaction between GPR143 and tyrosinase was demonstrated by 
immunoprecipitation studies in COS7 and melan-a cells. In addition, the physical 
interaction of GPR143 and tyrosinase was supported by two different FRET techniques. 
• A hypothesis involves GPR143 triggering the delivery of tyrosinase to the membrane 
where it is located, thus if the mutant GPR143 localizes at the plasma membrane, 
tyrosinase is delivered to the same compartment. Another hypothesis for these findings 
could be that GPR143 directly interacts with tyrosinase, and in this way the mutant 
GPR143 escorts the enzyme from the Golgi apparatus through vesicles, where they 
converge, to the plasma membrane.  
• We provide evidence for a direct interaction between GPR143 and tyrosinase through 
different methods. Our results are critical for understanding the GPR143 mechanism of 
action in melanosomal biogenesis. GPR143 might control the maturation of melanosomes 
by perceiving the presence of tyrosinase or by controlling the delivery of melanin-related 
proteins, including tyrosinase, to the organelles. These findings have important 
implications for the clarification of the pathophysiology of Ocular Albinism type I, since 
GPR143 mutations were found to be responsible for the disease. 
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5. Materials  
5.1 Chemicals and tested compounds 
ADA Roche, 10102105001 
Adenosine Sigma, A9251 
ATP Roth, 987-65-5 
Agarose Roth, 2267.2 
Amaxa kit for Nucleofector device  Lonza, Walkersville, MD 
Ampicillin sodium salt Applichem, A0839 
BAY60-6583 Dr. Thomas Krahn, Bayer AG 
BSA, albumin fraction V Applichem, A1391 
Bromophenol blue Applichem, 3640 
Calcium chloride dihydrate Fluka, 21097 
cAMP Enzo Life Science, 80-0056 
CGS21680 Tocris, 1063 
DMSO Applichem, A3608 
DMSO for cell culture Applichem, A3672 
EDTA Roth, 8040.3 
Ethacridine lactate Selleckchem, S4196 
Ethanol ZVE Universität Bonn, 123974 
FCS Sigma, F-0804 
Forskolin Applichem, 66575-29-9 
Fura-2 AM Molecular probes, F1221 
G418 Calbiochem, 345810 
Glacial acetic acid Merk, 1.00063.1011 
D-(+)-Glucose Sigma, G-7012 
Glycerine Applichem, A1123,1000 
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HEPES Sigma, H-3375 
Hydrochloric acid, 37% Applichem, A 0659 
IBMX Fluka, 58620 
Isopropanol ZVE Universität Bonn, 123903 
jetPRIME transfection kit Polyplus Transfection, Darmstadt, Germany 
L-Glutamine Cambrex Bioscience 
LB-Agar Invitrogen, 22700-041 
LB-powder medium Applichem, A0954,901 
Lipofectamine Invitrogen, 11668019 
Magnesium chloride Sigma, M-8266 
Magnesium sulphate Sigma, M-2643 
2-Mercaptoethanol Applichem, A4338 
Monopotassium phosphate Sigma, P-9791 
Mycophenolic acid Tocris, 1505 
MSX-2 Synthesis in AK Prof. Dr. C.E. Müller 
NECA Sigma, E-2387 
Niclosamide Sigma, N3510 
Oregon Green 488 BAPTA-1, AM Molecular probes, O6807 
Paraformaldehyde Applichem, 3813,025 
Pen-Strep solution Gibco, 15140 
Pimozide Sigma, P1793 
Pluronic F-127 Sigma, P2443 
Polybrene Aldrich, 10,768-9 
Poly(ethyleneimine) in 50% (w/v) water Sigma Aldrich, P 3143-1L 
Potassium chloride Fluka, 60128 
PSB-15826 Synthesis in AK Prof. Dr. C.E. Müller 
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PTU Sigma, P7629 
Ro20-1724 Hoffmann La Roche 
Scintillation cocktail Luma safe scintillation cocktail, Perkin Elmer, 
3087 
Sodium acetate Applichem, 4555,025 
Sodium butyrate Fluka, 19364 
Sodium chloride Sigma, P-9541 
Sodium hydrogen carbonate Sigma, S-5761 
Sodium hydroxide Fluka, 71689 
Trypsin Lonza, 17-160 
TRIS Roth, AE15.3 
Triton X-100 Sigma, X-100 
Xanthine Applichem, 6665,001 
 
5.2 Instruments 
Analytical balance Sartorius CP225D 
Autoclave VX-95, Systec 
Bacterial shaker Innova 4200, New Brunswick Scientific 
Cell incubator Haeraeus HERAcell 240 and Inc 246, 
Memmert 
Centrifuge Allegra 21 R, Beckman Coulter 
 Avanti J-201, Beckman 
Cell culture flask Cell Star – Greiner Bio-One 
Hamilton syringe Syringes 705, Roth 
Harvester Brandell M24, 48, Gaithersburg, MD, USA 
Heater Thermomixer comfort, Eppendorf 
Homogenizer RW 16 basic, IKA Labortechnik, Germany 
108 
 
Laminar airflow workbenches NUNC Safe flow 1.2 and NUNC BIOFLOW 
LSC-counter Tricarb 2900 TR, Canberra Packard/Perkin 
Elmer 
Microplates Greiner Bio-One 
Multipette Eppendorf Multipette Plus 
Microwave Microwave 800, Severin 
pH meter WTW pH Electrode SenTix 41 
Photometer Beckman DU, 530 Life Science 
Safe-lock tubes Eppendorf 
Softwares GraphPad Prism, version 5 
 Microsoft Excel and Word 
 QuantityOne, version 4.4.0 
 NIS ELEMENT viewer for Nikon 
microscope 
 ClustalW2, European Bioinformatics Institute 
 Clone Manager, version 9 
Sterile filters Fitropur 0.22 µm, Sarstedt 
Thermocycler Biometra TPersonal 
Vortexer IKA Labortechnik MS1 
Water bath GFL 1083 
Western blot equipment BioRad and Invitrogen 
 
5.3 Cell lines and culture media 
CHO cells Dulbecco’s Modified Eagle-F12 Medium (DMEM-F12) 
medium supplemented with 10% fetal calf serum (FCS), 100 
U/ml penicillin G and 100 µg/ml streptomycin (if transfected, 
0.2 mg/ml G418) 
β-arrestin CHO cells F12 medium supplemented with 10% fetal calf serum (FCS), 
100 U/ml penicillin G, 100 µg/ml streptomycin and 0.8 
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mg/ml hygromycin B (if transfected, 0.2 mg/ml G418) 
COS7 cells Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal calf serum (FCS), 100 U/ml penicillin G and 
100 µg/ml streptomycin (if transfected, 0.2 mg/ml G418) 
GP+envAM12 packaging 
cells 
HXM medium which consists of DMEM, 10% FCS, 100 
U/ml penicillin G, 100 µg/ml streptomycin, 1% 
ultraglutamine, 0.2 mg/ml hygromycin B, 15 µg/ml 
hypoxanthine, 250 µg/ml xanthine and 25 µg/ml 
mycophenolic acid 
Melan-a cells  
 
80% RPMI-20% DMEM medium supplemented with 10% 
FCS, 1% sodium pyruvate, 1% glutamate, 5 U/ml penicillin, 5 
µg/ml streptomycin, 1% non-essential amino acids and 200 
nM 12-O-tetradecanoyl phorbol 13-acetate 
 
5.4 Radioligands 
Radioligand Specific activity/Concentration Company 
[3H]MSX-2 84 Ci/mmol Amersham Life Science, UK 
[3H]cAMP 34 Ci/mmol Amersham Life Science, UK 
[3H]CGS21680 36.05 Ci/mmol Perkin Elmer Life Science 
[3H]NECA 17 Ci/mmol Amersham Life Science, UK 
 
5.5 Buffers  
Hanks buffer salt solution (HBSS), pH 7.3 (buffer for cAMP assay and calcium assay)  
Hepes (20 mM), NaCl (130 mM), glucose (5.5 mM), MgSO4 (0.83 mM), MgCl2.6 H2O (0.5 
mM), CaCl2.2H2O (1.4 mM), NaHCO3 (4.17 mM), KCl (5.36 mM), KH2PO4 (0.4 mM) and 
Na2HPO4 (0.3 mM) were dissolved in autoclaved water and the pH was adjusted to 7.4 using 
1 N NaOH. 
 
Lysis buffer pH 7.3 (buffer for cAMP assay)  
Na2EDTA (4 mM) were dissolved in 1 L of water and the pH was adjusted to 7.4 using HCl 
(37%). Then 0.01% Triton X-100 was added.  
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Phosphate buffered saline (PBS), pH 7.4 (washing buffer for cells)  
NaCl (137 mM), KCl (2.7 mM), Na2HPO4 (4.3 mM) and KH2PO4 (1.47 mM) were dissolved 
in 1 L of water. HCl (37%) was used to adjust the pH to 7.4. 
 
Tris-acetate-EDTA buffer (TAE), pH 8 (buffer for DNA agarose gel electrophoresis)  
TRIS (40 mM) was dissolved in 1 L of water. The pH was adjusted to 8 using acetic acid, 
then Na2EDTA (2 mM) was added. 
 
Tris-acetate-EDTA buffer (TAE), pH 8   
TRIS (40 mM) was dissolved in 1 L of water. The pH was adjusted to 8 using acetic acid, 
then Na2EDTA (2 mM) was added.  
 
Fura-2 stock solution  
Calcium-sensitive dye Fura-2 AM (50 µg) were dissolved in 49.9 µl DMSO to get a stock 
solution of 1 mM. Then it was aliquoted into Eppendorf vials and kept at -20 ° C. 
 
5.6 Antibodies 
Mouse monoclonal anti-HA  Covance, Munich, Germany 
Mouse monoclonal anti-ProLink/PK PathHunter DiscoverX, Birmingham, UK 
Rabbit polyclonal anti-pan Cadherin E Abcam, Cambridge, UK 
Mouse monoclonal anti-GPF  Covance, Freiburg, Germany 
Rabbit polyclonal anti-eGFP Thermo Scientific, Darmstadt, Germany 
Rabbit antiserum αPEP-7 Dr. V. J. Hearing, National Cancer Institute 
Goat anti-rabbit-AlexaFluor488 Jackson Immuno Research, Hamburg, Germany 
Donkey anti-mouse-AlexaFluor594  Jackson Immuno Research, Hamburg, Germany 
Donkey anti-rabbit-DyLight649  BioLegend, San Diego, CA 
Goat anti-mouse-HRP Jackson Immuno Research, Hamburg, Germany 
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Donkey anti-rabbit-HRP  Jackson Immuno Research, Hamburg, Germany 
Goat anti-mouse IRDye 800CW Odyssey, LI-COR, Lincoln, NE 
Goat anti-rabbit IRDye 680  Odyssey, LI-COR, Lincoln, NE 
 
 
5.7 Mutagenesis primers 
The base pairs in bold capital letters indicate the mutated region of the gene coding sequence. 
The primers used to generate the chimera A2A(ECL2 A2B) receptor by Gibson assembly are 
color coded as shown in Fig 43, indicating the annealing regions. 
f-hOA1-L223A-L224A  5’-gactgcagtggcctctGCAGCTaaaggaagacaaggca-3’ 
r-hOA1-L223A-L224A 5’-tgccttgtcttcctttAGCTGCagaggccactgcagtc-3’ 
f-hOA1-W329A-E330A  5’-caggaaggagatccagGCGGCAtcactgaccacctc-3’ 
r-hOA1-W329A-E330A 5’-gaggtggtcagtgaTGCCGCctggatctccttcctg-3’ 
hA2A(ECL2 hA2B) 1-f 5’-ggaattgatccgcggccgcaccggtaccatgcccatcatgggctcctcggtgtac-3’ 
hA2A(ECL2 hA2B) 1-r 5’-tgtctttactgttccaacctagcatgggagtcaggccgatg-3’ 
hA2A(ECL2 hA2B) 2-f 5’-ctcccatgctaggttggaacagtaaagacagtgccaccaacaactgcacagaacc-3’ 
hA2A(ECL2 hA2B) 2-r 5’-ccatgtagttcatggggaccacattctcaaagagacacttcacaaggcagcagc-3’ 
hA2A(ECL2 hA2B) 3-f 5’-aagtgtctctttgagaatgtggtccccatgaactacatggtgtacttcaac-3’ 
hA2A(ECL2 hA2B) 3-r 5’-gggagaggggcggaattccggatcctcaggacactcctgctccatcctgggccag-3’ 
f-hA2A C146S  5’-ggttggaacaacTCCggtcagccaaagg-3’ 
r-hA2A C146S 5’-cctttggctgaccGGAgttgttccaacc-3’ 
f-hA2A C159S 5’-gaaccactcccagggcTCCggggagggccaagtgg-3’ 
r-hA2A C159S 5’-ccacttggccctccccGGAgccctgggagtggttc-3’ 
f-hA2A C166S 5’-gagggccaagtggccTCTctctttgaggatgtg-3’ 
r-hA2A C166S 5’-cacatcctcaaagagAGAggccacttggccctc-3’ 
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5.8 Materials for molecular biology  
Deoxyribonuclease I – Amplification grade’ kit  Invitrogen 
DNA Clean and Concentrator kit  Zymo Research 
Gel DNA Recovery kit  Zymo Research 
Gel Red-Nucleic acid stain  Biotium 
HiPure Plasmid Filter Midiprep kit  Invitrogen 
Lambda DNA/HindIII Thermo Scientific 
PerfectPure RNA cultured cell 5 Prime 
PhiX174 DNA-HaeIII digest  Thermo Scientific 
Plasmid Miniprep-Classic kit  Zymo Research 
Q5® High-Fidelity DNA Polymerase NEB Biolabs 
QuantiTect Reverse Transcription kit Qiagen 
Real Master Mix SYBR Rox kit 5 Prime 
Restriction enzymes NEB Biolabs 
T4 DNA Ligase NEB Biolabs 
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6. Methods 
6.1 Cell culture 
6.1.1 General conditions and handling 
The cell lines are handled under sterile conditions (laminar air flow hood) using disposable 
sterile plastic pipettes and flasks. Different sizes of tissue flasks (25 cm2, 75 cm2, 175 cm2) 
are used depending on the aim of the culture. Incubation of cells occurs in a humidified 
incubator with a 5% CO2 at 37°C. Adherent cells are detached by a 0.01% trypsin/0.6 mM 
EDTA solution and counted using a haemocytometer (depth: 0.100 mm, Neubauer improved).  
6.1.2 Transient transfection 
Lipofection is a technique used to inject genetic material into a cell using liposomes, which 
are vesicles that can easily merge with the cell membrane since they are both made of a 
phospholipid bilayer. Lipofectamine reagent contains lipid subunits which can form 
liposomes in an aqueous environment entrapping DNA. Lipofectamine is a cationic liposome 
formulation, which complexes with negatively charged nucleic acid molecules to allow them 
to overcome the electrostatic repulsion of the cell membrane. The DNA-containing liposomes 
(with positive charge on their surfaces) can fuse with the negatively charged plasma 
membrane of living cells. In a 25 cm2 flask 1.5 million cells were seeded thus, their 
confluency was 80-90% at the time of transfection. Before the transfection (2 h), the cell 
medium was changed in medium without antibiotics. 600 µl of Optimem medium were mixed 
to 25 µl of Lipofectamine 2000 reagent and incubate 5 min at RT in order to form liposomes. 
After mixing 10 µg of plasmidic DNA to Optimem medium to reach a final volume of 625 µl, 
the lipofectamine suspension was added and mixed to the DNA solution, incubated 20 min at 
RT and finally transferred to the cells. One day after the cells were splitted (1:10 dilution) and 
seeded in normal medium. The day after the cell medium was changed in selection medium 
containing antibiotic for the only survival of cells that have incorporated the plasmid.   
Another transfection reagent used for transfection of COS7 cells was the jetPRIME 
transfection kit  according to the manufacturer’s recommendations. Finally, melan-a cells 
were transfected using the DNA electroporation method with the Nucleofector device 
following manufacturer’s instructions of Amaxa kit. 
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6.1.3 Stable transfection 
Taking advantage of viruses, genes can be delivered to target cells using the retroviral 
transfection procedure. The concept of virus-based gene delivery is to engineer the virus so 
that it can express the gene of interest and retain its ability to deliver the gene to target cells. 
The use of competent retrovirus is not feasible, since the infected cells will die. Therefore, 
genetically engineered viruses are used in which only genes responsible for viral RNA 
encapsulation, reverse transcription and integration are kept [143].  
Packaging cells (i.e. GP+envAM12, derived from mouse fibroblast) used for virus assembly 
are already transfected with two plasmids, one contains the env gene responsible for the viral 
envelop and the second one contains gag and pol genes of murine leukemia virus (MuLV) 
that are responsible for the group-specific antigen on capsids and the viral polymerase, 
respectively. The presence of hygromycin B, hypoxanthine, xanthine and mycophenolic acid 
in the culture medium causes a selective pressure on cells so they do not lose the three genes. 
The packaging cells are then transfected with a third plasmid that contains the packaging 
signal sequence (Ψ) necessary for the proper insertion of the RNA into the virion and the gene 
of interest cloned into the multi cloning site. Both of these genes are flanked by LTRs where 
the viral promoters and transcriptional enhancers are located. In order to increase the 
infectivity of viruses, a co-transfection with a vector encoding the glycoprotein G of the 
vesicular stomatitis virus (VSV-G) is done so the retrovirus will not only infect by binding to 
specific receptors but rather by binding to phospholipids unspecifically [143]. 
GP+envAM12 packaging cells were seeded in DMEM medium containing 10% FCS, 100 
U/ml penicillin G and 100 µg/ml streptomycin into a flask 24 h before the transfection. The 
cells were then transfected with the receptor DNA (6.75 µg) and the vesicular stomatitis virus 
G protein DNA (VSV-G, 3.75 µg) using Lipofectamine 2000. After 15 h of incubation, the 
medium was removed and replaced by 3 ml of DMEM medium containing 10% FCS, 100 
U/ml penicillin G and 100 µg/ml streptomycin, including 5 mM sodium butyrate. The 
packaging cells were incubated at 32 °C with 5% CO2 for 48 h. Then the supernatant of the 
GP+envAM12 cells was filtered, mixed with 6 µl of polybrene solution (4 mg/ml) and then 
incubated with CHO cells for 2.5 h at 37 °C. After 48 h the cells were selected using 0.8 
mg/ml of G418. After two weeks, the concentration of G418 was reduced to 0.2 mg/ml. 
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6.2 Membrane preparation 
Stably transfected CHO cells were cultured in dishes until confluency. In order to increase the 
exogenous protein expression, valproic acid was added (final concentration: 0.5 mg/ml) one 
day before harvesting [144]. Then cells were washed with sterile PBS and scraped off using 
ice-cold Tris buffer. The cell suspension was homogenized and centrifuged 10 min at 1000 x 
g to remove unbroken cells and nuclei. The supernatant was centrifuged at 30 000 g for 60 
min. The pellet was resuspended in ice-cold 50 mM Tris-HCl buffer (pH 7.4) and stored at -
80 °C until required. Protein concentrations were determined with the Bradford method [107]. 
 
6.3 Molecular biology 
6.3.1 Cloning 
6.3.1.1 Polymerase Chain Reaction (PCR) 
All the PCRs were carried out with the Q5 High Fidelity Polymerase to obtain an optimal 
cloning result with as less faults as possible. The optimal working condition for this enzyme is 
72°C. The annealing temperature (TA) of the primers depends on their sequence. It was 
chosen to be 2-5 °C below the melting temperature. In some cases DMSO can be added to the 
PCR mixture (with a final concentration of 2%) since it enhanced the PCR amplification of 
GC rich regions. The amplification was carried out on a Thermoblock.   
 
Reaction mixture for PCR:  
Template DNA ≈ 10 ng 
Primer forward  5 pmol/µl – final concentration 0.3 µM 
Primer reverse 5 pmol/µl – final concentration 0.3 µM 
 Q5 High Fidelity Polymerase 1 U/µl 
10X Q5 Buffer 5 µl 
dNTPs mix final concentration 0.2 mM 
PCR grade water until final volume of 50 µl  
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PCR program (step 2-4 repeated 20-30 times):  
Step 1: long denaturation 94 °C 4 minutes 
Step 2: denaturation 94 °C 1 minute 
Step 3: annealing Tm - 2-5 °C 1 minute 
Step 4: elongation 72 °C 1 minute/1000bp 
Step 5: final elongation 72 °C 10 minutes 
Step 6: storage 4 °C  
 
6.3.1.2 Analysis and separation of PCR products 
1% agarose gel in TAE buffer containing GelRed-Nucleic acid stain was used to analyze the 
PCR products and plasmids. Gels were run at 100 V for about 25 min. Lambda DNA/HindIII 
and phiX174 DNA-HaeIII digest served as markers. The bands corresponding to the expected 
size were excised from the gel and the DNA was extracted and purified using the Gel DNA 
Recovery kit according to the manufacturer's protocol. 
 
6.3.1.3 Enzymatic digestion 
Different enzymes were used corresponding to the restriction site present in the construct. In 
some cases a double digestion was feasible. The digestion was carried out at 37 °C for 1 h. 
The general reaction mixture was carried out on a Thermoblock and consisted in the 
following reagents. After the digestion the PCR product was purified using DNA Clean and 
Concentrator kit according to manufacturer's protocol. On the other hand, the digested vector 
was analyzed through an agarose gel together with a negative control (not digested vector) 
and then extracted with Gel DNA Recovery kit. 
PCR product or vector 0.5-1 µg 
Restriction enzyme(s) 1 U/µg of DNA 
10X Suggested buffer 1:10 dilution 
10X BSA (if needed) 1:10 dilution 
PCR grade water until final volume of 20-30 µl  
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6.3.1.4 Ligation 
The digested PCR product was ligated into the corresponding digested vector, which carries 
an antibiotic resistance, used afterwards to select the bacteria containing the plasmid. The 
insert/vector molar ratio is usually 4:1. The ligation was performed with the following 
protocol: 
 
Digested vector 50 ng 
Digested PCR product 150 ng 
T4 DNA Ligase 1 µl (~ 400 U) 
10X Ligase buffer 1:10 dilution 
ATP  Final concentration 10 mM 
PCR grade water until final volume of 20-50 µl  
 
The ligation mixture was incubated for 16 h at 16 °C or 30 min at RT. As negative control a 
ligation without the insert was simultaneously carried out. 
 
6.3.1.5 Production of competent E.coli with Calcium Chloride 
Untransformed Top10 E.coli bacteria (50 µl from a bacterial glycerol stock) were inoculated 
in 4 ml of LB medium without any antibiotic and cultivated overnight at 37 °C on a shaker 
(220 rpm). The culture was then inoculated in 40 ml of LB medium and after 45 min of 
incubation, the absorption of the bacteria suspension was measured at 550 nm until the OD550 
reached 0.5. Then the bacterial suspension was centrifuged (1700 g, 20 min, 4 °C), the pellet 
was resuspended in 20 ml of sterile cooled 0.1 M CaCl2 solution and incubated 30 min on ice. 
Bacteria were then centrifuged again, resuspended in 2 ml of CaCl2 solution and 0.5 ml of 
sterile glycerol was added. Aliquots of 100 µl were prepared and stored at –80 °C. 
 
6.3.1.6 Transformation of chemocompetent bacteria 
Aliquots of chemocompetent bacteria were thawed from –80 °C on ice for 30 min. The 
ligation mixture or 10-50 ng of plasmidic DNA were added to the bacterial suspension, 
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carefully mixed and incubated 30 min on ice. The heat shock to produce rearrangements in 
the bacterial membrane was performed at 42 °C for 30 sec and then back on ice for 2 min. 200 
µl of LB medium were then added and the bacterial suspension was incubated 1 h at 37 °C on 
a shaker (300 rpm) in order to let the bacteria recover. The complete mixture was transferred 
on an agar plate containing the selective antibiotic and incubated overnight at 37 °C. 
 
6.3.1.7 Colony screening and MiniPreps 
One day after the bacteria transformation with a ligation mixture, grown clones on the agar 
plates were checked for the right insertion. Several colonies were randomly picked up from 
the agar plate and cultivated in 4 ml of LB medium supplemented with the selective antibiotic 
overnight at 37 °C on a shaker. The next day plasmids were isolated from the bacterial culture 
using Plasmid Miniprep Classic kit. The isolated plasmids are then loaded on an agarose gel 
together with a negative control (vector without insert) to check their size. The negative 
control band should have a lower molecular weight than the vector ligated with the insert. The 
positive plasmids were then digested with the same restriction enzymes used for the insertion 
of the PCR product into the vector and the digestion mix is afterward loaded into a second 
agarose gel where the insert should be cut out from the vector. Sequencing of the positive 
clones is then performed by GATC Biotech, provider of DNA sequencing and bioinformatics 
for industry and academic research. 
 
6.3.1.8 Plasmid preparation by Midipreps 
When high amount of plasmidic DNA is needed (i.e. for mammalian cell transfection), a large 
scale plasmid isolation should be performed. 50 µl of bacterial or glycerol culture was 
inoculated in 4 ml of LB medium with the selective antibiotic and incubated 6-7 h at 37 °C on 
the shaker. The bacterial culture was then amplified to a 100 ml culture and cultivated 
overnight. The day after MidiPreps were performed using HiPure Plasmid Filter Midiprep kit 
according to manufacturer's protocol. 
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6.3.1.9 Site-directed mutagenesis  
The site-directed mutagenesis can be performed by PCR in order to introduce specific and 
intentional changes in the DNA sequence of a gene. The gene of interest has to be subcloned 
in a small plasmid (i.e. pUC19 contains ≈ 2700 bp) to obtain as less fault as possible. The first 
step is a common PCR reaction with small changes, followed by a DNA purification using 
DNA Clean and Concentrator kit according to manufacturer's protocol.  
Mutagenesis PCR program (step 2-4 repeated 30 times):  
Step 1: long denaturation 94 °C 4 minutes 
Step 2: denaturation 94 °C 1 minute 
Step 3: annealing Tm - 2-5 °C 1 minute 
Step 4: elongation 72 °C 10 minutes 
Step 5: final elongation 72 °C 10 minutes 
Step 6: storage 4 °C  
 
The original wildtype DNA differs from the new synthesized molecule in the methylation. For 
this reason the wildtype DNA is then digested by a methylation sensitive DpnI restriction 
enzyme. DpnI is a Type II restriction enzyme which specifically cleaves DNA containing 
methylated adenine (mA) in the recognition sequence GmATC. The general reaction mixture 
and digestion program were the following: 
Purified DNA derived from mutagenesis PCR 10 µl 
DpnI 1µl (≈ 20 U) 
10X NEB Buffer 4 2 µl 
PCR grade water until final volume of 20 µl 7 µl 
 
The reaction was carried out at 37 °C for 90 min then the enzyme was inactivated at 80 °C for 
20 min. The final mixture was transformed into chemocompetent bacteria and transferred on 
agar plate containing the selective antibiotic. The plasmids isolated from the colonies were 
sequenced to confirm the presence of the mutation. 
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6.3.1.10 Gibson assembly master mix 
The technique allows for the successful assembly of multiple DNA fragments, regardless of 
fragment length or end compatibility. Gibson Assembly efficiently joins multiple overlapping 
DNA fragments in a single-tube isothermal reaction [75]. The Gibson Assembly Master Mix 
includes three different enzymatic activities that perform in a single buffer:  
• The exonuclease creates a single-stranded 3´ overhang that facilitates the annealing of 
fragments that share complementarity at one end.  
• The polymerase fills in gaps within each annealed fragment.  
• The DNA ligase seals nicks in the assembled DNA.  
The result is a double-stranded DNA molecule that can serve as template for PCR, RCA or a 
variety of other molecular biology applications, including direct transformation (a short 
overview is shown in Fig 46). The method has been successfully used to assemble 
oligonucleotides, DNA with varied overlaps (15–80 bp) and fragments hundreds of kilobases 
long. 
 
Figure 46. Gibson assembly technique. Overlapping DNA segments can be assembled in a single 
double stranded DNA molecule using the Gibson Assembly master mix, which contains three enzymes 
(exonuclease, DNA polymerase and DNA ligase) working at the same temperature [145]. 
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The Gibson Assembly Master Mix was used to generate a human A2A(ECL2 A2B)AR chimera 
where the human A2A ECL2 was exchanged with the human A2B ECL2. For this purpose, 
three sets of primers were designed to create three PCR products with specific overlapping 
regions (see Material, Mutagenesis primers). Figure 47 shows the final plasmid product with 
the annealing regions of the primers.  
 
Figure 47. Final chimera human A2A(ECL2 human A2B)AR in pQCXIN plasmid generated by 
Gibson Assembly reaction. The three sets of primers created for the reaction are indicated (forward 
and reverse 1-3). The colors correspond to the annealing regions. The “f” and “r” refer to forward and 
reverse primer, respectively. 
 
6.3.2 Quantitative PCR (qPCR) 
6.3.2.1 mRNA extraction 
The mRNA extraction was performed using 5 Prime – PerfectPure RNA cultured cell kit.  
Cells were seeded in a 6 well-plate and cultivated until they reached 80-90% confluency. The 
cells were then washed with PBS, scraped off and transferred in sterile RNase-free tubes. 
After centrifugation, the pellet was resuspended in lysis buffer and kept on ice. The lysate was 
transferred into the purification column where the mRNA binds and centrifuged until it 
completely passed through the column. The mRNA bound to the column was washed with 
washing buffer 1 and 2 and then eluted with the elution buffer. The mRNA concentration was 
determinated by spectral absorption at 260 nm using a 1 cm quartz cuvette, knowing that 1 
OD260 unit corresponds to 40 µg/mL solution of single stranded RNA. The extracted mRNA 
is stored at -80 °C. 
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6.3.2.2 DNaseI digestion 
In order to remove the genomic DNA contamination, the mRNA solutions were treated with 
Deoxyribonuclease I. The DNA digestion was performed using Deoxyribonuclease I – 
Amplification grade kit. 1 µg of mRNA sample was mixed to 1 U of DNaseI (stock: 1 U/µl) 
and reaction buffer and incubated 15 min at RT. Then, 25 mM EDTA was added to the 
reaction mix and incubated 10 min at 65 °C for the inactivation of the enzyme.  
 
6.3.2.3 Reverse transcription 
The mRNA was transcribed in cDNA to be then quantified using the qPCR. The reverse 
transcription was performed using QuantiTect Reverse Transcription kit. The first step 
consisted in an additional genomic DNA digestion, mixing the DNaseI digested mRNA with 
gDNA Wipeout buffer and incubating them 2 min at 42 °C. The second step included the 
reverse transcription which was performed at 42 °C for 30 min mixing the mRNA sample 
from the first step, the reverse transcriptase, the Quantiscript buffer and RT primers. The 
enzyme was then inactivated for 3 min at 95 °C.  
 
6.3.2.4 Real Time PCR  
The quantification of a gene expression was performed using Real Master Mix SYBR Rox 
kit. The cDNA was diluted and mixed to the Real Master Mix buffer containing the 
intercalant dye Syber Green and to specific primers (5 pmol/µL) for the gene of interest. As 
positive control, the quantification of a housekeeping gene, such as the β actin gene, was 
performed at the same time. As negative control, a sample without primers was included. For 
each sample a negative control using not retro-transcribed mRNA was also added. 
The PCR process goes through three main phases as the number of cycles and the amount of 
product generated increase. Initially, when the amount of product is small and enzyme and 
reagents are not limiting, product generation is exponential and the reaction is closest to 100% 
efficiency. This exponential growth is hard to detect initially through real-time fluorescence 
because the amount of product is small. During the linear phase products continue to 
accumulate (Fig 48), but the reaction efficiency begins to fall and reagents become limiting. 
Finally, in the plateau phase of the reaction, accumulation of product ceases as the reaction is 
exhausted.  
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Relative quantification determines the changes in steady-state mRNA levels of a gene across 
multiple samples and expresses it relative to the levels of an internal control RNA or of a 
background control. Therefore, relative quantification does not require standards with known 
concentrations and calculations are based on the comparison of the distinct cycle determined 
by various methods, i.e. crossing points (Cp) and cycle threshold values (Ct) at a constant 
level of fluorescence (Fig 48) [146].  
 
 
Figure 48. Schematic graph of a typical qPCR cycle (adapted from [146]). 
 
6.4 Immunohystochemistry 
Transfected cells were cultured on coverslips in 12-well plates and fixed with a cold 1:1 
methanol/aceton solution for 20 min at -20 °C. Cells were then washed with PBS and blocked 
1 h with 1% BSA/PBS solution. Cells were incubated in the dark 60 min with the first 
antibody and then 30 min with the secondary antibody, both diluted in 1% BSA/PBS. In 
between and after antibody incubations, cells were washed with PBS. Nuclei staining was 
carried out using DAPI. At last coverslips were mounted using ProLong Gold antifade reagent 
(Invitrogen, Darmstadt, Germany) and stored in the dark at 4 °C. A Nikon A1 Spectral 
confocal microscope (Pharmaceutical Institute, University of Bonn, Germany) and Carl Zeiss 
LSM 700 (Ronald O. Perelman Department of Dermatology and Department of Cell Biology, 
New York) were used for imaging. 
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6.5 Bradford protein assay 
The Bradford assay is a spectroscopic analytic procedure for the detection and quantification 
of total amount of proteins. When mixed with a protein solution, the acidic dye reagent 
(Comassie Brilliant Blue G-250) changes color from brown to blue in proportion to the 
amount of protein present in the sample. The difference between the two forms of the dye is 
greatest at 595 nm thus, that is the optimal wavelength to measure the Coomassie dye-protein 
complex. Development of color has been associated with the presence of certain basic amino 
acids (primarily arginine, lysine and histidine) in the protein. The number of Coomassie dye 
ligands bound to each protein molecule is approximately proportional to the number of 
positive charges found on the protein.  
Protein determination was made by comparison to the color response of protein standards, 
prepared as a series of known dilutions (0.5–3 mg/ml in PBS) of BSA (Fig 49). Afterward, 
200 µl of Bradford reagent was mixed to 1 µl of the cell lysate and the absorbance was 
measured at 595 nm. 
 
Figure 49. Example of BSA standard curve for Bradford protein assay. Absorbance measured at 
595 nm. 
 
6.6 Western Blot 
A known amount of protein (∼ 30 µg) was mixed with loading buffer (3X loading buffer for 
GPR143: 0.2 M Tris-HCl pH 6.8, 12% Glycerin, 42% SDS, 15% Mercaptoethanol, 0.03% 
(w/v) Bromphenolblue – 4X loading buffer for tyrosinase: 0.25 M Tris-HCl pH 6.8, 15% 
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Glycerin, 8% SDS, 20% Mercaptoethanol, 0.04% (w/v) Bromphenolblue) and separated in 
10% SDS-PAGE gel and then transfered onto a nitrocellulose membrane (PROTRAN – 
Nitrocellulose Transfer Membrane – Whatman, Sigma, Taufkirchen, Germany) or 
polyvinylidene difluoride membrane (Immobilon, Millipore, Waltham, MA). The Precision 
Plus Protein Kaleidoscope Prestained Protein Standard was used as marker. The membrane 
was blocked 1 hour in a 5% powdered milk/PBS-Tween solution (for COS7 lysates) or 
StartingBlock (TBS) Blocking buffer (for melan-a lysates, Thermo Fisher Scientific, Grand 
Island, NY). Afterward, the membrane was incubated with the primary antibody overnight at 
4 °C or 1 hour at RT, washed 1 h with PBS-Tween, incubated with secondary antibody and 
washed again. The detection was performed with ECL kit (GE Healthcare, Amersham, 
Arlington, IL – Dassel, Germany) according to the manufacturer's instructions. Western blots 
of melan-a lysates were detected with Odyssey (LI-COR, Lincoln, NE) using the following 
secondary antibodies: ODYSSEY goat anti-rabbit IRDye 680 and ODYSSEY goat anti-
mouse IRDye 800CW. 
 
6.7 Immunoprecipitation  
Two days after DNA transfection, COS7 and melan-a cells were scraped off the dishes and 
lysed on ice with lysis buffer (20 mM HEPES pH 7.2, 1% NP-40, 10% glycerol and protease 
inhibitor cocktail (Sigma, Taufkirchen, Germany). The lysate was centrifuged 15 min at 
21000 g and the protein concentration was determined with BCA Protein assay reagent kit 
(Thermo Fisher Scientific, Grand Island, NY) or with Bradford reagent. The protein samples 
were mixed with loading buffer containing 2% SDS (or 14% SDS for GPR143) and boiled for 
2 min (or warmed at 37 °C for 30 min for GPR143). For immunoprecipitation samples, 1 mg 
of lysate was mixed to 2 µg of antibody and incubated overnight at 4 °C on a rotating wheel. 
Protein A-agarose beads (50 µl of suspension for each sample - Thermo Fisher Scientific, 
Grand Island, NY) were washed twice with lysis buffer and then pre-incubated 1 h in 0.1% 
BSA/lysis buffer. Then, beads were washed in lysis buffer twice and incubated with the 
lysate-antibody for 2 hours at 4 °C on a rotating wheel. After the beads were washed four 
times, the proteins were eluted in loading buffer containing 2% SDS (or 14% SDS for 
GPR143) and boiled for 2 min (or warmed at 37 °C for 30 min for GPR143). 
Immunoprecipitated proteins were separated in a 10% SDS-PAGE, transferred to a membrane 
and detected with antibodies (see Western Blot).  
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6.8 Glycosylation studies 
The glycosylation studies were performed using two enzymes: Peptide N-Glycosidase 
(PNGase F) and endoglycosidase H (Endo H).  
PNGase F is an amidase which cleaves N-linked oligosaccharides between the innermost 
GlcAc and asparagine residues of high mannose, hybrid and complex oligosaccharides from 
N-linked glycoproteins. 
Endo H is a highly specific endoglycosidase which cleaves asparagine-linked mannose rich 
oligosaccharides, but not highly processed complex oligosaccharides from glycoproteins. It is 
commonly used to monitor post-translational modification in the Golgi apparatus. Most 
proteins destined for the cell surface are translated by ribosomes in the rough endoplasmic 
reticulum (ER) and translocated into the Golgi. Upon entering the ER a molecule containing 
14 sugar subunits is linked en bloc to an asparagine in a selective manner by the enzyme 
oligosaccharyl transferase. This oligosaccharide molecule moves through the different 
compartments of the Golgi apparatus. Endoglycosidase H is able to cleave each structure of 
this oligosaccharide as it is processed until the enzyme Golgi alpha-mannosidase II removes 
two mannose subunits. Since all later oligosaccharide structures are resistant to Endo H 
cleavage the enzyme is widely used to report the extent of oligosaccharide processing a 
protein has undergone (Fig 50).  
 
 
Figure 50. Peptide N-Glycosidase (PNGase F) and endoglycosidase H (Endo H) cleavage sites 
[147].  
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Cells were transiently transfected and after 48 h of incubation they were detached and 
sonicated (3 times for 10 sec). 50 µg of total lysates were mixed with proper buffers, 
following the manufacturer´s instruction. The reaction mixture was incubated 1 h at 37 °C. 
Thereafter, each reaction was mixed with loading buffer, the proteins were separated into a 
10% SDS-PAGE and transferred to a membrane (see Western Blot).  
 
6.9 Fluorescence Resonance Energy Transfer (FRET) 
Fluorescence Resonance Energy Transfer (FRET) methods are able to detect interactions 
between proteins in living or fixed cells. The FRET process involves a transfer of energy from 
one fluorophore in the excited state (donor) to a second fluorophore (acceptor) [148]. For an 
efficient FRET, there must be an overlap between the donor fluorescence emission spectra 
and the acceptor fluorescence excitation spectra (Fig 51a). In addition, FRET occurs only if 
the two fluorophores are within 2-10 nm distance to each other (Fig 51b). The two proteins of 
interest are linked to the fluorophores and expressed in a cell system [148]. The FRET 
experiment measures the amount of acceptor protein emission after excitation of the donor. In 
this project we used YFP (Yellow Fluorescent Protein) as acceptor fluorophore linked to 
GPR143 receptor and CFP (Cyan Fluorescent Protein) as donor fluorophore linked to 
tyrosinase (TYR).   
FRET detection methods include sensitized emission and acceptor bleaching. The sensitized 
emission technique is based on measuring the FRET signal, exciting only the donor and 
filtrating the emission of the acceptor, from a series of cell sample and control images. Images 
of the donor and the FRET signal are collected and corrected for background intensity, noise 
and contributions that do not arise directly from the FRET signal. On the other hand, the 
principle of the acceptor photobleaching is that in the absence of the acceptor no FRET 
occurs. If the acceptor is photobleached in a defined region of the sample where FRET signal 
is present, the result consists in an increased intensity of the donor signal [148]. 
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Figure 51. Schematic representation of the Fluorescence Resonance Energy Transfer (FRET) 
mechanism of action. (a) The donor emission energy must be absorbed by the acceptor thus, the 
excitation spectra of the acceptor have to overlap with the emission spectra of the donor. (b) The 
FRET occurs only if the fluorophores are within 10 nm of one another. The represented donor is CFP 
(Cyan Fluorescent Protein) and the acceptor is Venus (a variant of Yellow Fluorescent Protein). 
Adapted from [148].  
 
The GPR143 coding sequence was cloned into the pEYFP-N1 vector using KpnI and AgeI 
restriction enzymes, while the TYR was cloned into the pECFP-N1 plasmid using HindIII and 
BamHI. The fusion protein ECFP-EYFP was created by cloning ECFP into the pEYFP-N1 
plasmid using KpnI and AgeI restriction enzymes. COS7 cells (105 cells well-1) were seeded 
on sterile glass coverslips in 12 well-plates and transfected with different combinations of 
DNA plasmids. After 48 h cells were fixed with an ice-cold 1:1 methanol/aceton solution for 
20 min and mounted on slides using Mowiol 4-88 medium (Roth, Karlsruhe, Germany). A 
Nikon A1 Spectral confocal microscope operating with an argon laser was used for imaging. 
Cells were examined with a 60X oil immersion objective. NIS Element Advanced Research 
software 4.0 was used for image analysis.  
For the sensitized emission method, different optical configurations were set up: “Dd 
channel” for excitation and emission of the donor chromophore (ECFP, excitation filter: 457 
nm, emission filter: 482/35 nm), “Aa channel” for excitation and emission of the acceptor 
chromophore (EYFP, excitation filter: 514 nm, emission filter: 540/30 nm) and “FRET 
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channel” for the excitation of the donor and emission of the acceptor chromophore (excitation 
filter: 457 nm, emission filter: 540/30 nm).  
For each image, parameters (high voltage, offset and laser intensity) were adjusted in order to 
limit the spectral bleed through and to avoid the pixel over-saturation. The laser intensity was 
equalized in both FRET and donor channel, while the high voltage was equalized in both 
FRET and acceptor channel. The FRET calibration was performed with single transfected 
cells expressing either GPR143-YFP or TYR-CFP. Correction parameters, CoA (1) and CoB 
(2) were calculated by the software using the following formulas:  
 
where Aa corresponds to the channel where the excitation and the emission of acceptor is 
measured, Dd corresponds to the channel of excitation and emission of the donor and Da 
corresponds to the channel of the excitation of the donor and emission of the acceptor. 
XxDONOR/ACCEPTOR coefficients are average intensities of the donor/acceptor-only images.  
The corrected FRET signal (3) and the FRET efficiency (4) were calculated for each image 
using the following formulas:  
 
where XxFRET members are average intensities of assigned FRET image components. 
For the acceptor photobleaching method, images were captured before and after the 
photobleaching of acceptor molecules in a specific region of the cell. If any interactions 
leading to energy transfer were present, photobleaching of the acceptor will lead to an 
increase of donor fluorescence, as it is no longer quenched by the acceptor. Acceptor 
photobleaching was performed with a high-intensity laser pulse at 514 nm. Images in the Aa 
130 
 
and Dd channels were captured simultaneously before and after the photobleaching. FRET 
efficiency (5) was calculated using the following formula:  
 
where IA is the CFP intensity emission after bleaching and IB is the CFP intensity emission 
before bleaching.  
 
6.10 Enzyme-linked immunosorbent assay (ELISA) 
The cell surface expression of adenosine receptors in CHO cells was verified by enzyme-
linked immunosorbent assay (ELISA). 200000 cells/well were seeded in 24-well plates 24 h 
before the assay. Cells were washed with PBS, blocked 5 min with 1% BSA/PBS and then 
incubated with a HA antibody solution, diluted 1:1000 in 1% BSA/PBS, for 1 h at room 
temperature. After washing with PBS, cells were fixed with a cold 1:1 (v/v) methanol/acetone 
solution for 15 min at -20 °C, washed and blocked again at the same conditions decribed 
above. The horseradish peroxidase-coupled secondary antibody was diluted 1:5000 in 1% 
BSA/PBS and incubated 1 h with the cells at room temperature. Finally, the cells were 
washed with PBS and incubated 50 min with 300 µl of ABTS substrate (Thermo scientific 
Pierce, Rockford, USA). 170 µl of the substrate was transferred in a 96-well plate and the 
absorbance was measured at 405 nm. Independent experiments were performed in triplicates. 
 
6.11 MTT assay 
Melan-a cells (5000 cells/well) were seeded in a 96-well plate and cultivated overnight in the 
incubator. The compounds dissolved in DMSO and ethanol were diluted in the medium (80% 
RPMI-20% DMEM medium), added to the cells and incubated 72 h at 37 °C with 10% CO2. 
The reagent is composed by a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] which needs to be mixed with an 
electron coupling reagent (phenazine methosulfate). The mixed reagents were applied on the 
cells (100 µl) after the supernatant disposal and the cells were incubated for 1 h at the same 
conditions described above. The absorbance was then read at 490 nm. The cells treated with 
the vehicles were used as control and set as 100% cell viability. Independent experiments 
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were performed in quadruplicates. 
 
6.12 Melanin assay 
Melan-a cells were seeded in 10 cm2 dishes (60000 cells/dish) and cultivated overnight at 37 
°C with 10% CO2. Different concentrations of compounds (pimozide, niclosamide and 
ethacridine lactate) were added in each dish and incubated for 5 days at the same conditions 
described above. At the third day the cell medium was disposed and exchanged with fresh 
medium containing the compounds. Cells were treated with vehicles (DMSO and ethanol) as 
negative control, while propylthiouracil (PTU, 300 µM final concentration) and 3-isobutyl-1-
methylxanthine (IBMX, 150 µM final concentration) were used as agents to decrease and 
increase, respectively, the pigmentation of melan-a cells. Afterwards, cells were washed with 
PBS, scraped off the dishes with lysis buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.5, 300 
mM NaCl, 5 mM EDTA and protease inhibitor) and centrifuged 20 min 14000 g at 4 °C. The 
supernatant was transferred in a fresh tube and the protein concentration was determined 
using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Grand Island, NY). The 
cell pellet was washed twice with a solution 1:1 ethanol/ether and let it dry under the fume 
hood. A water solution of 2 N NaOH was added to the dried pellets and warmed up to 80 °C 
in order to dissolve the melanin. A fixed volume of melanin solution (100-200 µl) was 
transferred to a 96-well plate and the absorbance was read at 490 nm. Independent 
experiments were performed in triplicates. 
 
6.13 Tyrosinase activity in cell lysates 
Melan-a cell lysates were used to test the activation of tyrosinase [149]. The reaction mixture 
contained 1 mM cold tyrosine, 0.3 µCi/sample [3H]-tyrosine, 1 mM L-DOPA, 30 µg of 
protein lysate and the proper compound concentration. Lysates derived either from melan-a 
cells treated with compounds for the melanin assay, in this case no compound was added in 
the reaction mixture, or from the lysis of untreated melan-a cells. The reaction was incubated 
at 37 °C for 60 min then separated on a Dowen column. The radioactivity contained in the 
eluted tritium water released during the enzymatic hydroxylation of tyrosine to L-DOPA was 
quantified in a liquid scintillation analyser. Data were normalized to the tyrosinase 
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hydroxylase activity in absence of compounds, set as 100%. Independent experiments were 
performed in triplicates. 
 
6.14 Functional assays 
6.14.1 β-arrestin recruitment assay 
The β arrestin assay is a cell-based method developed by DiscoverX to detect GPCR 
activation after ligand stimulation. The assay is based on Enzyme Fragment Complementation 
(EFC) and it is carried out using a particular cell line where an enzyme, the β-galactosidase, is 
splitted into two inactive fragments: the Enzyme Acceptor (EA) part is linked to the β arrestin 
and the ProLink (PL) part is linked to the GPCR of interest. If a ligand binds and activates the 
receptor, the β arrestin is recruited near the GPCR since this protein is involved in the 
receptor recycling. The recruitment causes the complementation of the enzyme, which is at 
this point active and can hydrolyze a substrate creating chemoluminescence (Fig 52).  
The β arrestin assay is performed with an engineered CHO cell line containing the β arrestin 
protein linked to the EA fragment. This cell line is transfected with the GPCR gene of interest 
linked to the ProLink tag.  
 
Figure 52. General working principle of β-arrestin assay. 
 
The day before the assay, CHO β arrestin cells (20000 cells/well) were seeded in a 96-well 
plate in 90 µl of F12 medium with 10% FCS, 100 U/ml penicillin G and 100 µg/ml 
streptomycin and cultivated overnight. Then, 10 µl of diluted compounds were added to the 
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cell plate and incubated at 37 °C for 90 min. F12 medium was used as negative control. The 
final DMSO concentration in each well was 1%. Afterwards, the PathHunter detection reagent 
(DiscoverX, Birmingham, UK) was added to the cell plate (50 µl/well), incubated 1 h at room 
temperature in the dark and finally chemoluminescence was detected. The high-throughput 
screening was performed adding 1 µl of 1 mM DMSO diluted compound in 99 µl of F12 
medium in each well, in order to test the compounds at 10 µM and keep the 1% DMSO final 
concentration.  
 
6.14.2 Calcium mobilization assay 
Among fluorescence-based assays, measurement of transient calcium mobilization from 
intracellular stores in response to the activation of Gαq protein coupled GPCRs is considered a 
standard approach for the pharmacological characterization of receptors.  
Cells expressing the GPCR of interest are pre-loaded with a fluorescent calcium indicator dye 
which crosses the cell membrane (Oregon Green or Fluo-4). Once inside the cell, the 
lipophilic blocking groups of the dye are cleaved by esterases resulting in a negatively 
charged fluorescent dye that stays inside the cell. If the receptor is activated by a stimulus, 
calcium is released from the endoplasmic reticulum and binds to the dye causing the 
enhancement of fluorescence (Fig 53).  
 
 
Figure 53. General working principle of the calcium mobilization assay (adapted from [150]). 
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CHO β arrestin cells expressing the wt or the mutant GPR143 receptor were seeded in one 
175cm2 flask and cultivated until they reach 80-90% of confluency. The cells were detached 
with trypsin, transferred to a falcon tube containing medium and placed into a 37 °C incubator 
for 45 min allowing them to recover. Afterward, cells were centrifuged and the pellet 
resuspended in Hank’s Balanced Salt Solution (HBSS). The calcium sensitive dye was added 
(Fluo-4 AM, 3 µM diluted in DMSO) together with Pluronic F-127 (60 µM final 
concentration), a detergent permealizing the cell membrane to permit the dye-uptake from the 
cells. Cells were incubated 1 h at room temperature in the dark on a rotating wheel. The 
reagent plate was prepared with the compound dilutions, negative control (HBSS) and 
positive control (100 µM ATP). Then, the cells were centrifuged at lowest velocity and the 
pellet was washed three times with buffer (HBSS). The cells were seeded in a 96-well plate 
with clear flat bottom and incubated under light exclusion for 30 minutes allowing the cells to 
settle down in the wells. The cell and reagent plates were placed into the microplate reader 
which measured the fluorescence intensity at a wavelength of 520 nm following excitation at 
480 nm.  
 
6.14.3 cAMP accumulation assay 
Receptor activation through Gi or Gs proteins is evaluated by analyzing the activity of cellular 
adenylate cyclase.  
CHO cells (200000 cells/well) were seeded in 24-well plates 24 h before performing the 
assay. Cells are then washed and incubated 2 h at 37 °C and 5% CO2 with HBSS. If adenosine 
receptors were analyzed the HBSS was supplemented with 1 U/ml of adenosine deaminase 
(ADA). Where adenosine was tested as an agonist, ADA was omitted. Cells were then 
incubated 15 min with the phosphodiesterase inhibitor Ro20-1724 (final concentration 40 
µM) at 37 °C and 5% CO2.  
To detect the Gi protein signaling pathway, different concentrations of compounds in 5% 
DMSO/HBSS buffer (final DMSO concentration: 1%) were added and, after a 5 min 
incubation at 37 °C, forskolin (10 µM final concentration) was added in every well. The 
supernatant was removed after an incubation of 15 mins at 37 °C. On the other hand, to detect 
the Gs protein signaling pathway, different dilutions of compounds in 5% DMSO/HBSS 
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buffer were added to the cells and incubated 15 min at the same conditions described above. 
The supernatant was then removed and 500 µl of hot lysis buffer (90 °C) were added. 
Cyclic AMP levels were quantified by incubation of an aliquot with cAMP binding protein 
and [3H]cAMP. The assay is based on competition between unlabelled cAMP and a fixed 
amount of [3H]cAMP for binding to a protein which has high affinity for cAMP. The amount 
of labelled protein-cAMP complex formed is inversely related to the amount of unlabelled 
cAMP present in the assay sample. Measurement of the protein–bound radioactivity enables 
the amount of unlabelled cAMP in the sample to be calculated.  
After one hour of mixing on ice, the cAMP amount in the lysates was determined by 
competitive radioligand binding experiments [151]. 50 µl of lysate was incubated with 30 µl 
of [3H]cAMP solution in lysis buffer (final radioligand concentration 3 nM) and 40 µl of 
cAMP binding protein (50 µg/vial) [151]. For the cAMP standard curve, 50 µl of different 
cAMP concentrations were measured instead of the cell lysate. Total binding was obtained 
mixing radioligand solution and cAMP binding protein to lysis buffer, and the background 
was defined in the absence of binding protein. For experiments in reducing conditions, cells 
were preincubated for 2 h with a final concentration of 10 mM dithiothreitol (DTT). The 
mixture was incubated 60 min on ice and then filtered through GF/B glass fiber filters using a 
Brandel harvester. The filters were then washed with ice-cold Tris buffer (50 mM, pH 7.4), 
transferred into vials and incubated for 6 h with 2.5 ml of scintillation cocktail. The vials were 
then counted in liquid scintillation counter. Independent experiments were performed in 
duplicates. Amounts of cAMP were calculated by linear regression from a standard curve and 
normalized to the maximal effect induced by 100 µM forskolin (set as 100%). 
 
Analysis of data 
• Average of the cpm for samples in the absence of unlabeled cAMP is calculated (C0 – 
Total binding). 
• C0/Cx is also determined for each concentration of cAMP and unknowns in the assay. 
• The cpm of known amounts of cAMP (40, 20, 10, 5 and 2.5 pmol) are measured in 
order to calculate a calibration curve. 
• C0/Cx was plotted against pmoles of standard cAMP; a straight line should be 
obtained with an intercept of 1. 
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Scheme of pipetting   
 
 
6.15 Radioligand binding 
Competition experiments were performed with [3H]CGS21680 (2-p-[2-
carboxyethyl]phenethylamino)-5'-N-ethylcarboxamidoadenosine), [3H]MSX-2 (3-(3-
hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) and [3H]NECA (5'-N-
ethylcarboxamidoadenosine) in a final volume of 400 µl. The vial contained 10 µl of 
dissolved compound in DMSO, 90 µl of Tris buffer (50 mM, pH 7.4), 100 µl of MgCl2 
solution (final concentration: 10 mM, only for CGS21680 and NECA), 100 µl of radioligand 
solution (final radioligand concentration: 5 nM [3H]CGS21680, 1 nM [3H]MSX-2 and 3 nM 
[3H]NECA) and 100 µl of membrane preparation (70-150 µg/vial), which was previously 
incubated with 2 U/mg of adenosine deaminase for 20 min. Total binding was measured in 
absence of test compound, while nonspecific binding was determined in the presence of 50 
µM NECA in experiments with [3H]CGS21680 and [3H]MSX-2 and 100 µM N6-((R)-(2-
phenylisopropyl)adenosine (R-PIA) in experiments with [3H]NECA. After an incubation time 
(1 h for [3H]CGS21680, 3 h for [3H]NECA and 30 min for [3H]MSX-2 experiments), the 
assay mixture was filtered through GF/B glass fibre filters using a Brandel harvester (Brandel, 
Gaithersburg, USA). Filters used for binding with [3H]MSX-2 were pre-soaked in 0.3% 
Polyethylenimine solution for 30 min. When adenosine was tested, adenosine deaminase was 
omitted and membranes were washed with 50 mM Tris buffer (pH 7.4) four times more to 
remove as much endogenous adenosine as possible. After harvesting, the filters were washed 
with ice-cold Tris buffer (50 mM, pH 7.4), transferred into vials and incubated for 6 h with 
2.5 ml of scintillation cocktail. The vials were then counted in liquid scintillation counter. 
Independent experiments were performed in duplicates. 
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6.16 Molecular Docking 
The molecular docking studies and the following models of the A2A cysteine mutant receptors 
have been performed by Dr. Vigneshwaran Namasivayam (University of Bonn).  
The recent X-ray structure of the human A2AAR bound to the agonist CGS21680 (4UHR.pdb) 
was obtained from the RCSB Protein Data Bank [152]. The agonist structure PSB-15826 was 
docked into the binding pocket of the A2AAR using AutoDock 4.2 [153]. As an initial step, 
the crystallographic waters and co-crystallized ligand were removed from the X-ray structure. 
The hydrogen atoms were added and protonated using Protonate in Molecular Operating 
Environment (MOE 2014.08) [154]. The AutoDockTools package was applied to calculate 
the partial charges, generate the docking input files and analyze the docking results [153]. 
Three-dimensional energy scoring grids of size 60 × 60 × 60 points with a spacing of 0.375 Å 
were computed. To define the binding pocket for the docking procedure, the grids were 
centered based on the co-crystallized ligand. In the final step, PSB-15826 was docked into the 
binding site using the search algorithm Lamarckian Genetic Algorithm and the default scoring 
function, which is a hybrid scoring function (semi-empirical and free-energy) implemented in 
AutoDock4.2. The putative binding mode of PSB-15826 was selected on the basis of the 
lowest binding energy and visual inspection of the interactions. For obtaining the comparison 
with the binding conformation of NECA, adenosine, the X-ray crystal structures (PDB ID 
2YDO and 2YDV) were downloaded from RCSB and superimposed on the structure obtained 
with CGS21680 [52]. For the mutant receptors, we generated a receptor model by substituting 
the residues using the protein builder and minimization modules of MOE 2014.08.  
 
 
138 
 
7. References 
[1] International Human Genome Sequencing Consortium. Initial sequencing and analysis 
of the human genome. Nature 2001;409:860–921. 
[2] Fredriksson R, Lagerstrom MC, Lundin L, Schioth HB. The G-protein coupled 
receptors in the human genome form five main families. Phylogenetic analysis, 
paralogon groups, and fingerprints. Mol Pharmacol 2003;63:1256–72. 
[3] Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. Molecular 
signatures of G-protein-coupled receptors. Nature 2013;494:185–94. 
[4] Kolakowski LFJ. GCRDb: a G-protein-coupled receptor database. Recept Channels 
1994;2:1–7. 
[5] Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, et al. The GPCR 
Network: a large-scale collaboration to determine human GPCR structure and function. 
Nat Rev Drug Discov 2013;12:25–34. 
[6] Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-
protein-coupled receptors. Nature 2009;459:356–63. 
[7] Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: 
emerging paradigms. Trends Pharmacol Sci 2001;22:368–76. 
[8] Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing 
seven-transmembrane receptors. Nat Rev Drug Discov 2010;9:373–86. 
[9] DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β-arrestins and cell signaling. Annu 
Rev Physiol 2007;69:483–510. 
[10] Palczewski K, Kumasaka T, Hori T, Behnke C, Motoshima H, Fox B, et al. Crystal 
structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739–45. 
[11] Katritch V, Cherezov V SR, Katritch V, Cherezov V, Stevens RC. Structure-function 
of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 
2013;53:531–56. 
[12] Yang J, Zhang Y. GPCR-EXP: a database of experimentally solved GPCR structure 
2015. http://zhanglab.ccmb.med.umich.edu/GPCR-EXP/. 
[13] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein 
Data Bank. Nucleic Acids Res 2000;28:235–42. 
[14] Hollenstein K, Kean J, Bortolato A, Cheng RKY, Doré AS, Jazayeri A, et al. Structure 
of class B GPCR corticotropin-releasing factor receptor 1. Nature 2013;499:438–43. 
[15] Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, et al. Structure of the human 
glucagon class B G-protein-coupled receptor. Nature 2013;499:444–9. 
[16] Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, et al. Structure of a class C 
GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 
2014;344:58–64. 
[17] Doré AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, et al. Structure 
of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 
2014;511:557–62. 
139 
 
[18] White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, et al. Structure of the agonist-
bound neurotensin receptor. Nature 2012;490:508–13. 
[19] Egloff P, Hillenbrand M, Klenk C, Batyuk A, Heine P, Balada S, et al. Structure of 
signaling-competent neurotensin receptor 1 obtained by directed evolution in 
Escherichia coli. Proc Natl Acad Sci USA 2014;111:E655–62. 
[20] Wang C, Wu H, Evron T, Vardy E, Han GW, Huang X-P, et al. Structural basis for 
Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat 
Commun 2014;5:4355. 
[21] Weierstall U, James D, Wang C, White TA, Wang D, Liu W, et al. Lipidic cubic phase 
injector facilitates membrane protein serial femtosecond crystallography. Nat Commun 
2014;5:3309. 
[22] Bortolato A, Doré AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of 
Class B GPCRs: new horizons for drug discovery. Br J Pharmacol 2014;171:3132–45. 
[23] Ballesteros JA, Weinstein H. Integrated methods for the construction of three-
dimensional models and computational probing of structure-function relations in G 
protein-coupled receptors. Methods Neurosci 1995;25:366–428. 
[24] Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling 
in the nervous system: an overview. Trends Neurosci 2009;32:19–29. 
[25] Velasquez S, Eugenin EA. Role of Pannexin-1 hemichannels and purinergic receptors 
in the pathogenesis of human diseases. Front Physiol 2014;5:1–12. 
[26] Fredholm B, Abbracchio M, Burnstock G, Daly J, Harden T, Jacobson K, et al. 
Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143–56. 
[27] Brunschweiger A, Müller CE. P2 receptors activated by uracil nucleotides - an update. 
Curr Med Chem 2006;13:289–312. 
[28] Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International union of 
basic and clinical pharmacology. LXXXI. Nomenclature and classification of 
Adenosine Receptors - An update. Pharmacol Rev 2011;63:1–34. 
[29] Linden J, Thai T, Figler H, Jin X, Robeva AS. Characterization of human A(2B) 
adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in 
human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 
1999;56:705–13. 
[30] Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their 
potential as novel drugs. Biochim Biophys Acta 2011;1808:1290–308. 
[31] Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A 
adenosine receptor. ScientificWorldJournal 2011;11:320–39. 
[32] Leone RD, Lo Y-C, Powell JD. A2AR antagonists: next generation checkpoint 
blockade for cancer immunotherapy. Comput Struct Biotechnol J 2015;13:265–72. 
[33] Popoli P, Pepponi R. Potential therapeutic relevance of adenosine A2B and A2A 
receptors in the central nervous system. CNS Neurol Disord Drug Targets 
2012;11:664–74. 
[34] Wilson CN, Nadeem A, Spina D, Brown R, Page CP, Mustafa SJ. Adenosine receptors 
and asthma. Handb Exp Pharmacol 2009;193:329–62. 
140 
 
[35] Hajiahmadi S, Panjehpour M, Aghaei M, Shabani M. Activation of A2b adenosine 
receptor regulates ovarian cancer cell growth: involvement of Bax/Bcl-2 and caspase-3. 
Biochem Cell Biol 2015:1–9. 
[36] Melani A, Pugliese AM, Pedata F. Adenosine receptors in cerebral ischemia. Int Rev 
Neurobiol 2014;119:309–48. 
[37] Antonioli L, Blandizzi C, Csóka B, Pacher P, Haskó G. Adenosine signalling in 
diabetes mellitus-pathophysiology and therapeutic considerations. Nat Rev Endocrinol 
2015;11:228–41. 
[38] Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K, Linden J. International Union of 
Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. 
Pharmacol Rev 2001;53:527–52. 
[39] Seibt BF, Schiedel AC, Thimm D, Hinz S, Sherbiny FF, Müller CE. The second 
extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as 
evidenced by loop exchange study at A2 adenosine receptors. Biochem Pharmacol 
2013;85:1317–29. 
[40] Thimm D, Schiedel AC, Sherbiny FF, Hinz S, Hochheiser K, Bertarelli DCG, et al. 
Ligand-specific binding and activation of the human adenosine A2B receptor. 
Biochemistry 2013;52:726–40. 
[41] Beukers MW, van Oppenraaij J, van der Hoorn PPW, Blad CC, den Dulk H, Brouwer 
J, et al. Random mutagenesis of the human adenosine A2B receptor followed by 
growth selection in yeast. Identification of constitutively active and gain of function 
mutations. Mol Pharmacol 2004;65:702–10. 
[42] Beukers MW, den Dulk H, van Tilburg EW, Brouwer J, Ijzerman AP. Why are A(2B) 
receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases 
affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. Mol Pharmacol 
2000;58:1349–56. 
[43] Matharu AL, Mundell SJ, Benovic JL, Kelly E. Rapid agonist-induced desensitization 
and internalization of the A(2B) adenosine receptor is mediated by a serine residue 
close to the COOH terminus. J Biol Chem 2001;276:30199–207. 
[44] Peeters MC, Li Q, van Westen GJP, Ijzerman AP. Three “hotspots” important for 
adenosine A(2B) receptor activation: a mutational analysis of transmembrane domains 
4 and 5 and the second extracellular loop. Purinergic Signal 2012;8:23–38. 
[45] Peeters MC, van Westen GJP, Guo D, Wisse LE, Müller CE, Beukers MW, et al. 
GPCR structure and activation: an essential role for the first extracellular loop in 
activating the adenosine A2B receptor. FASEB J 2011;25:632–43. 
[46] Peeters MC, Li Q, Elands R, van Westen GJP, Lenselink EB, Müller CE, et al. 
Domains for activation and inactivation in G protein-coupled receptors - a mutational 
analysis of constitutive activity of the adenosine A2B receptor. Biochem Pharmacol 
2014;92:348–57. 
[47] Liu R, Groenewoud NJA, Peeters MC, Lenselink EB, IJzerman AP. A yeast screening 
method to decipher the interaction between the adenosine A2B receptor and the C-
terminus of different G protein α-subunits. Purinergic Signal 2014;10:441–53. 
141 
 
[48] Liu R, Nahon D, le Roy B, Lenselink EB, IJzerman AP. Scanning mutagenesis in a 
yeast system delineates the role of the NPxxY(x)5,6F motif and helix 8 of the 
adenosine A2B receptor in G protein coupling. Biochem Pharmacol 2015;95:290–300. 
[49] Jaakola V, Griffith MT, Hanson MA, Cherezov V, Ellen YT, Lane JR, et al. The 2.6 
angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. 
Science 2008;322:1211–7. 
[50] Liu W, Chun E, Thompson AA, Chubukov P, Xu F, Katritch V, et al. Structural basis 
for allosteric regulation of GPCRs by sodium ions. Science 2012;337:232–6. 
[51] Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, et al. Structure of the 
adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and 
caffeine. Structure 2011;19:1283–93. 
[52] Lebon G, Warne T, Edwards PC, Bennett K, Christopher J, Leslie AGW, et al. 
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR 
activation. Nature 2011;474:521–5. 
[53] Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao Z-G, et al. Structure of an 
agonist-bound human A2A adenosine receptor. Science 2011;332:322–7. 
[54] Lebon G, Edwards PC, Leslie AGW, Tate CG. Molecular determinants of CGS21680 
binding to the human adenosine A2A receptor. Mol Pharmacol 2015;87:907–15. 
[55] Schiedel AC, Hinz S, Thimm D, Sherbiny F, Borrmann T, Maass A, et al. The four 
cysteine residues in the second extracellular loop of the human adenosine A2B 
receptor: role in ligand binding and receptor function. Biochem Pharmacol 
2011;82:389–99. 
[56] Sherbiny FF, Schiedel AC, Maass A, Müller CE. Homology modelling of the human 
adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-
adrenergic receptor and the human adenosine A2A receptor. J Comput Aided Mol Des 
2009;23:807–28. 
[57] Peeters MC, van Westen GJP, Li Q, Ijzerman AP. Importance of the extracellular loops 
in G protein-coupled receptors for ligand recognition and receptor activation. Trends 
Pharmacol Sci 2011;32:35–42. 
[58] Congreve M, Andrews SP, Dore AS, Hollenstein K, Hurrell E, Langmead CJ, et al. 
Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A antagonists using structure 
based drug design. J Med Chem 2012;55:1898–903. 
[59] Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, Jacobson KA. Glutamate residues in 
the second extracellular loop of the human A2a adenosine receptor are required for 
ligand recognition. Mol Pharmacol 1996;49:683–91. 
[60] Jaakola V-P, Lane JR, Lin JY, Katritch V, Ijzerman AP, Stevens RC. Ligand binding 
and subtype selectivity of the human A(2A) adenosine receptor: identification and 
characterization of essential amino acid residues. J Biol Chem 2010;285:13032–44. 
[61] De Zwart M, Vollinga RC, Beukers MW, Sleegers DF, von Frijtag Drabbe Künzel JK, 
de Groote M, et al. Potent antagonists for the human adenosine A2B receptor. 
Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high 
affinity. Drug Dev Res 1999;48:95–103. 
142 
 
[62] TOPO2. Transmembrane protein display software. Johns, SJ  
http://www.sacs.ucsf.edu/TOPO2/. 
[63] Zhang K, Zhang J, Gao Z-G, Zhang D, Zhu L, Han GW, et al. Structure of the human 
P2Y12 receptor in complex with an antithrombotic drug. Nature 2014;509:115–8. 
[64] Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A. 
Critical role for the second extracellular loop in the binding of both orthosteric and 
allosteric G protein-coupled receptor ligands. J Biol Chem 2007;282:25677–86. 
[65] Unal H, Jagannathan R, Bhat MB, Karnik SS. Ligand-specific conformation of 
extracellular loop-2 in the angiotensin II type 1 receptor. J Biol Chem 
2010;285:16341–50. 
[66] Klco JM, Wiegand CB, Narzinski K, Baranski TJ. Essential role for the second 
extracellular loop in C5a receptor activation. Nat Struct Mol Biol 2005;12:320–6. 
[67] De Graaf C, Foata N, Engkvist O, Rognan D. Molecular modeling of the second 
extracellular loop of G-protein coupled receptors and its implication on structure-based 
virtual screening. Proteins 2008;71:599–620. 
[68] Rader AJ, Anderson G, Isin B, Khorana HG, Bahar I, Klein-Seetharaman J. 
Identification of core amino acids stabilizing rhodopsin. Proc Natl Acad Sci U S A 
2004;101:7246–51. 
[69] Goddard WA, Kim S-K, Li Y, Trzaskowski B, Griffith AR, Abrol R. Predicted 3D 
structures for adenosine receptors bound to ligands: comparison to the crystal structure. 
J Struct Biol 2010;170:10–20. 
[70] Naranjo AN, Chevalier A, Cousins GD, Ayettey E, McCusker EC, Wenk C, et al. 
Conserved disulfide bond is not essential for the adenosine A2A receptor: Extracellular 
cysteines influence receptor distribution within the cell and ligand-binding recognition. 
Biochim Biophys Acta 2015;1848:603–14. 
[71] Ni F, So S-P, Cervantes V, Ruan K-H. A profile of the residues in the second 
extracellular loop that are critical for ligand recognition of human prostacyclin 
receptor. FEBS J 2008;275:128–37. 
[72] Ott TR, Troskie BE, Roeske RW, Illing N, Flanagan CA, Millar RP. Two mutations in 
extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist. 
Mol Endocrinol 2002;16:1079–88. 
[73] Ahn KH, Bertalovitz AC, Mierke DF, Kendall DA. Dual role of the second 
extracellular loop of the cannabinoid receptor 1: ligand binding and receptor 
localization. Mol Pharmacol 2009;76:833–42. 
[74] Olah ME, Jacobson KA, Stiles GL. Role of the second extracellular loop of adenosine 
receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine 
receptors. J Biol Chem 1994;269:24692–8. 
[75] Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO. Enzymatic 
assembly of DNA molecules up to several hundred kilobases. Nat Methods 
2009;6:343–5. 
[76] Yan L, Burbiel JC, Maass A, Müller CE. Adenosine receptor agonists: from basic 
medicinal chemistry to clinical development. Expert Opin Emerg Drugs 2003;8:537–
76. 
143 
 
[77] Katritch V, Kufareva I, Abagyan R. Structure based prediction of subtype-selectivity 
for adenosine receptor antagonists. Neuropharmacology 2011;60:108–15. 
[78] Luthin DR, Linden J. Comparison of A4 and A2A binding sites in striatum and COS 
cells transfected with adenosine A2A receptors. J Pharmacol Exp Ther 1995;272:511–
8. 
[79] Murphree LJ, Marshall MA, Rieger JM, Macdonald TL, Linden J, M DPLJ, et al. 
Human A2A adenosine receptors: high-affinity agonist binding to receptor-G protein 
complexes containing Gbeta4. Mol Pharmacol 2002;61:455–62. 
[80] Varani K, Gessi S, Merighi S, Iannotta V, Cattabriga E, Spisani S, et al. Effect of low 
frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. Br 
J Pharmacol 2002;136:57–66. 
[81] Sabbadin D, Moro S. Supervised Molecular Dynamics (SuMD) as a helpful tool to 
depict GPCR-ligand recognition pathway in a nanosecond time scale. J Chem Inf 
Model 2014;54:372–6. 
[82] Takezako T, Unal H, Karnik SS, Node K. Structure-function basis of attenuated inverse 
agonism of ARBs for active-state AT1 receptor. Mol Pharmacol 2015;88:488–501. 
[83] Scarselli M, Li B, Kim S-K, Wess J. Multiple residues in the second extracellular loop 
are critical for M3 muscarinic acetylcholine receptor activation. J Biol Chem 
2007;282:7385–96. 
[84] Hillmann P, Ko G, Spinrath A, Raulf A, Ku I Von, Wolff SC, et al. Key determinants 
of nucleotide-activated G protein-coupled P2Y2 receptor function revealed by 
chemical and pharmacological experiments, mutagenesis and homology modeling. J 
Med Chem 2009;52:2762–75. 
[85] O’Malley MA, Naranjo AN, Lazarovab T, Robinson AS. Analysis of adenosine A2A 
receptor stability: effects of ligands and disulfide bonds. Biochemistry 2010;49:9181–
9. 
[86] Mazzoni MR, Giusti L, Rossi E, Taddei S, Lucacchini A. Role of cysteine residues of 
rat A2A adenosine receptors in agonist binding. Biochim Biophys Acta 
1997;1324:159–70. 
[87] Scholl DJ, Wells JN. Serine and alanine mutagenesis of the nine native cysteine 
residues of the human A1 adenosine receptor. Biochem Pharmacol 2000;60:1647–54. 
[88] Zhang J, Zhang K, Gao Z, Paoletta S, Zhang D, Won G, et al. Agonist-bound structure 
of the human P2Y12 receptor. Nature 2014;509:119–22. 
[89] Jeffery G. The albino retina: an abnormality that provides insight into normal retinal 
development. Trends Neurosci 1997;20:165–9. 
[90] The National Organization for Albinism and Hypopigmentation. NOAH  
http://www.albinism.org/site/c.flKYIdOUIhJ4H/b.9194783/k.C775/Welcome.htm. 
[91] Cortese K, Giordano F, Surace EM, Venturi C, Ballabio A, Tacchetti C, et al. The 
ocular albinism type 1 (OA1) gene controls melanosome maturation and size. Invest 
Ophthalmol Vis Sci 2005;46:4358–64. 
[92] Garner A, Jay BS. Macromelanosomes in X-linked ocular albinism. Histopathology 
1980;4:243–54. 
144 
 
[93] Palmisano I, Bagnato P, Palmigiano A, Innamorati G, Rotondo G, Altimare D, et al. 
The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, 
regulates melanosome transport in pigment cells. Hum Mol Genet 2008;17:3487–501. 
[94] Incerti B, Cortese K, Pizzigoni A, Surace EM, Varani S, Coppola M, et al. Oa1 knock-
out: new insights on the pathogenesis of ocular albinism type 1. Hum Mol Genet 
2000;9:2781–8. 
[95] Young A, Jiang M, Wang Y, Ahmedli NB, Ramirez J, Benjamin E, et al. Specific 
interaction of Gai3 with the Oa1 G-protein coupled receptor controls the size and 
density of melanosomes in retinal pigment epithelium. PLoS One 2011;6. 
[96] Bassi MT, Incerti B, Easty DJ, Sviderskaya F V, Ballabi A. Cloning of the murine 
homolog of the Ocular Albinism type 1 (OA1) gene: sequence, genomic structure and 
expression analysis in pigment cells. Genome Res 1995;1:880–5. 
[97] Schiaffino MV, Addio M, Alloni A, Baschirotto C, Valetti C, Cortese K, et al. Ocular 
albinism: evidence for a defect in an intracellular signal transduction system. Nat Genet 
1999;23:108–12. 
[98] Winder AJ, Wittbjer A, Rosengren E, Rorsman H. The mouse brown (b) locus protein 
has dopachrome tautomerase activity and is located in lysosomes in transfected 
fibroblasts. J Cell Sci 1993;166:153–66. 
[99] Piccirillo R, Palmisano I, Innamorati G, Bagnato P, Altimare D, Schiaffino MV. An 
unconventional dileucine-based motif and a novel cytosolic motif are required for the 
lysosomal and melanosomal targeting of OA1. J Cell Sci 2006;119:2003–14. 
[100] Schiaffino MV, Baschirotto C, Pellegrini G, Montalti S, Tacchetti C, De Luca M, et al. 
The ocular albinism type 1 gene product is a membrane glycoprotein localized to 
melanosomes. Proc Natl Acad Sci U S A 1996;93:9055–60. 
[101] Shen B, Rosenberg B, Orlow SJ. Intracellular distribution and late endosomal effects of 
the Ocular Albinism type 1 gene product: consequences of disease-causing mutations 
and implications for melanosome biogenesis. Traffic 2001;2:202–11. 
[102] Krogh A, Larsson B, Heijne G von, Sonnhammer ELL. Predicting transmembrane 
protein topology with a hidden Markov model: Application to complete genomes. J 
Mol Biol 2001;305:567–80. 
[103] Giordano F, Bonetti C, Surace EM, Marigo V, Raposo G. The ocular albinism type 1 
(OA1) G-protein-coupled receptor functions with MART-1 at early stages of 
melanogenesis to control melanosome identity and composition. Hum Mol Genet 
2009;18:4530–45. 
[104] Samaraweera P, Shen B, Newton JM, Barsh GS, Orlow SJ. The mouse ocular albinism 
1 gene product is an endolysosomal protein. Exp Eye Res 2001;72:319–29. 
[105] Addio M, Pizzigoni A, Bassi MT, Baschirotto C, Valetti C, Incerti B, et al. Defective 
intracellular transport and processing of OA1 is a major cause of ocular albinism type 
1. Hum Mol Genet 2000;9:3011–8. 
[106] Schiaffino MV, Dellambra E, Cortese K, Baschirotto C, Bondanza S, Clementi M, et 
al. Effective retrovirus-mediated gene transfer in normal and mutant human 
melanocytes. Hum Gene Ther 2002;13:947–57. 
145 
 
[107] Raposo G, Tenza D, Murphy DM, Berson JF, Marks MS. Distinct protein sorting and 
localization to premelanosomes, melanosomes, and lysosomes in pigmented 
melanocytic cells. J Cell Biol 2001;152:809–23. 
[108] Kushimoto T, Basrur V, Valencia J, Matsunaga J, Vieira WD, Ferrans VJ, et al. A 
model for melanosome biogenesis based on the purification and analysis of early 
melanosomes 2001:1–6. 
[109] Schiaffino MV, Tacchetti C. The ocular albinism type 1 (OA1) protein and the 
evidence for an intracellular signal transduction system involved in melanosome 
biogenesis. Pigment Cell Res 2005;18:227–33. 
[110] Giordano F, Simoes S, Raposo G. The ocular albinism type 1 (OA1) GPCR is 
ubiquitinated and its traffic requires endosomal sorting complex responsible for 
transport (ESCRT) function. PNAS 2011;108:11906–11. 
[111] Innamorati G, Piccirillo R, Bagnato P, Palmisano I, Schiaffino MV. The 
melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptor. 
Pigment Cell Res 2006;19:125–35. 
[112] Sone M, Orlow SJ. The ocular albinism type 1 gene product, OA1, spans intracellular 
membranes 7 times. Exp Eye Res 2007;85:806–16. 
[113] Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS. L-DOPA is an 
endogenous ligand for OA1. PLoS Biol 2008;6:e236. 
[114] Fukuda N, Naito S, Masukawa D, Kaneda M, Miyamoto H, Abe T, et al. Expression of 
ocular albinism 1 (OA1), 3, 4- dihydroxy- L-phenylalanine (DOPA) receptor, in both 
neuronal and non-neuronal organs. Brain Res 2015;1602:62–74. 
[115] Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, et 
al. The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor 
and bradycardic responses to DOPA in the nucleus tractus solitarii. Br J Pharmacol 
2014;171:403–14. 
[116] Roffler-Tarlov S, Liu JH, Naumova EN, Bernal-Ayala MM, Mason CA. L-Dopa and 
the albino riddle: content of L-Dopa in the developing retina of pigmented and albino 
mice. PLoS One 2013;8:e57184. 
[117] Ilia M, Jeffery G. Retinal cell addition and rod production depend on early stages of 
ocular melanin synthesis. J Comp Neurol 2000;420:437–44. 
[118] Simmen T, Schmidt A, Hunziker W, Beermann F. The tyrosinase tail mediates sorting 
to the lysosomal compartment in MDCK cells via a di-leucine and a tyrosine-based 
signal. J Cell Sci 1999;53:45–53. 
[119] Jones K, Padmapriya A, Blume G. Aqueous composition comprising active ingredients 
for the de-pigmentation of the skin. Patent., 1999. 
[120] Vijayasaradhi S, Xu Y, Bouchard B, Houghton AN. Intracellular sorting and targeting 
of melanosomal membrane proteins: identification of signals for sorting of the human 
brown locus protein, GP75. J Cell Biol 1995;130:807–20. 
[121] Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in 
mammalian skin and its hormonal regulation. 2004:1155–228. 
146 
 
[122] Winder AJ, Wittbjer A, Rosengren E, Rorsman H. Fibroblasts expressing mouse c 
locus tyrosinase produce an authentic enzyme and synthesise phaeomelanin. J Cell Sci 
1993;104:467–75. 
[123] Wittbjer A, Dahlbäck B, Odh G, Rosengren A, Rosengren E, Rorsman H. Isolation of 
human tyrosinase from cultured melanoma cells. Acta Derm Venereol 1989;69:125–
31. 
[124] Shen B, Samaraweera P, Rosenberg B, Orlow SJ. Ocular Albinism type 1: more than 
meets the eye. Pigment Cell Res 2001;14:243–8. 
[125] Falletta P, Bagnato P, Bono M, Monticone M, Schiaffino MV, Bennett DC, et al. 
Melanosome-autonomous regulation of size and number: the OA1 receptor sustains 
PMEL expression. Pigment Cell Melanoma Res 2014;27:565–79. 
[126] Vetrini F, Auricchio A, Du J, Angeletti B, Fisher DE, Ballabio A, et al. The 
Microphthalmia Transcription Factor (Mitf) controls expression of the Ocular Albinism 
type 1 gene: link between melanin synthesis and melanosome biogenesis. Mol Cell Bio 
2004;24:6550–9. 
[127] Burgoyne T, Jolly R, Martin-Martin B, Seabra MC, Piccirillo R, Schiaffino M V., et al. 
Expression of OA1 limits the fusion of a subset of MVBs with lysosomes - a 
mechanism potentially involved in the initial biogenesis of melanosomes. J Cell Sci 
2014;127:700–700. 
[128] Brady AE, Limbird LE. G protein-coupled receptor interacting proteins: emerging roles 
in localization and signal transduction. Cell Signal 2002;14:297–309. 
[129] King RA, Hearing VG, Creel DJ, Oetting WS. Albinism. Metabolic and Molecular 
Bases of Inherited Disease. Ed 8. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., 
McGraw-Hill, New York: 1995, p. 4353–92. 
[130] Guha S, Baltazar GC, Tu L-A, Liu J, Lim JC, Lu W, et al. Stimulation of the D5 
dopamine receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and 
decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 
2012;122:823–33. 
[131] So CH, Verma V, Alijaniaram M, Cheng R, Rashid AJ, Dowd BFO, et al. Calcium 
signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a 
mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. Mol 
Pharmacol 2009;75:843–54. 
[132] Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 
2002;47:27–38. 
[133] Pan J-X, Ding K, Wang C-Y. Niclosamide, an old antihelminthic agent, demonstrates 
antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J 
Cancer 2012;31:178–84. 
[134] Brunton L, Chabner B, Knollman B. Goodman and Gilman’s The Pharmacological 
Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. 2010. 
[135] Nguyen-Legros J, Versaux-Botteri C, Vernier P. Dopamine receptor localization in the 
mammalian retina. Mol Neurobiol 1999;19:181–204. 
[136] Burchill S, Thody A. Dopaminergic inhibition of tyrosinase activity in hair follicular 
melanocytes of the mouse. J Endocrinol 1986;111:233–7. 
147 
 
[137] Gu Y, Di W, Kelsell D, Zicha D. Quantitative fluorescence resonance energy transfer 
(FRET) measurement with acceptor photobleaching and spectral unmixing. J Microsc 
2004;215:162–73. 
[138] Wilson MC, Meredith D, Halestrap AP. Fluorescence resonance energy transfer studies 
on the interaction between the lactate transporter MCT1 and CD147 provide 
information on the topology and stoichiometry of the complex in situ. J Biol Chem 
2002;277:3666–72. 
[139] Karpova T, Baumann C, He L, Wu X, Grammer A, Lipsky P, et al. Fluorescence 
resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor 
photobleaching using confocal microscopy and a single laser. J Microsc 2003;209:56–
70. 
[140] Lopes VS, Wasmeier C, Seabra MC, Futter CE. Melanosome maturation defect in 
Rab38-deficient retinal pigment epithelium results in instability of immature 
melanosomes during transient melanogenesis. Mol Biol Cell 2007;18:3914–27. 
[141] Young A, Wang Y, Ahmedli NB, Jiang M, Farber DB. A constitutively active Gai3 
protein corrects the abnormal retinal pigment epithelium phenotype of Oa1 -/- mice. 
PLoS One 2013;8:4–13. 
[142] Shukla AK, Singh G, Ghosh E. Emerging structural insights into biased GPCR 
signaling. Trends Biochem Sci 2014;39:594–602. 
[143] Hu W-S, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. 
Pharmacol Rev 2000;52:493–511. 
[144] Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DL, Wurm FM. Valproic 
acid: a viable alternative to sodium butyrate for enhancing protein expression in 
mammalian cell cultures. Biotechnol Bioeng 2008;101:182–9. 
[145] New England BioLabs. NEB https://www.neb.com/. 
[146] VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for 
gene expression analysis. Biotechniques 2008;44:619–26. 
[147] Promega Corporation. Promega www.promega.com. 
[148] Broussard JA, Rappaz B, Webb DJ, Brown CM. Fluorescence resonance energy 
transfer microscopy as demonstrated by measuring the activation of the 
serine/threonine kinase Akt. Nat Protoc 2013;8:265–81. 
[149] Pomerantz SH. The Tyrosine Hydroxylase Activity of Mammalian Tyrosinase. J Biol 
Chem 1966;241:161–9. 
[150] Enzo Life Science I. Enzo Life Science enzolifesciences.com. 
[151] Nordstedt C, Fredholm BB. A modification of a protein-binding method for rapid 
quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem 
1990;189:231–4. 
[152] Bank RPD. RCSB Protein Data Bank - RCSB PDB 
[153] Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. 
AutoDock4 and AutoDockTools4: Automated docking with selective receptor 
flexibility. J Comput Chem 2009;30:2785–91. 
[154] Computing GC, Inc. Molecular Operating Environment (MOE) 2014.09 2014.  
148 
 
8. Appendices 
Appendix 1 
Alignments of human and mouse GPR143 and tyrosinase. Conserved amino acids are 
indicated with a straight line, double dots (:) and single dots (.) indicate conserved and semi-
conserved amino acids, respectively. Alignments are performed using EMBOSS Needle. 
Human and mouse GPR143 amino acid sequences: 79% identity and 85% similarity 
hGPR143            1 MASPRLGTFCCPTRDAATQLVLSFQPRAFHALCLGSGGLRLALGLLQLLP     50 
                     |||||||.|||||.|||||||||||||.|||||||||.|||.|||||||. 
mGPR143            1 MASPRLGIFCCPTWDAATQLVLSFQPRVFHALCLGSGTLRLVLGLLQLLS     50 
 
hGPR143           51 GRRPAGPGSPATSPPASVRILRAAAACDLLGCLGMVIRSTVWLGFPNFVD    100 
                     |||..|..:|||||.|||.|||||.|||||||||:|||||||:.:|.|:: 
mGPR143           51 GRRSVGHRAPATSPAASVHILRAATACDLLGCLGIVIRSTVWIAYPEFIE    100 
 
hGPR143          101 SVSDMNHTEIWPAAFCVGSAMWIQLLYSACFWWLFCYAVDAYLVIRRSAG    150 
                     ::|::|.|:||||.||||||||||||||||||||||||||.||||||||| 
mGPR143          101 NISNVNATDIWPATFCVGSAMWIQLLYSACFWWLFCYAVDVYLVIRRSAG    150 
 
hGPR143          151 LSTILLYHIMAWGLATLLCVEGAAMLYYPSVSRCERGLDHAIPHYVTMYL    200 
                     .||||||||||||||.|||||||.|||||||||||||||||||||||.|| 
mGPR143          151 RSTILLYHIMAWGLAVLLCVEGAVMLYYPSVSRCERGLDHAIPHYVTTYL    200 
 
hGPR143          201 PLLLVLVANPILFQKTVTAVASLLKGRQGIYTENERRMGAVIKIRFFKIM    250 
                     |||||||||||||.||||:||||||||:|:||||||.||||||.|||||| 
mGPR143          201 PLLLVLVANPILFHKTVTSVASLLKGRKGVYTENERLMGAVIKTRFFKIM    250 
 
hGPR143          251 LVLIICWLSNIINESLLFYLEMQTDINGGSLKPVRTAAKTTWFIMGILNP    300 
                     ||||.||||||||||||||||||.||:|||||.::.||:||||||||||| 
mGPR143          251 LVLIACWLSNIINESLLFYLEMQPDIHGGSLKRIQNAARTTWFIMGILNP    300 
 
hGPR143          301 AQGFLLSLAFYGWTGCSLGFQSPRKEIQWESLTTSAAEGAHPSPL---MP    347 
                     |||.||||||||||||||....|:..||||::|.|||||.:.:|:   :| 
mGPR143          301 AQGLLLSLAFYGWTGCSLDVHPPKMVIQWETMTASAAEGTYQTPVRSCVP    350 
 
hGPR143          348 HENPASGKVSQVGGQTSDEALSMLSEGSDASTIEIHTASESCNKNEGDPA    397 
                     |:||.  ||..|||.||||.||:|||.|||||:|||||:.|||..|.|.. 
mGPR143          351 HQNPR--KVVCVGGHTSDEVLSILSEDSDASTVEIHTATGSCNIKEVDSI    398 
 
hGPR143          398 LPTHGDL    404 
                     ....|:| 
mGPR143          399 SQAQGEL    405 
 
Human and mouse tyrosinase amino acid sequences: 86% identity and 92% similarity 
mTyr               1 MFLAVLYCLLWSFQISDGHFPRACASSKNLLAKECCPPWMGDGSPCGQLS     50 
                     |.||||||||||||.|.|||||||.|||||:.|||||||.||.||||||| 
hTyr               1 MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLS     50 
 
mTyr              51 GRGSCQDILLSSAPSGPQFPFKGVDDRESWPSVFYNRTCQCSGNFMGFNC    100 
                     ||||||:||||:||.||||||.|||||||||||||||||||||||||||| 
hTyr              51 GRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNC    100 
 
mTyr             101 GNSKFGFGGPNCTEKRVLIRRNIFDLSVSEKNKFFSYLTLAKHTISSVYV    150 
                     ||.||||.||||||:|:|:||||||||..||:|||:|||||||||||.|| 
hTyr             101 GNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYV    150 
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mTyr             151 IPTGTYGQMNNGSTPMFNDINIYDLFVWMHYYVSRDTLLGGSEIWRDIDF    200 
                     ||.||||||.||||||||||||||||||||||||.|.||||||||||||| 
hTyr             151 IPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDF    200 
 
mTyr             201 AHEAPGFLPWHRLFLLLWEQEIRELTGDENFTVPYWDWRDAENCDICTDE    250 
                     |||||.||||||||||.|||||::||||||||:|||||||||.||||||| 
hTyr             201 AHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDE    250 
 
mTyr             251 YLGGRHPENPNLLSPASFFSSWQIICSRSEEYNSHQVLCDGTPEGPLLRN    300 
                     |:||:||.||||||||||||||||:|||.|||||||.||:|||||||.|| 
hTyr             251 YMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRN    300 
 
mTyr             301 PGNHDKAKTPRLPSSADVEFCLSLTQYESGSMDRTANFSFRNTLEVFASP    350 
                     ||||||::|||||||||||||||||||||||||:.||||||||||.|||| 
hTyr             301 PGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASP    350 
 
mTyr             351 LTGIADPSQSSMHNALHIFMNGTMSQVQGSANDPIFLLHHAFVDSIFEQW    400 
                     ||||||.|||||||||||:||||||||||||||||||||||||||||||| 
hTyr             351 LTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQW    400 
 
mTyr             401 LRRHRPLLEVYPEANAPIGHNRDSYMVPFIPLYRNGDFFITSKDLGYDYS    450 
                     |||||||.||||||||||||||:|||||||||||||||||:||||||||| 
hTyr             401 LRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYDYS    450 
 
mTyr             451 YLQESDPGFYRNYIEPYLEQASRIWPWLLGAALVGAVIAAALSGLSSRLC    500 
                     |||:|||..:::||:.|||||||||.||||||:||||:.|.|:||.|.|| 
hTyr             451 YLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLC    500 
 
mTyr             501 LQKKKKKKQPQEERQPLLMDKDDYHSLLYQSHL    533 
                        :.|:||..||:|||||:|:|||| |||||| 
hTyr             501 ---RHKRKQLPEEKQPLLMEKEDYHS-LYQSHL    529 
 
 
Appendix 2 
Immunoprecipitation Western Blots - COS7 cells transfected with GPR143-PL and 
TYR-EGFP - Immunoprecipitation realized with anti-GFP antibody 
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Immunoprecipitation Western Blots - melan-a cells transfected with GPR143-EYFP - 
Immunoprecipitation realized with anti-PEP7 antibody (against tyrosinase) 
 
 
 
Immunoprecipitation Western Blots - COS7 cells transfected with GPR143-PL and 
TYR-EGFP – Immunoprecipitation realized with anti-ProLink antibody 
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9. Abbreviations 
ADA Adenosine deaminase 
ADP Adenosine diphosphate 
AMP Adenosine monophosphate 
ARs Adenosine receptors 
ARPE-19 cells Arising retinal pigment epithelia cell (from a 19-years old man) 
ATP Adenosine triphosphate 
BAY60-6583 2-[6-amino-3,5-dicyano-4-[4 (cyclopropylmethoxy)phenyl]pyridin-2-
ylsulfanyl]acetamide  
Bmax Measure of receptor density in membranes 
BSA Bovine serum albumin 
CADO 2-chloroadenosine 
cAMP Cyclic adenosine-3’,5’-monophosphate 
CCPA 2-Chloro-N6-cyclopentyladenosine 
cDNA Complementary DNA 
eCFP (enhanced) Cyan fluorescent protein 
CGS21680 (2-p-[2-carboxyethyl]phenethylamino)-5'-N-ethylcarboxamidoadenosine 
CHO cells Chinese Hamster Ovary cells 
Ci Curie (1 Ci = 37 GBq) 
Cl-IB-MECA 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-
methyl-β-D-ribofuranuronamide 
COS7 cells CV-1 (simian) in Origin and carrying the SV40 genetic material 
CPA N6-cyclopentyladenosine 
cpm Counts per minute 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethylsulfoxide 
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DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
DOPA Dopamine 
DTT Dithiothreitol 
EC50 50% effective concentration 
ECL Extracellular loop 
E. coli Escherichia coli 
EDTA Ethylene diamine tetracetic acid 
EE Early endosome 
EGF Epidermal growth factor 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
f forward 
FCS Fetal calf serum 
FRET Fluorescent Resonance Energy Transfer 
G418 Geneticin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GF/B Glass fiber filter type B 
eGFP (enhanced) Green fluorescent protein 
GPCRs G protein-coupled receptors 
h Human 
HA Haemoagglutinin (tag) 
HBSS Hank buffer salt solution 
HEPES 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid  
HTS High throughput screening 
IBMX Isobutylmethylxanthine 
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IC50 50% inhibitory concentration 
ICL Intracellular loop 
IP Immunoprecipitation 
KD Dissociation binding constant 
kDa Kilo Dalton 
Ki Inhibition constant 
LB medium Luria-Bertani medium 
L-DOPA Levodopa 
min Minutes 
MITF Microphthalmia-associated transcription factor 
MNT-1 cells Human melanoma cell line 
mRNA Messenger ribonucleic acid 
MRP Melanin-related proteins 
MSX-2 (3-(3-hydroxypropyl)- 7-methyl-8-(m-methoxystyryl)-1-
propargylxanthine)  
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MVBs Multivesicular bodies 
NECA 5'-N-ethylcarboxamidoadenosine 
OA1 Ocular Albinism type I 
PCR Polymerase chain reaction 
PBS Phosphate buffered saline 
PDB ID Protein Data Bank identification code 
PEI Polyethyleneimine 
PL ProLink (tag) 
Pmel17 Premelanosome protein 17 
PSB-15826 2-(4-(4-fluorophenyl)piperazin-1-yl)ethylthioadenosine 
PTU Propylthiouracil 
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qPCR or RT-PCR Quantitative or reverse transcription polymerase chain reaction 
Ro20-1724 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone  
ROI Region of interest 
RPE Retinal pigment epithelium 
R-PIA (R)-N6-phenylisopropyladenosin 
rpm Rotations per minute 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
rv reverse 
SDS-PAGE Sodium dodecyl sulfat – Poly Acrylamide Gel Electrophoresis 
SEM Standard error of the mean 
siRNA Silencing RNA 
TAE buffer Tris-Acetate-EDTA buffer 
Tm Melting temperature 
TMD Transmembrane domain 
TRP1/2 Tyrosinase-related protein 1 or 2 
TRIS 2-amino-2-hydroxymethyl-propane-1,3-diol (tris(hydroxyl methyl)amino 
methane)  
Triton X-100 t-octylphenoxypolyethoxyethanol  
TYR Tyrosinase  
UK432097 2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl-6-N-(2,2-
diphenylethyl)-5′-N-ethylcarboxamidoadenosine-2-carboxamide 
wt Wildtype 
XAC Xanthine amine congener 
eYFP (enhanced) Yellow fluorescent protein 
ZM241385 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol 
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